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1. Introduction 
Pituitary adenomas are rare and benign tumors, but can cause serious morbidity
due to local mass effects and pituitary insufficiency, and/or due to excessive se-
cretion of pituitary hormones. Pituitary adenomas can be treated by surgery, ra-
diotherapy, and medical therapy. However, despite curative treatment of the
adenomas per se, multiple physical and psychological complaints may persist, even
after long-term remission. The studies described in this thesis focus on the long-
term psychological consequences of pituitary adenomas. 
2. The neuroendocrine system: an overview
The pituitary gland and hypothalamus form a functional unit. The hypothalamus
relays endocrine and neural signals to the pituitary which in turn releases hor-
mones that influence most endocrine systems in the body. Together, the hypo-
thalamus and the pituitary exert control over the function of the thyroid gland,
the adrenal glands, and the gonads (1). 
The hypothalamus is located below the third ventricle and just above the optic
chiasm and pituitary gland and links with the central nervous system (2). The hy-
pothalamus secretes important regulating hormones: growth hormone releasing
hormone (GHRH), somatostatin, dopamine, thyrotropin releasing hormone
(TRH), corticotropin releasing hormone (CRH), and gonadotropin releasing hor-
mone (GnRH). In addition, the hypothalamus is involved in the regulation of
other important processes including the regulation of body temperature and food
intake (1). 
The pituitary is located at the base of the skull in the sella turcica and consists of
a posterior (neurohypophysis) and anterior (adenohypophysis) lobe. The posterior
lobe secretes two hormones: antidiuretic hormone (ADH) and oxytocin. ADH is
an important regulator of water balance and plays a role in cardiovascular func-
tion. Oxytocin is a hormone important in for example the contraction of smooth
muscles. The anterior lobe of the pituitary is the most richly vascularized tissue
of al mammalian tissues and secretes six major hormones (1): 
1. Adrenocorticotropic hormone (ACTH)
2. Somatotropin or growth hormone (GH)
3. Prolactin (PRL)
4. Thyrotropin or thyroid-stimulating hormone (TSH)
5. Luteinizing hormone (LH)
6. Follicle-stimulating hormone (FSH)
The hormones that play a central role in this thesis are detailed below. 
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Adrenocorticotropic hormone and the HPA-axis
The hypothalamus-pituitary-adrenal (HPA) axis is important in the physiology
of the stress response. In addition, alterations in the HPA-axis are involved in de-
pression (3;4), post-traumatic stress disorder (5), and other stress-related disor-
ders. 
In response to a stressful event, the hypothalamus secretes CRH into the hypo-
thalamic-pituitary portal venous circulation. CRH, in turn, stimulates ACTH re-
lease from the pituitary. After ACTH is released into the bloodstream, it reaches
the adrenal glands and stimulates the adrenal cortex to release cortisol and other
steroids. In turn, cortisol has an inhibitory effect on CRH and ACTH secretion
through a negative feedback mechanism (1;6). Cortisol is secreted in a pulsatile
fashion and in a circadian rhythm. Plasma ACTH and cortisol concentrations are
highest at the time of waking in the morning and decline during the day (1). 
Growth hormone 
The hypothalamus secretes GHRH to stimulate GH transcription and secretion
from the pituitary in a pulsatile manner. The hypothalamus also secretes somato-
statin, which inhibits GH secretion. GH secretion is related to emotional, physi-
cal, and chemical stress, including surgery, electroshock therapy, trauma, sepsis,
and exercise (1). GH secretion is also affected by nutritional factors; subjects who
are malnourished or fasting have increased GH secretion (7). 
The primary function of GH is promotion of linear growth. GH is involved in
bone remodeling, muscle growth, and immunomodulation. GH stimulates insulin-
like growth factor-I (IGF-1) secretion in other tissues, especially the liver. Most
of the growth promoting effects are caused by IGF-I. In turn, IGF-I inhibits GH
secretion from the pituitary (1). 
3. Pituitary adenomas
Cushing’s disease 
ACTH producing adenomas cause excessive cortisol production from the adrenal
gland and the resultant hypercortisolism induces a constellation of signs and
symptoms referred to as Cushing’s disease. These ACTH secreting adenomas are
almost always benign in origin. Cushing’s disease is characterized by obesity with
central fat distribution (see Figure 1b), moon face (see Figure 1a), plethora, os-
teopenia, proximal muscle weakness, striae (see Figure 1b), hirsutism, acne, poor
wound healing, easy bruisability, superficial fungal infections, hypertension, glu-
cose intolerance, and gonadal dysfunction (1). 
Cushing’s disease can be treated by selective removal of the pituitary adenoma
via transsphenoidal surgery. When surgery is not curative, pituitary irradiation is
Chapter 110
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one of the alternative treatment options (8). Bilateral adrenalectomy is the final
definitive cure when surgery and irradiation fail. Bilateral adrenalectomy leads
to lifelong daily glucocorticoid and mineralcorticoid replacement therapy (9).
Currently, medical strategies are under investigation, for example with SOM 230
(10). Following cure of Cushing’s disease, symptoms and mortality improve, but
do not normalize (11). Patients frequently experience a corticosteroid withdrawal
syndrome, with complaints like fatigue and muscle pain (12).
Acromegaly 
GH-producing pituitary adenomas cause acromegaly (13). Acromegaly is a rare
disease characterized by acral enlargement and coarse facial features (see Figure
2). The biochemical hallmarks are elevated growth hormone (GH) and insulin-
like growth factor I (IGF-I) concentrations. GH overproduction in children leads
to gigantism, while GH overproduction in adults leads to phenotypical changes
like kyphosis, frontal bossing, macroglossia, soft tissue swelling with enlargement
of hands and feet leading to increased ring and shoe size and organomegaly (14).
Increased sweating, greasy skin, fatigue, paresthesias, headache, sleep distur-
bances, lethargy, and weight gain are often seen. Carpal tunnel syndrome, sleep
apnea syndrome, hypertension, diabetes mellitus and arthropathy cardiomyopa-
General Introduction 11
Figure 1. Common clinical features in Cushing’s disease, adapted from Pearson Education, Inc. 2007,
publishing as Benjamin Cummings.
Figure 2. Features of acromegaly over time, adapted from Chauvet, 1935.
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thy, valvular abnormalities, and malignancies especially of the gastro-intestinal
tract are also well known problems in acromegaly (1;13;15-19). The early features
of acromegaly are usually very subtle and difficult to diagnose. This is why diag-
nosis is often delayed, in most cases for more than ten years. 
Acromegaly can be treated by selective removal of the pituitary adenoma via
transsphenoidal surgery or by primary medical treatment with somatostatin
analogs. Radiotherapy is not routinely used anymore because of side-effects, es-
pecially hypopituitarism. Following radiotherapy there is a long delay of many
years in achieving normal GH levels (20). The GH receptor antagonist Pegviso-
mant is also a very effective medical treatment option, able to control GH excess
in almost all patients (21). 
Non-functioning pituitary macroadenoma 
Non-functioning pituitary macroadenomas (NFMA) are benign in origin, although
mass effects of the adenoma can cause clinical symptoms, such as visual field de-
fects, pituitary insufficiency and chronic headache. Therefore, treatment is nec-
essary in the majority of cases with clinical symptoms of mass effects (22;23). The
primary therapy for patients with NFMA and visual field defects is transsphe-
noidal surgery (24-27). Additional radiotherapy can be used to reduce the re-
growth of the adenoma. Although radiotherapy is successful in adenoma
treatment, it can also induce complications, such as hypopituitarism (28;29) and
in rare cases damage to the optic nerve (30). Since NFMAs are also classified as pi-
tuitary tumors and are treated in the same way as ACTH-secreting adenomas and
GH-secreting adenomas, NFMAs can serve as a reference population to compare
the effects of ACTH or GH overproduction per se versus the effects of pituitary
adenomas and/or their treatment. 
4. Illness perceptions
Persistent thoughts about a present disease and/or its treatment can influence gen-
eral well-being. The sources of thoughts of a patient about the illness are diverse.
They can be derived from information from doctors, relatives, friends, or media,
but also from first hand experience with someone in the close proximity who suf-
fers from an illness. Therefore, illness perceptions are subjective, may be partly or
completely incorrect, and do not necessarily represent the medical status of the
disease. Patients and their doctors may have (totally) discrepant perceptions of
the severity of the disease and the success of treatment. This concept has hardly
been elaborated for endocrine diseases and can be studied by measuring illness
perceptions. 
Chapter 112
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Illness perceptions pertain to the way in which patients make sense of, and re-
spond to, their illness. Illness perceptions are conceptualized in the parallel process
model, later referred to as the Common Sense Model of self-regulation (CSM),
which is depicted in Figure 3 (31). This CSM explains how patients generate both
cognitive representations of, and emotional reactions to, their illness, integrating
internal and external stimulus information with their pre-existing illness theory
(32). Leventhal et al. (33) designed the CSM which starts from the premise that in-
dividuals are active problem solvers who make sense of a threat to their health by
developing a cognitive representation of the threat, which determines how the in-
dividual responds. The specific procedures and strategies that are chosen by the
patient for regulation of the health threat are defined by 1) the properties of the
health threat, and 2) the resources that are available to the patient and the social
context and culture (31). 
Patients cluster representations or ideas about the illness around five cognitive
components, which contain specific types of somatic and perceptual information
about an illness threat: 
1. The label that is used by the individual to describe the condition and the as-
sociated symptoms; 
2. Beliefs about the cause of the condition; 
3. Expectations about the likely duration of the condition; 
4. The physical, psychological, and social consequences of the condition; 
5. The extent to which the condition is amenable to cure and/or control. 
These cognitive components are congruent with two basic propositions that un-
derlie the CSM. The first proposition states that when people construct illness
representations, they act as a common sense scientist. The second proposition
states that the illness representations generate goals for self-management and that
General Introduction 13
Figure 3. The parallel process model (CSM), adapted from Leventhal et al., 2003 (31).
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these representations suggest procedures for goal attainment and criteria for eval-
uating response efficacy (31). 
The components that form the illness representations determine the patients’ cop-
ing procedures (34-36). Coping is the way in which someone reacts (behaviorally,
cognitively, and emotionally) to situations that require adjustments in dealing
with an adverse event and/or its consequences, for example an illness and its treat-
ment (37). It is thought that both illness perceptions and coping strategies are im-
portant factors that influence medical, psychological, and behavioral outcomes
and thereby determine quality of life (38-40). 
5. Quality of life and psychological functioning 
Quality of Life (QoL) refers to the perception of patients of their physical, men-
tal, and social health. QoL has been studied in patients with pituitary adenomas
with untreated and treated disease. QoL generally improves after treatment, but
research indicates that QoL remains impaired even after successful treatment (41-
44). There are disease specific impairments in QoL, which is also shown in Figure
4. A recent study by van der Klaauw et al. (45) reported that patients with long-
term follow-up of acromegaly had the largest impairment in QoL, compared to pa-
tients after long-term follow-up of other pituitary adenomas. This difference is
mostly due to the fact that patients with acromegaly reported impairment in phys-
ical performance and an increase in bodily pain. Patients with long-term remis-
sion of Cushing’s disease also reported impairments in physical functioning. The
authors concluded that QoL is most severely impaired in patients during long-
term follow-up of successful biochemical disease control of acromegaly and Cush-
Chapter 114
Figure 4. Quality of life in pituitary adenomas (higher Z-score represents a worse QoL), adapted
from Van der Klaauw et al., 2008 (45).
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ing’s disease in comparison to patients with non-functioning pituitary adenoma or
prolactinoma. 
In those previous QoL studies, patients reported psychological impairments on
various quality of life questionnaires, both general health and disease specific ques-
tionnaires. However, the QoL questionnaires are not designed to assess these psy-
chological aspects thoroughly. There are, to date, several studies on psychological
aspects (i.e. cognition and psychopathology) in patients with active Cushing’s dis-
ease and acromegaly and some studies after short-term remission (<18 months)
of these diseases (41;46-48;48-84). However, it is unclear to which extent im-
pairments in cognitive function and the increase in prevalence of psychopathol-
ogy are present in patients with (much longer duration) remission of Cushing’s
disease or acromegaly. 
Psychological functioning in Cushing’s disease
Patients with active Cushing’s disease have cognitive impairments, especially in
the memory domain. Previous studies reported impairments in memory, visual
and spatial information, reasoning, verbal learning, and language performance
(46-52). Structures important in cognitive functioning, like the hippocampus and
cerebral cortex, are rich in glucocorticoid receptors and are therefore particularly
vulnerable to the glucocorticoid excess present in Cushing’s disease (49). 
A large number of studies in humans and animal models have documented that
prolonged, increased endogenous or exogenous exposure to glucocorticoids may
have long-lasting adverse effects on behavioral and cognitive functions, due to
functional and, over time, structural alterations in specific brain target areas (85-
88). Following successful treatment of hypercortisolism, both physical and psy-
chiatric signs and symptoms improve substantially (62;63). 
Psychological functioning in acromegaly
Previous studies on acromegaly documented that patients with active acromegaly
suffer from cognitive dysfunction, personality changes, and various forms of psy-
chopathology (75-77;79;82-84). These observations suggest that the central nerv-
ous system is involved in the clinical syndrome of active acromegaly. This notion
is supported by the presence of GH receptors in various brain areas outside the
classical pathways of the GH-IGF-1 axis (89). Some of these structures are crucial
for cognitive functioning, and influence mental status and personality through
connections with the limbic system and frontal lobe (90). Many of the systemic
changes induced by previous excess of GH and/or IGF-I are not completely re-
versed upon successful biochemical treatment of active acromegaly (91), which
may also be true for the effects of GH and/or IGF-1 on the central nervous system.
For instance, 36% of the patients with cured acromegaly showed elevated scores
for anxiety and depression (41). 
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6. Scope of the present thesis
QoL is impaired in patients after treatment of pituitary adenomas, even during
long-term follow-up. From previous studies in other (chronic) diseases it is evi-
dent that QoL and psychological factors, like illness perceptions and psy-
chopathology, are related. Therefore, the aim of this thesis was to assess long-term
psychological consequences of treated pituitary adenomas. 
Illness perceptions and coping strategies
Although the decreased QoL may originate from persisting limitations due to ir-
reversible effects of excessive hormone exposure, an alternative hypothesis is that
the psychological impact of suffering from this disease results in quality of life re-
duction. This can be assessed by asking how patients perceive the effects of the pi-
tuitary adenoma and/or of its treatment. It was unknown how pituitary patients
perceive their illness and its symptoms. We therefore explored illness perceptions
in patients after long-term remission of Cushing’s syndrome in Chapter 2, using
a validated questionnaire, not previously used in endocrine diseases. We com-
pared the illness perceptions of patients after long-term remission of Cushing’s
syndrome with various reference samples. We also studied the relation between
QoL and illness perceptions. 
In addition, we explored the illness perceptions of patients after long-term re-
mission of acromegaly in Chapter 3. We also assessed the relationship between
QoL and illness perceptions in these patients. 
The components that form illness representations determine the coping proce-
dures of patients. We therefore assessed these coping procedures in Chapter 4 in
patients with pituitary adenomas. We compared these patients to Dutch reference
groups using a validated questionnaire on coping strategies. 
The prevalence of cognitive impairment and psychopathology
Earlier studies on cognitive functioning in patients with treated Cushing’s disease
documented impaired cognitive function in some but not all studies. In addition,
these studies included only small numbers of subjects, and patients were tested rel-
atively short after treatment for Cushing’s disease. It was unclear to which extent
impairments in cognitive functioning remain present in patients with long dura-
tion of cure of Cushing’s disease. Therefore, we evaluated cognitive functioning
in patients after long-term remission of Cushing’s disease in Chapter 5, and com-
pared these data with those of age- and sex-matched controls. To assess to which
extent treatment of pituitary adenomas per se affected our parameters, we addi-
tionally compared patients with long-term cure of Cushing’s disease to patients
treated for NFMA using Z-scores.
Chapter 116
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In addition, we also investigated the prevalence of psychopathology and mal-
adaptive personality traits in patients during long-term remission of Cushing’s
disease. Patients with Cushing’s disease were compared with age- and sex-
matched controls as well as with patients treated for NFMA using Z-scores. The
results of this analysis are described in Chapter 6. A review giving an overview of
all studies on psychopathology and Cushing’s disease is presented in Chapter 7. 
Cognitive functioning and prevalence of psychopathology in patients after long-
term remission of acromegaly were analyzed in Chapter 8. The aim was to assess
whether previous GH and/or IGF-I excess is associated with psychopathology,
maladaptive personality traits, and cognitive dysfunction. We compared psy-
chopathology, personality traits, and cognitive function between patients with
long-term cure of acromegaly and age- and sex-matched controls as well as with
patients treated for NFMA using Z-scores.
General Introduction 17
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Abstract
Objective: Illness perceptions pertain to the pattern of beliefs patients develop
about their illness. Illness perceptions are determinants of quality of life (QoL).
Factors contributing to persisting impaired QoL after Cushing’s syndrome (CS)
remain largely unknown. Therefore, the objective of the current study was to ex-
plore illness perceptions, as potentially modifiable psychological factors, in rela-
tion to QoL in patients with long-term remission of Cushing’s syndrome.
Design: This was a cross-sectional study.
Methods: We included patients with long-term remission of CS (n=52). Illness
perceptions were evaluated using the Illness Perception Questionnaire-Revised
(IPQ-R), and QoL was measured using the physical symptom checklist, EuroQoL-
5D, and the CushingQoL. Reference data were derived from recent studies and in-
cluded patients with vestibular schwannoma (n=80), acute (n=35) or chronic
(n=63) pain, and chronic obstructive pulmonary disease (COPD; n=171). 
Results: Illness perceptions showed a strong correlation with QoL. Patients with
CS scored distinctively more negative on the IPQ-R compared with patients with
vestibular schwannoma and patients with acute pain, and also reported more ill-
ness related complaints (all P<0.01). There were also some differences in illness
perceptions between patients with CS and patients with chronic pain and patients
with COPD, but there was no distinct pattern. 
Conclusions: Patients after long-term remission of CS report more negative ill-
ness perceptions compared with patients with other acute or chronic conditions.
Further research is needed to assess whether QoL in CS can be improved by ad-
dressing these illness perceptions, for example, by a self-management intervention
program.
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Introduction
Cushing’s syndrome is characterized by excessive glucocorticoid levels, mostly
caused by ACTH-producing pituitary adenomas, but in one third of the cases by
ectopic ACTH-producing neuroendocrine tumors or by adrenal adenomas/carci-
nomas. Following successful treatment of hypercortisolism, signs and symptoms
improve substantially. However, prolonged, excessive  exposure to glucocorti-
coids may have long-lasting adverse effects on behavioral and cognitive functions,
due to functional and structural alterations in specific brain target areas (1-4). Fur-
thermore, these patients do not completely return to their premorbid level of
functioning, and quality of life (QoL) is persistently impaired despite long-term
cure of Cushing’s syndrome (5). Although the decreased QoL may originate from
persisting limitations due to irreversible effects of excessive glucocorticoid expo-
sure, an alternative hypothesis is that the psychological impact of suffering from
this disease results in QoL reduction. We recently reported that coping strategies
are indeed ineffective in patients with pituitary disease (6). Persistent inappro-
priate thoughts about the disease and/or its treatment can influence general well-
being. Patients and their doctors may have (totally) discrepant perceptions of the
severity of the disease and the success of treatment. This concept has not been
elaborated for endocrine diseases and can be studied by measuring illness per-
ceptions. 
Illness perceptions pertain to the way patients make sense of, and respond to, their
illness. Illness perceptions are conceptualized in the common sense model (CSM)
of self-regulation. The CSM explains how patients generate both cognitive repre-
sentations of, and emotional reactions to, their illness, integrating internal and
external stimulus information with their pre-existing illness-theory (7). Leven-
thal et al. (8) designed the CSM which starts from the premise that individuals
are active problem solvers, who make sense of a threat to their health by devel-
oping a cognitive representation of the threat, which determines how the indi-
vidual responds. Patients cluster these representations or ideas about the illness
around five cognitive components: 1) identity: the label that is used by the indi-
vidual to describe the condition and the associated symptoms; 2) cause: personal
ideas about the cause of the condition; 3) time-line: expectations about the likely
duration of the condition; 4) consequences: the physical, psychological, and social
effects of the condition; 5) cure/control: the extent to which the condition is
amenable to cure and/or control. These components form the illness representa-
tions, which determine the patient’s coping procedures (9).  The source of pa-
tient’s perceptions is diverse. It can be based on information from doctors,
relatives, friends, or media, but also from first hand experience with someone in
the close proximity who suffers from an illness. Therefore, patients’ illness per-
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ceptions are subjective, may be partly or completely incorrect, and do not neces-
sarily represent the medical status of the disease. 
At present, there are no studies that have evaluated illness perceptions in patients
with long-term remission of Cushing’s syndrome. Therefore, the aim of the pres-
ent study is to explore the illness perceptions of patients after long-term remission
of Cushing’s syndrome in relation to reported QoL using the Illness Perception
Questionnaire-Revised (IPQ-R) and several QoL questionnaires. The IPQ-R ques-
tionnaire assesses perceptions on each of the five components by asking the pa-
tient for their own beliefs about the Cushing’s syndrome.  Since there are no




Cushing’s syndrome had been diagnosed based on internationally agreed guide-
lines, i.e. the clinical manifestations and positive biochemical tests including in-
creased urinary excretion rates of free cortisol, decreased overnight suppression by
dexamethasone (1mg) and, since 2004, elevated midnight salivary cortisol values.
All patients had been treated by transsphenoidal surgery or adrenalectomy, if nec-
essary followed by repeated surgery and/or postoperative radiotherapy. Cure of
Cushing’s syndrome was defined by normal overnight suppression of plasma cor-
tisol levels (<50nmol/l) after administration of dexamethasone (1mg) and normal
24h urinary excretion rates of cortisol (<220nmol/24h). Hydrocortisone inde-
pendency was defined as a normal cortisol response to CRH or insulin-tolerance
test (ITT). 
All patients were followed at our outpatient department. Patients were monitored
for (recurrence of) disease, according to appropriate dynamic tests. Pituitary func-
tion was monitored and pituitary hormone replacement was prescribed depend-
ent on the results of the yearly evaluation of pituitary functions. In case of
corticotrope insufficiency, confirmed by ITT or CRH test, the average dose of hy-
drocortisone was 20mg/d divided into two to three dosages. Evaluation of GH de-
ficiency was performedby ITT and/or GHRH-arginine test, only inpatients under
the age of 70yr and only after at least 2yr of remission. Somatotrope insufficiency
was treated with rhGH replacement, aiming at IGF-I concentrations in the nor-
mal range for age. In addition, free T4 and testosterone levels (in male patients)
were assessed. If results were below the lower limit of the respective reference
ranges, substitution with L-T4 and/or testosterone was prescribed. In the case of
amenorrhea and low estradiol levels in premenopausal women, estrogen replace-
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ment was provided. Progesterone replacement was also provided to women with
an intact uterus.
Education level was based on the Dutch education system, which is comparable
to the International Standard Classification of Education. Low education level was
defined as primary education to lower secondary education. Medium education
level incorporated (upper) secondary education to post-secondary non-tertiary
education, while high level education was defined as the first stage of tertiary ed-
ucation to the second stage of tertiary education.
Inclusion criteria for this study were age over 18yr and remission defined by strict
biochemical criteria for at least 1yr. The protocol was approved by the LUMC
Medical Ethics Committee.  
Protocol
We performed a clinical chart review of 77 patients with Cushing’s syndrome.
All were in remission at the time of the current study for at least 1yr. The long-
term treatment outcome of these patients has been characterized and described in
detail (10). We invited these patients to participate in the current study. Twenty-
five patients (32%) refused to participate, and 52 patients (68%) participated in the
current study and completed all questionnaires. The clinical characteristics of the
subjects who did not participate, did not differ from those of the participants. Pa-
tients were asked to complete questionnaires on illness perceptions and QoL at
home and return these questionnaires in a prepaid envelope. 
Illness Perception Questionnaire-Revised (IPQ-R)
The IPQ-R was used to measure cognitive and emotional representations of Cush-
ing’s syndrome (11;12). The questionnaire was developed to assess the compo-
nents of the illness representation of Leventhal’s Self-Regulatory Model and is
frequently used to study illness perceptions in chronic conditions (13-17). The
IPQ-R is divided into three sections. The first part consists of the illness identity
dimension, with a list of 14 general commonly occurring symptoms and 13 symp-
toms commonly occurring in Cushing’s syndrome. Patients are asked to rate
whether or not they experienced the symptoms, and if they believe the symptom
to be related to Cushing’s syndrome (yes/no). The summed up yes-rated items of
the disease-related symptoms were used in the analysis. 
The second part of the questionnaire, assessing illness perception dimensions, con-
sists of 38 statements concerning views on the illness, scored on a five-point Lik-
ert scale (from strongly disagree to strongly agree). The questions were
transformed to seven dimensions: timeline acute/chronic (beliefs about the
chronic nature of the condition), timeline cyclical (beliefs regarding the cyclical
nature of the condition), consequences (negative consequences of the disease),
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emotional representations (the likelihood to seek medical care), personal control
(perceived personal controllability of the disease), treatment control (perceived
treatment controllability of the disease), and illness coherence (personal under-
standing of the disease). A higher score indicates a stronger belief in that partic-
ular dimension. The third and final part of the questionnaire was about the causal
attributions. This section consists of 18 statements concerning possible causes that
patients considered that contributed to their disease, scored on a five-point Lik-
ert scale (strongly disagree to strongly agree). 
As recommended by the developers of the questionnaire, a principal component
analysis with varimax rotation was performed on the causal items to cluster vari-
ables with shared variance (11). The analysis produced 4 factors accounting for
72% of the variance. The first factor labeled psychological attributions accounted
for 31% of the variance and consisted of the items emotional state, personality,
overwork, stress or worries, mental attitude, family problems/worries, ageing, al-
tered immunity, and own behavior. The second factor labeled risk factors ac-
counted for 22% of the variance and consisted of the items pollution in
environment, diet or eating habits, bacteria or virus, accident/injury, and poor
medical care. The third factor behavioral attributions accounted for 11% of the
variance and consisted of the items smoking and alcohol use. The fourth factor
chance accounted for 9% of the variance and consisted of the items hereditary
and chance/bad luck. This fourth factor demonstrated insufficient internal relia-
bility (α<0.50), and was excluded from further analysis. Higher scores on the other
three causal subscales indicate stronger beliefs in those attributions in causing
Cushing’s syndrome. 
Quality of life questionnaires
Physical symptoms checklist: This is a checklist of 55 physical symptoms that
are mentioned in the DSM-III classification (18). The symptoms cover most organ
systems. There are 11 general/ neurological items, 10 autonomic items, 8 muscu-
loskeletal/pain items, 13 gastrointestinal items, 5 genital items and 4 items about
feeling hot/cold. The presence of symptoms is rated on a severity scale from 0 to
3. We excluded the gender specific items (n=4) from the analyses to rule out bias
by gender. The total symptom score ranges from 0 to 153. A higher score indicates
more (severe) physical symptoms in the preceding week (19). 
EuroQoL-5D: This QoL questionnaire measures five health dimensions; mobil-
ity, self-care, usual activities, pain/discomfort, and anxiety/depression. Scores are
expressed on a 1-3 scale per dimension, with a higher score indicating a worse
QoL. The questionnaire also includes a visual analogue scale (VAS) which com-
prises a standard vertical 20 cm scale (similar to a thermometer) for recording an
individual’s rating for their current health-related QoL state (20). The VAS score
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ranges from 0 to 100, with higher scores indicating a better QoL. 
CushingQoL: This is a disease specific QoL questionnaire specifically designed to
assess QoL in patients with Cushing’s syndrome. The questionnaire consists of 12
questions on a five-point Likert scale ranging from always to never. The total score
ranges from 12 to 60, with a lower score indicating a greater impact on health re-
lated QoL (21). 
Three patients did not complete all QoL questionnaires. 
Reference populations
Since the general population is not assumed to have an illness, there are no nor-
mative values of the IPQ-R available for the general population. Scores of patients
with acute and chronic pain may be used instead (22). The other reference groups
were chosen based on available data of the IPQ-R in Dutch samples. 
Patients with acute and chronic pain are described in the paper that presents the
revised version of the IPQ (11). The reference group with acute pain consisted of
35 subjects who were recruited from a private practice for physical therapy (20
men, 15 women, mean age of 36±12yr). The patients presented with a first-time
peripheral painful injury that had been present for less than six weeks. The ref-
erence group of patients with chronic pain consisted of 63 subjects (26 men and
37 women, with a mean age of 54±11yr) who were recruited from hospital based
chronic pain clinics. All patients experienced pain for longer than 3 months that
was unexplained by medical signs alone.
The third reference group consisted of 171 Dutch patients (112 men and 59
women, mean age 66±10yr) suffering from chronic obstructive pulmonary dis-
ease (COPD) (23). A chest physician diagnosed all patients as suffering from em-
physema and/or chronic bronchitis. 
The fourth reference group consisted of 80 patients with vestibular schwannoma
who just had been told the diagnosis, but who had not received a treatment pro-
posal at the time of the study (36 men, 43 women, and one anonymous respon-
der. Mean age 57yr, range 26-79yr) (22). Thirty-eight percent of the patients
suffered from an intracanalicular tumor, and 8% from a cystic component. The
symptoms experienced by these patients included tinnitus, unsteadiness, vertigo,
headache, and earache.
Statistical analysis
Data were analyzed using PASW Statistics version 17.0.2 (SPSS Inc., Chicago, IL,
USA). All data were presented as mean ± standard deviations, unless mentioned
otherwise. The primary analysis comprised the relationship between illness per-
ceptions and QoL. Partial correlations were calculated controlling for duration of
remission. The level of significance for this analysis was set at P≤0.05. The com-
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parison of patients with a relatively better QoL and patients with a worse QoL
consisted of a Student’s t-test with the level of significance set at P≤0.01, because
of multiple comparisons. The possible effects of duration of remission and dura-
tion of follow-up were explored by linear regression analysis. The standardized β
coefficients of this analysis were reported.
Secondary analysis comprised the comparison of results in patients with long-
term cure of Cushing’s syndrome and of results in various reference groups. Means
were calculated for all subscales of the IPQ and compared between groups using
Student’s t-test. Patients with cure of Cushing’s syndrome with and without hy-
drocortisone substitution were also compared using a Student’s t-test, while the
different treatment modalities were compared using an ANOVA with a post hoc
analysis when appropriate. Since multiple comparisons were used, the level of
significance was set at P≤0.01. 
Results
Sociodemographic and clinical characteristics 
Clinical characteristics of the patients are detailed in Table 1. Forty-six patients
(88%) had pituitary ACTH-dependent hypercortisolism, and 6 patients (12%) had
Cushing’s syndrome due to adrenal tumor. There were no significant differences
between patients who had been treated for Cushing’s syndrome caused by an ad-
renal cortisol producing tumor and patients who had been treated for Cushing’s
disease on the IPQ-R, nor on any of the QoL questionnaires.
Thirty-four patients (65%) had been treated by transsphenoidal surgery, seven
patients (14%) by both transsphenoidal surgery and adrenalectomy and 11 pa-
tients (21%) had been treated by adrenalectomy. Fourteen patients (27%) had
been treated by additional pituitary irradiation for persistent disease after sur-
gery. At the time of this study, all patients were in remission and the mean dura-
tion of remission was 16±12yr (range 2-46yr). Twenty-three patients were GH
deficient, of whom 21 received GH therapy. A total of 32 patients (62%) were
treated for some degree of pituitary insufficiency, and 30 patients (58%) were sub-
stituted with hydrocortisone. Figure 1 shows the self-reported symptoms of var-
ious organ systems in patients after long-term remission of Cushing’s syndrome.
Most complaints involved musculoskeletal pain. 
Illness perceptions in Cushing’s syndrome as measured with the IPQ-R 
Illness identity dimension 
More than half of the patients reported to suffer from symptoms like gaining
weight, less muscle strength, less energy, concentration problems, memory im-
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Table 1 Clinical characteristics 










Gender (male/female) 7/45 5/25 2/20 
Age in yrs 54 (11) 53 (11) 55 (11) 
Educational level (n) Low: 16 (31%) 
Medium: 18 (35%) 
High: 16 (31%) 
Unknown: 2 (4%) 
Low: 9 (30%) 
Medium: 11 (37%) 
High: 9 (30%) 
Unknown: 1 (3%) 
Low: 7 (32%) 
Medium: 7 (32%) 
High: 7 (32%) 
Unknown: 1 (5%) 
Transspenoidal surgery, n (%) 41 (79%) 16 (53%) 18 (82%) 
Adrenal surgery, n (%) 11 (21%) 7 (23%) 4 (18%) 
Transspenoidal and adrenal 
surgery, n (%) 
7 (14%) 7 (23%) 0 (0%) 
Postoperative radiotherapy, n (%) 14 (27%) 10 (33%) 4 (18%) 
Duration of remission in yrs 16 (12) 18 (13) 14 (10) 
Duration of follow-up in yrs 17 (12) 18 (13) 15 (10) 
Hypopituitarism, n (%) Any axis: 32 (62%) 
GH: 23 (44%) 
LH/FSH: 14 (27%) 
TSH: 19 (37%) 
ADH: 8 (15%) 
Any axis: 30 (100%) 
GH: 21 (70%) 
LH/FSH: 13 (43%) 
TSH: 17 (57%) 
ADH: 8 (27%) 
Any axis: 2 (9%) 
GH: 2 (9%) 
LH/FSH: 1 (5%) 
TSH: 2 (9%) 
ADH: 0 (0%) 
HC substitution,  n(%) 30 (58%) 30 (100%) 0 (0%) 
Data are mean ± SD or number and %; HC, hydrocortisone  
 
Figure 1. Scores of patients after long-term remission of Cushing’s syndrome on the various organ
systems  
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pairment, and vulnerable skin and believed that these symptoms are solely caused
by Cushing’s syndrome (Table 2). 
Causal attributions dimension
In the last part of the questionnaire, patients after remission of Cushing’s syn-
drome reported relatively frequently psychological attributions as their perceived
cause of Cushing’s syndrome. Risk factors and behavioral attributions were in-
frequently mentioned as being the cause of their illness. 
Illness perception dimensions
There were no differences in the IPQ-R dimensions between patients who had
been treated by different treatment modalities (i.e. transsphenoidal surgery ver-
sus both transsphenoidal surgery and adrenalectomy versus adrenalectomy, and
secondly additional radiotherapy versus no additional radiotherapy). 
When using a linear regression model, gender and age were not associated with
any of the illness perception dimensions. Duration of remission was also not as-
sociated with any of the illness perception dimensions, except for illness coher-
ence, which constitutes the personal understanding of the disease (β=-2.698,
P=0.04). Furthermore, there were differences between patients with hydrocorti-
sone substitution (n=29) and patients without cortisol substitution (n=23) in the
perceived chronicity (P=0.005) and fluctuations in the disease (P=0.002). The clin-
ical characteristics of patients with and without hydrocortisone substitution are
detailed in Table 1.
In addition, hypopituitarism was associated with the number of symptoms at-
tributed to the disease (β=0.303, P=0.030), chronicity (β=0.468, P=0.001) and fluc-
tuations (β =0.333, P=0.016) of the disease, and the perceived consequences
(β=0.323, P=0.019).
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Table 2. Symptoms related to Cushing’s syndrome  
Symptoms Cushing’s syndrome, n=52 
Less muscle strength 35 (67%) 
Less energy 30 (58%) 
Gaining weight 28 (54%) 
Concentration problems 28 (54%) 
Vulnerable skin 27 (52%) 
Memory impairment 27 (52%) 
Sore joints 25 (48%) 
Bad physical condition 22 (42%) 
Muscle pain 19 (37%) 
Slow wound healing 19 (37%) 
Visual impairment 13 (25%) 
Hair growth 13 (25%) 
Hair loss 9 (17%) 
Data are n (%), from the dimension ‘illness identity’ of the IPQ-R 
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Relationship between illness perceptions and QoL
The scores of patients with Cushing’s syndrome on the various QoL question-
naires are depicted in Table 3. Levels of association between the IPQ-R dimen-
sions and the QoL scales are shown in Table 4 as partial correlations, controlled
for duration of remission. 
The IPQ-R dimension illness identity showed positive correlations with the phys-
ical symptoms checklist (PSC), mobility, activity, and anxiety, and inverse corre-
lation with the VAS and the CushingQoL, all reflecting worse QoL when more
symptoms are attributed to the disease on the illness identity dimension. The di-
mension timeline (acute/chronic) also showed an inverse correlation with the
VAS and the CushingQoL. This indicates that patients who perceive their disease
as chronic have a lower QoL. The dimension negative consequences showed a
positive correlation with activity, and a negative correlation with the VAS and the
CushingQoL. Furthermore, the emotional representations dimension showed a
positive correlation with the PSC, mobility, and anxiety and an inverse correla-
tion with the CushingQoL. The dimension personal control showed an inverse
correlation with self-care and a positive correlation with the VAS. Perceived treat-
ment control showed an inverse correlation with mobility and pain, and a posi-
tive correlation with the VAS and the CushingQoL. The dimension illness
coherence (understanding of the disease) also showed an inverse correlation with
mobility. Lastly, psychological attributions as a cause of Cushing’s syndrome
showed a positive correlation with the PSC and mobility, but an inverse correla-
tion with the CushingQoL. The dimensions timeline (cyclical), risk factors, and
behavioral attributions did not correlate with any of the QoL questionnaires. 
In addition, patients with low scores and patients with high scores on the various
QoL questionnaires were compared. The median value was used to define low
Illness perceptions and QoL in Cushing’s syndrome 33




Physical Symptoms Checklist  
    Total Score 40.8 (26) 
EuroQoL-5D  
     Mobility 1.4 (1) 
     Self-care 1.1 (0) 
     Activity 1.7 (1) 
     Pain 1.8 (1) 
     Anxiety 1.4 (1) 
     VAS 65.5 (18) 
Cushing QoL  
     Total Score 52 (18) 
Data are mean (SD). A higher score on the PSC, mobility, self-care, activity, pain, and anxiety indicates a 
worse QoL, whereas higher scores on the VAS and the CushingQoL indicate a better QoL. 
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versus high scores. Patients with high scores on the PSC (indicating a more im-
paired QoL, n=25) attributed significantly more symptoms to Cushing’s syndrome
(P=0.002) than patients with a lower score (n=24).
On the VAS, patients with a lower score (indicating a more impaired QoL, n=25) at-
tributed more symptoms to Cushing’s syndrome (P=0.010) than patients with a
higher score (n=24). Patients with a lower score on the CushingQoL (indicating a
more impaired QoL, n=23) attributed more symptoms to Cushing’s syndrome
(P<0.001), scored higher on timeline acute/chronic (P=0.004), higher on conse-
quences (P<0.001), higher on treatment control (P=0.010), and lower on emotional
representations (P<0.001). These analyses indicate that patients with a worse QoL
report more affected illness perceptions than patients with a better QoL. 
There were no significant differences in QoL between patients with and without
hydrocortisone substitution (data not shown). 
The above mentioned findings make clinical sense, in that the IPQ dimensions and
the closely related QoL subscales measure the same concepts or concepts that log-
ically interact with each other, i.e. disease related symptoms and daily activities,
or (negative) consequences and perceived well-being.
Illness perceptions in Cushing’s syndrome compared with reference groups 
Illness perceptions in patients after long-term cure of Cushing’s syndrome
compared with acute and chronic pain patients 
Illness perceptions of patients with Cushing’s syndrome were compared with
acute pain patients (Table 5, Figure 2). Patients with Cushing’s syndrome reported
more illness related complaints (P=0.008), more chronicity and fluctuations in the
disease (both P<0.0001), perceived more negative consequences of the disease,
and less personal (P<0.0001) and treatment (P=0.002) control. However, patients
with Cushing’s syndrome had a better personal understanding of the disease
(P<0.0001) than patients with acute pain. 
In comparison with chronic pain patients, patients with Cushing’s syndrome re-
ported less illness related complaints (P=0.003), perceived less negative conse-
quences of the disease (P<0.001), and reported a smaller likelihood to seek medical
care (P<0.0001). Patients with Cushing’s syndrome reported more treatment con-
trol (P=0.002) and had a better personal understanding of the disease (P<0.0001)
than patients with chronic pain. 
Illness perceptions in patients after long-term cure of Cushing’s syndrome
compared with patients with a chronic disease 
Illness perceptions of patients with Cushing’s syndrome were also compared with
patients with another chronic disease, i.e. COPD (Table 5). Patients with Cush-
ing’s syndrome reported less illness related complaints (P<0.001), less chronicity
Illness perceptions and QoL in Cushing’s syndrome 35
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in the disease (P=0.002), and more perceived more treatment controllability
(P=0.001). However, patients with Cushing’s syndrome perceived less personal
controllability of the disease (P<0.0001) than COPD patients. 
Illness perceptions in patients after long-term cure of Cushing’s syndrome
compared with reference populations with vestibular schwannoma 
Illness perceptions of patients with Cushing’s syndrome were compared with pa-
tients suffering from untreated vestibular schwannoma (Table 5). Patients with
Cushing’s syndrome reported more illness-related complaints (P=0.002) and more
chronicity in the disease (P=0.004). Furthermore, patients with Cushing’s syn-
drome reported more negative consequences of the disease (P<0.0001) and per-
ceived less personal control of the disease (P=0.010) than patients with vestibular
schwannoma.





































































Figure 2. Distribution of IPQ-R scores of patients after long-term remission of Cushing’s syndrome,
patients with acute pain, and patients with chronic pain.
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Discussion
This study was performed to assess the illness perceptions of patients after long-
term remission of Cushing’s syndrome in relation to QoL parameters. This is the
first time that this is addressed in endocrine diseases. The results indicate that af-
fected illness perceptions and reduced QoL parameters are strongly related. More-
over, patients after long-term remission of Cushing’s syndrome report more
negative illness perceptions compared with several reference groups. 
This explorative study demonstrates that patients in long-term remission after
treatment for Cushing’s syndrome attribute more symptoms to (the aftermath of)
their disease than patients with acute pain or vestibular schwannoma, but less
than patients with chronic pain or COPD. Furthermore, patients with long-term
cure of Cushing’s syndrome show more strongly held beliefs regarding the chronic
nature of the condition compared with patients with acute pain or vestibular
schwannoma, but less than COPD patients. Patients with long-term cure of Cush-
ing’s syndrome also believe that their illness is more cyclical than patients with
acute pain. Patients with long-term remission of Cushing’s syndrome report more
negative consequences of the disease compared with patients with acute pain or
vestibular schwannoma, but less negative consequences than patients with
chronic pain. In addition, patients with long-term remission of Cushing’s syn-
drome are less likely to seek medical care than patients with chronic pain. More-
over, patients with long-term cure of Cushing’s syndrome have a lower perceived
personal controllability of the disease compared with patients with acute pain,
COPD, or vestibular schwannoma. Furthermore, patient with long-term cure of
Cushing’s syndrome have a lower perceived treatment controllability of the dis-
ease than patients with acute pain, but a higher perceived treatment controlla-
bility than patients with chronic pain or COPD. Finally, patients with long-term
remission of Cushing’s syndrome have a better personal understanding of their
disease compared with patients with acute or chronic pain. 
Patients’ perceptions can be based on information from different sources. There-
fore, patients’ illness perceptions do not necessarily represent the medical status
of the disease. This could explain why patients in remission of Cushing’s syn-
drome perceive their illness as chronic or cyclical and believe that a psychologi-
cal attribution might have caused Cushing’s syndrome. 
Patients with hydrocortisone dependency had stronger beliefs regarding the
chronic nature and the cyclical nature of Cushing’s syndrome than patients with-
out hydrocortisone dependency. Furthermore, hypopituitarism was associated
with the number of symptoms attributed to Cushing’s syndrome, chronicity and
fluctuations of the disease, and the perceived consequences of Cushing’s syn-
drome. Therefore, hydrocortisone dependency and hypopituitarism both influ-
Chapter 238
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ence illness perceptions. 
This study also demonstrates that there is a strong relationship between illness
perceptions and QoL. Affected illness perceptions are correlated with a more im-
paired QoL. This has already been observed in multiple other medical conditions
(24). This relationship is a relevant observation, since patients with long-term
cure of Cushing’s syndrome have persistent complaints reflected in impaired QoL
(3-5). These complaints are often misunderstood and difficult to treat. Therefore,
awareness of how these patients perceive their disease and its consequences could
lead to better understanding of Cushing’s syndrome and its long-term effects. Fur-
thermore, the current data on persisting perceptions of a chronic, rather than of
a cured disease in combination with altered coping strategies in these patients (6)
permit the design of an intervention based on combinations of strategies includ-
ing cognitive behavioral therapy, self-management training, and information on
the negative effects of the disease. Self-management training involves exploring,
eliciting, and changing illness perceptions of the patient, which in turn deter-
mines coping styles and self-management behavior (7;25). The intervention
should be led by a health psychologist and endocrinologist and includes topics
such as information about the illness and treatment, beliefs about consequences,
beliefs about personal control, beliefs in self-efficacy, and the role of the social
network (26). We speculate that with a targeted intervention, patients could be
taught self-management skills and be better informed about the consequences of
their disease. We believe that this approach might lead to improved QoL, since the
present study shows that illness perceptions and QoL are strongly correlated. Sim-
ilar self-management and educational interventions are currently available for
patients with e.g. inflammatory bowel disease (27) and after stroke (28). Increas-
ingly, partners of patients are involved in such self-management training, with
encouraging results; the partners help in ensuring that the patient actually per-
forms self-management skills in the home situation (26). 
A possible limitation of this study might be the fact that the symptoms commonly
occurring in Cushing’s syndrome, which are described in the illness identity di-
mension, were not validated but instead based on the input of experienced en-
docrinologists. However, these symptoms were not used in the comparison of
patients with Cushing’s syndrome versus the patients from the reference samples
and, therefore, do not influence the results of this study. A second limitation is the
possibility that the difference in age distribution between the various groups
might have affected the results. Nonetheless, in this study, age did not have an ef-
fect on illness perceptions. However, this does not necessarily control for the pos-
sibility of age as a confounder because of the relatively small sample size. Another
possible limitation of this study is the use of convenience reference samples. Ill-
ness perceptions have never been studied in patients with endocrine diseases be-
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fore, and therefore it was not straightforward to compare our patients to patients
with other endocrine diseases. In the current explorative study, we decided to in-
vite a large sample of patients with Cushing’s syndrome and to compare them
with existing available reference samples. Future studies examining the differ-
ences in illness perceptions between patients with various (endocrine) disorders
in larger samples should include correction for possible confounders like age and
gender.
In summary, there is strong correlation between illness perceptions and decreased
QoL. Patients after long-term remission of Cushing’s syndrome reported more
negative illness perceptions compared with various reference samples. These re-
sults strongly point towards the need to develop, to apply and to evaluate a self-
management and/or educational intervention aimed to improve these illness
perceptions and thereby QoL in patients after remission of Cushing’s syndrome. 
Chapter 240
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Abstract
Context and objective: Illness perceptions pertain to the beliefs patients develop
about their illness, and these views are determinants of behavior directed at the
illness. Illness perceptions are determinants of quality of life (QoL). QoL remains
impaired in patients with biochemical control of acromegaly, but illness percep-
tions were never studied in these patients. 
Aim: The aim of the current study was to explore illness perceptions and their as-
sociation with QoL in patients with long-term biochemical control of acromegaly.
Design: This was a cross-sectional study.
Subjects: We included patients with long-term biochemical control of acromegaly
(n=81), and compared them with Dutch reference populations: patients with acute
pain (n=35) or chronic pain (n=63), Cushing’s syndrome (n=52), chronic obstruc-
tive pulmonary disease (COPD; n=171), and vestibular schwannoma (n=80). Ill-
ness perceptions were evaluated using the Illness Perception Questionnaire-
Revised, and QoL was assessed with the Physical Symptoms Checklist, EuroQoL-
5D, and AcroQoL. 
Results: Illness perceptions showed strong correlations with QoL. Patients after re-
mission of acromegaly have a good understanding of their disease, but they expe-
rience a lack of personal control and are not likely to seek medical care compared
with patients with acute disease (all P<0.01). 
Conclusion: Illness perceptions of patients after long-term remission of
acromegaly are affected and strongly related to QoL. Patients reported more neg-
ative illness perceptions than patients with acute illness, but more positive illness
perceptions than patients with chronic diseases. Additional research is necessary
to assess whether a self-management intervention might help in improving af-
fected illness perceptions, and thereby improve QoL. 
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Introduction
Acromegaly is associated with typical signs and symptoms caused by excess of
growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Many of the sys-
temic changes induced by previous excess of GH and/or IGF-I are not completely
reversed upon successful biochemical treatment of active acromegaly (1). Impaired
quality of life (QoL) persists despite long-term remission in acromegaly (2). Al-
though decreased QoL may originate from persisting limitations due to irreversible
effects of excessive GH and IGF-I exposure, an alternative hypothesis is that the
psychological impact of suffering from this disease reduces QoL. This concept is
supported by the observation that coping strategies are ineffective in patients with
pituitary disease (3). Persistent, inappropriate thoughts about the disease and/or
its treatment can influence general well-being. Moreover, patients and their doc-
tors may have discrepant perceptions of the severity of the disease and the success
of treatment. This concept can be studied by measuring illness perceptions. 
Illness perceptions pertain to the way patients make sense of, and respond to, their
illness and are conceptualized in the common sense model (CSM) of self-regula-
tion. The CSM explains how patients generate both cognitive representations of,
and emotional reactions to, their illness, integrating internal and external stimu-
lus information with their pre-existing illness-theory (4). Leventhal et al. (5) de-
signed the CSM, which starts from the premise that individuals are active problem
solvers, who make sense of a threat to their health by developing a cognitive rep-
resentation of the threat, which determines how the individual responds. Patients
cluster these representations or ideas about the illness around five cognitive com-
ponents: 1) identity: the label that is used by the individual to describe the con-
dition and the associated symptoms, 2) cause: personal ideas about the cause of
the condition, 3) time-line: expectations about the likely duration of the condition,
4) consequences: the physical, psychological, and social effects of the condition,
5) cure/control: the extent to which the condition is amenable to cure and/or con-
trol. These components form the illness representations, which determine the
coping procedures of the patient (6). The sources of these perceptions are diverse.
Therefore, these illness perceptions are subjective, may be partly or completely in-
correct, and do not necessarily represent the actual medical status of the disease. 
At present, there are no studies that have evaluated illness perceptions in patients
with acromegaly. Therefore, the aim of the study was to explore the illness per-
ceptions of patients after long-term biochemical remission of acromegaly and
compare these to reference groups from the literature. 
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Patients and Methods
Patients 
We performed a clinical chart review of 156 patients with acromegaly. All were
in biochemical remission at the time of the current study for at least 1yr. We in-
vited these patients to participate in the current study. Seventy-five patients (48%)
refused to participate for several reasons including old age, and/or debilitating
disease. Eighty-one patients (52%) participated in the current study and com-
pleted the questionnaire on illness perceptions. Seventy-five patients also com-
pleted the QoL questionnaires.
The diagnosis of acromegaly had been established by clinical signs and symptoms
and by biochemical tests, including insufficient suppression of GH during glucose
tolerance test and increased IGF-1 levels for age. Biochemical control of
acromegaly was defined by normal serum IGF-1 levels for age and serum GH lev-
els below 1.9 µg/liter for all patients and, in patients without somatostatin ana-
logue treatment, also by normal suppression of GH levels (<0.38 mcg/l) during
glucose tolerance test (7). Remission was confirmed by repeating the tests at yearly
intervals. Pituitary function was monitored and pituitary hormone replacement
was prescribed dependent on the results of the yearly evaluation of pituitary func-
tions. In case of corticotrope insufficiency, documented by insulin tolerance test
(ITT) or CRH test, hydrocortisone was prescribed (20mg/d divided into 2-3
dosages). Evaluation of GH deficiency was performed by ITT or GHRH-arginine
test, only in patients under the age of 70yr and only after at least 2yr of remission.
Somatotrope insufficiency was treated with rhGH replacement, aiming at IGF-I
concentrations in the normal range for age. Patients were treated with rhGH from
2005 onwards during a controlled trial of rhGH replacement (8). In addition, free
T4 and testosterone levels (in male patients) were assessed. If results were below
the lower limit of the respective reference ranges, substitution with L- T4 and/or
testosterone was prescribed. In the case of amenorrhea and low estradiol levels in
premenopausal women, estrogen replacement was provided. 
Inclusion criteria for the current study were age over 18yr and remission defined
by strict biochemical criteria for at least 1yr. The protocol was approved by the
Medical Ethics Committee.  
Protocol
Patients were asked to complete a questionnaire on illness perceptions and three
questionnaires on QoL at home and return these in a prepaid envelope. 
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Illness Perception Questionnaire Revised (IPQ-R)
The IPQ-R was used to measure cognitive and emotional representations of
acromegaly (9). This questionnaire was developed to assess the components of the
illness representation of Leventhal’s Self-Regulatory Model and is frequently used
to study illness perceptions in chronic conditions (10-14). The IPQ-R is divided
into three sections. The first part consists of the illness identity dimension, with
a list of 14 commonly occurring symptoms and 11 symptoms commonly occurring
in acromegaly. Patients are asked to rate whether or not they experienced the
symptoms, and if they believe the symptom to be related to acromegaly (yes/no).
The summed yes-rated items of the disease related symptoms are used in the
analysis. 
The second part of the questionnaire, assessing illness perception dimensions, con-
sists of 38 statements concerning views on the illness, scored on a five-point Lik-
ert scale (from strongly disagree to strongly agree). The questions are transformed
to seven dimensions: timeline acute/chronic (beliefs about the chronic nature of
the condition), timeline cyclical (beliefs regarding the cyclical nature of the con-
dition), consequences (negative consequences of the disease), emotional repre-
sentations (the likelihood to seek medical care), personal control (perceived
personal controllability of the disease), treatment control (perceived treatment
controllability of the disease), and illness coherence (personal understanding of
the disease). A higher score indicates a stronger belief in that particular dimension.
The third and final part of the questionnaire entails causal attributions. This sec-
tion consists of 18 statements concerning possible causes that patients consider
that contributed to their disease, scored on a five-point Likert scale (strongly dis-
agree to strongly agree). 
As recommended by the developers of the questionnaire, a principal component
analysis with varimax rotation was performed on the causal items to cluster vari-
ables with shared variance (9). A principal component analysis is a technique for
identifying clusters/factors in a large set of variables. Once factors have been ex-
tracted, it is possible to calculate to what degree variables load onto these factors.
Factor rotation can be used to calculate this and discriminate between factors. A
varimax rotation is an orthogonal rotation that attempts to maximize the disper-
sion of factor loadings within factors. The rotation tries to load a smaller number
of variables highly onto each factor, which in turn results in more interpretable
clusters of factors (15). The analysis produced four factors accounting for 73% of
the total variance. The first factor labeled psychological attributions accounted
for 33% of the variance and consisted of the items stress or worries, family prob-
lems or worries, emotional state, mental attitude, own behavior, overwork, age-
ing, personality, altered immunity, and poor medical care. The second factor
labeled risk factors accounted for 25% of the variance and consisted of the items
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smoking, alcohol use, accident/injury, bacteria or virus, diet or eating habits, and
pollution in environment. The third factor was labeled hereditary and accounted
for 9% of the variance. This factor consisted of the item hereditary. The fourth fac-
tor labeled chance accounted for 6% of the variance and consisted of the item
chance or bad luck. Because the third and fourth factor included only one item,
no Cronbach’s alpha could be calculated. Therefore, these last two factors were ex-
cluded from further analysis. Higher scores on the first and second causal sub-
scales indicate stronger beliefs in those attributions in causing acromegaly. 
Quality of life questionnaires
Physical Symptoms Checklist (PSC): This is a checklist of 55 physical symptoms
that are mentioned in the DSM-III classification (16). The symptoms cover most
organ systems. There are 11 general/ neurological items, 10 autonomic items, 8
musculoskeletal/pain items, 13 gastrointestinal items, 5 genital items and 4 items
about feeling hot/cold. The presence of symptoms is rated on a severity scale from
0 to 3. We excluded the gender specific items (n=4) from the analyses to rule out
bias by gender. The total symptom score ranges from 0 to 153. A higher score in-
dicates more (severe) physical symptoms in the preceding week (17). 
EuroQoL-5D (EQ-5D): This QoL questionnaire measures five health dimensions;
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Scores are expressed on a 1-3 scale per dimension, with a higher score indicating
a worse QoL. The questionnaire also includes a visual analogue scale (VAS) which
comprises a standard vertical 20 cm scale (similar to a thermometer) for record-
ing an individual’s rating for their current health-related QoL state (18). On the
VAS, a higher score indicates a better QoL.
AcroQoL: This is a disease specific QoL questionnaire designed to assess QoL in
acromegaly (19). The AcroQoL consists of 22 questions on a five-point Likert scale.
The response choices are divided into frequency of occurrence (ranging from ‘al-
ways’ to ‘never’) and degree of agreement with the items (ranging from ‘com-
pletely agree’ to ‘completely disagree’). The total score ranges from 0-100, with a
lower score indicating a greater impact on health-related QoL. 
Six patients did not complete all QoL questionnaires. 
Reference populations
We obtained reference values in patients with acute and chronic pain from the
study that presented the revised version of the IPQ (9). The reference group with
acute pain consisted of 35 subjects who were recruited from a private practice for
physical therapy (20 men, 15 women, mean age of 36±12yr). These patients pre-
sented with a first-time peripheral painful injury that had been present for less
than 6wk. The reference group of patients with chronic pain consisted of 63 sub-
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jects (26 men and 37 women, with a mean age of 54±11yr) who were recruited
from hospital-based chronic pain clinics. All patients experienced pain for longer
than 3 months which was unexplained by medical signs alone. The reference
group of patients treated for Cushing’s syndrome was recruited from the Leiden
University Medical Center outpatient clinic and consisted of 52 patients (7 men,
45 women, mean age of 54±11yr). Patients had been treated by transsphenoidal
surgery, additional postoperative radiotherapy, or adrenal surgery. All patients
were in remission with a mean duration of 16yr. Forty six patients (88%) had pi-
tuitary ACTH-dependent hypercortisolism, and six (12%) had Cushing’s syn-
drome due to adrenal tumor. There were no significant differences between both
groups of patients in the answers on the IIPQ-R (20).  The fourth reference group
consisted of 171 Dutch patients (112 men and 59 women, mean age 66±10yr) suf-
fering from chronic obstructive pulmonary disease (COPD) (21). A chest physi-
cian had diagnosed all patients as suffering from emphysema and/or chronic
bronchitis. We chose the reference sample of patients with COPD because COPD
is a chronic illness and might therefore be comparable with respect to chronic
complications of acromegaly after long-term remission. The fifth reference group
consisted of 80 patients with vestibular schwannoma before treatment proposal
and treatment (36 men, 43 women, and one anonymous responder). Mean age
was 57yr (22). Thirty-eight percent of these patients suffered from an intra-
canalicular tumor. We included patients with vestibular schwannoma because
these patients have to cope with the knowledge that there is a benign tumor pres-
ent inside their head, which was also the case in patients with GH-secreting ade-
noma. 
Because illness perceptions assess the perceptions of a specific disease, there are no
norm values for the general population. Scores of patients with acute and chronic
pain may be used instead (22). 
Statistical analysis
Data were analyzed using PASW Statistics version 17.0.2 (SPSS Inc., Chicago, IL,
USA). All data were presented as mean ± standard deviations, unless mentioned
otherwise. Different treatment modalities of acromegaly were compared using an
ANOVA with a post hoc analysis when appropriate, whereas patients with and
without hypopituitarism were compared using a Student’s t-test. The possible ef-
fect of duration of follow-up was explored by linear regression analysis. The stan-
dardized β coefficients of this analysis were reported. The level of significance for
these analyses was set at P≤0.05. The primary analysis comprised the relationship
between illness perceptions and QoL. Partial correlations were calculated con-
trolling for duration of follow-up, and the level of significance was set at P≤0.05.
The comparison of patients with a relatively better QoL and patients with a worse
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QoL consisted of a Student’s t-test with the level of significance set at P≤0.01, be-
cause of multiple comparisons. 
Secondary analysis comprised the comparison of results in patients with long-
term remission of acromegaly and of results in various reference groups. Means
were calculated for all subscales of the IPQ and compared between groups using
Student’s t-test. Since multiple comparisons were used, the level of significance
was set at P≤0.01.
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Results
Sociodemographic and clinical characteristics 
All 81 patients had long-term biochemical control of acromegaly, with a duration
of follow-up of 16±10yr. Sixty-nine patients (85%) had been treated by transsphe-
noidal surgery and 19 patients (24%) by additional radiotherapy. Twenty-nine
patients (36%) were treated with somatostatin analogues, 8 patients (10%) with
pegvisomant, and 6 patients (7%) with dopamine agonists. Thirty patients (37%)
were treated for some degree of pituitary insufficiency (Table 1). Figure 1 shows
the self-reported symptoms of various organ systems. Most complaints involved
musculoskeletal pain. 
Illness perceptions in acromegaly as measured with the IPQ-R 
Illness identity dimension 
Table 2 shows that 17-25% of the patients suffered from weight gain, sweating,
back pain, snoring, and muscle pain, which they attributed solely to acromegaly.
In addition, stiffness of the joints was one of the symptoms of the general illness
identity dimension. This symptom was reported by 65% of the patients. 
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Table 1 Clinical characteristics 
 Acomegaly, n=81 
 
Gender (male/female) 47/34 
Age (yrs) 60 (12) 
Educational level (n) Low: 23 
Medium: 26  
High: 32 
Transsphenoidal surgery, n (%) 69 (85%) 
Somatostatin analogue therapy, n (%) 29 (36%) 
Pegvisomant therapy, n (%) 8 (10%) 
Dopamine agonist therapy, n (%) 6 (7%) 
Postoperative radiotherapy, n (%) 19 (24%) 
Duration of follow-up (yrs) 16 ± 10 
Hypopituitarism, n (%) Any axis: 30 (37%)  
GH: 12 (15%) 
ACTH: 21 (26%) 
LH/FSH: 15 (19%) 
TSH: 21 (26%) 
ADH: 3 (4%) 
Data are mean ± SD or number and %  
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Causal attributions dimension 
On the causal attributions dimension, patients during remission of acromegaly
reported psychological attributions as the main perceived cause of acromegaly.
Psychological attributions consist of stress or worries, family problems or wor-
ries, emotional state, mental attitude, own behavior, overwork, ageing, personal-
ity, altered immunity, and poor medical care as having caused acromegaly. Risk
factors were also reported, but less frequently. The causal attribution risk factors


































































Figure 1. Scores of patients after long-term remission of acromegaly on the various organ systems
measured by the PSC. The minimal score on each scale is zero, whereas the maximum score is three. 
Table 2 Symptoms related to acromegaly  
Symptoms Acromegaly, n=81 
Gaining weight 21 (25%) 
Sweating 19 (23%) 
Back pain 18 (21%) 
Snoring  17 (20%) 
Muscle pain  17 (20%) 
Hard time exercising  15 (18%) 
Tingling hands 11 (13%) 
Concentration problems  11 (13%) 
Dental problems 11 (13%) 
Memory impairment 8 (10%) 
Abdomen complaints  5 (6%) 
Data are n (%), symptoms commonly occurring in acromegaly of the ‘illness identity’ dimension of the 
IPQ-R 
Scores of patients with long-term remission of acromegaly on various organ systems  
Tiemensma hfd 3:Layout 1  23-01-2012  16:31  Pagina 52
or eating habits, and pollution in environment.
Illness perception dimensions
We divided the patients in three treatment groups: 1) biochemical control by sur-
gery, 2) biochemical control by surgery and radiotherapy and 3) biochemical con-
trol by primary or secondary medical treatment. Patients who received
postoperative radiotherapy perceived more negative consequences (P=0.037) and
had a worse personal understanding (P=0.041) compared with patients who had
been cured by surgery alone. Additionally, patients with and without hypopitu-
itarism were compared. Patients who were treated for some degree of pituitary in-
sufficiency perceived less treatment control than patients who were free of
pituitary insufficiency (P=0.034). 
In a linear regression model, duration of follow-up was associated with perceived
treatment control (β=-0.252, P=0.026) and personal understanding of the disease
(β=-0.279, P=0.013). 
Relationship between illness perceptions and QoL 
The scores of patients with acromegaly on the various QoL questionnaires are
shown in Table 3. There were no significant differences in QoL between the three
treatment groups. Levels of association between the IPQ-R dimensions and the
QoL scales are shown in Table 4 as partial correlations, controlled for duration of
follow-up. 
There was a very consistent pattern of correlations between QoL and illness per-
ceptions. A better QoL score was associated with better scores on the number of
complaints attributed to acromegaly, perceived chronicity and fluctuations of
acromegaly, perceived negative consequences, and the likelihood to seek medical
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Table 3 Quality of life in patients with acromegaly  
 N=75 
Physical Symptoms Checklist  
    Total Score 27.6 (18) 
EQ-5D  
     Mobility 1.4 (1) 
     Self-care 1.0 (0) 
     Activity 1.5 (1) 
     Pain 1.8 (1) 
     Anxiety 1.4 (1) 
     VAS 69.4 (15) 
AcroQoL  
     Total Score 67.5 (15) 
Data are mean (SD) 
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care. A better QoL score was also associated with better scores on perceived per-
sonal and treatment control, and personal understanding of the disease. 
Patients with low versus high scores on the various QoL questionnaires were com-
pared, using the median value to define low versus high. Patients with high scores
on the Physical Symptoms Checklist (indicating a more impaired QoL) attributed
more symptoms to acromegaly (P<0.001), perceived more fluctuations (P<0.001),
perceived more negative consequences (P=0.001), and were more likely to seek
medical care (P<0.001) than patients with lower (and thus better) scores on this
questionnaire. On the EQ-5D VAS, patients with a lower score (indicating a more
impaired QoL) perceived more negative consequences (P<0.001), and were more
likely to seek medical care (P<0.001) than patients with higher and better scores
on the VAS scale. Patients with a lower score on the AcroQoL (indicating a more
impaired acromegaly-specific QoL) attributed more symptoms to the acromegaly
(P=0.001), perceived more negative consequences (P<0.001), and were more likely
to seek medical care (P=0.001). 
Illness perceptions in acromegaly compared with reference groups 
Illness perceptions in patients after long-term cure of acromegaly compared
with patients with acute or chronic pain 
Compared with patients with acute pain, patients in remission of acromegaly per-
ceived more chronicity (P<0.0001), more negative consequences (P=0.007), were
less likely to seek medical care (P<0.0001), and perceived less personal control
(P<0.0001), but had a better personal understanding of the disease (P<0.0001). Ill-
ness perceptions of patients with acromegaly were also compared with patients
with chronic pain. Compared with those patients, patients with acromegaly were
less likely to seek medical care (P<0.0001), but attributed less symptoms to their
disease (P<0.0001), perceived less fluctuations (P<0.0001), perceived less negative
consequences (P<0.0001), perceived more treatment control (P<0.0001), and had
a better personal understanding of their disease (P<0.0001), see also Table 5 and
Figure 2. 
Illness perceptions in patients after long-term cure of acromegaly compared
with patients treated for Cushing’s syndrome 
Compared with patients in long-term remission of Cushing’s syndrome, patients
with long-term biochemical control of acromegaly were less likely to seek med-
ical care (P=0.001), but attributed less symptoms to their disease (P=0.007), per-
ceived less fluctuations (P=0.01), and less negative consequences (P=0.0001), see
also Table 5. 
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Illness perceptions in patients after long-term cure of acromegaly compared
with patients with COPD 
The illness perceptions of patients in long-term remission of acromegaly were also
compared with patients with COPD (Table 5). Patients with acromegaly perceived
less personal control (P<0.0001), but attributed less symptoms to their disease
(P<0.0001), perceived less chronicity (P<0.0001) and fluctuations (P<0.001), per-
ceived less negative consequences (P=0.0020), and perceived more treatment con-
trol (P<0.0001). 
Illness perceptions in patients after long-term cure of acromegaly compared
with patients with vestibular schwannoma 
Compared with patients suffering from a vestibular schwannoma, patients with
acromegaly perceived more chronicity (P=0.005), were less likely to seek med-
ical care (P<0.0001), and perceived less personal control (P=0.006), see also Table
5.





































































Figure 2. Scores on the IPQ-R of patients after long-term remission of acromegaly, and patients
with acute or chronic pain.
Distribution of IPQ-R scores of patients with long-term remission of acromegaly, patients with
acute pain, and patients with chronic pain
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Discussion
This is the first study that describes illness perceptions in patients with
acromegaly. In general, patients with long-term remission of acromegaly have a
good understanding of their disease, but they experience a lack of personal con-
trol and are not very likely to seek medical care. Interestingly, there are clear dif-
ferences between illness perceptions in acromegaly and other diseases. For
example, acromegalic patients reported more negative illness perceptions than
patients with acute pain or vestibular schwannoma, but more positive illness per-
ceptions than patients with chronic conditions, like COPD. In addition, patients
in long-term remission of acromegaly reported somewhat more positive illness
perceptions than patients after long-term remission of Cushing’s syndrome. Pa-
tients with long-term remission of acromegaly perceive impaired QoL. The ill-
ness perceptions in patients with acromegaly correlated strongly with QoL
parameters, in accordance with observations in other conditions (23).  
Treatment control and personal understanding of the disease were worse in pa-
tients after a longer duration of follow-up. We speculate that patients after longer
duration of follow-up have less desire to have personal control over their
acromegaly compared with patients with a shorter duration of follow-up. It might
also be that longer follow-up of acromegaly indicated (at least for the patient) that
acromegaly is a severe and chronic illness, which leads to less treatment control
since patients feel the treatment they received did not cure acromegaly and also
leads to less personal understanding since the doctors can not cure acromegaly
and/or its (long-term) symptoms.
Illness perceptions in endocrine diseases have not been frequently studied. We
documented some differences in illness perceptions between the various treat-
ment groups of acromegalic patients. Moreover, there were also differences be-
tween patients with Cushing’s syndrome and acromegaly. It is tempting to
speculate that there are disease-specific characteristics in illness perceptions in
addition to more general influences related to complaints or chronicity. Addi-
tional research is needed to see whether these findings can be extended to other
endocrine diseases. 
The reference groups all have their limitations since they differ considerably from
acromegaly, but we believe that it is important to explore the illness perceptions
of patients with acromegaly in reference to other illnesses since there are no data
available on other hormonal illnesses. In addition, the essence of illness percep-
tion research is the perspective of the patient, independent of the medical objec-
tive of symptoms. A recent study by Figueiras and Alves (24) reported on
perceptions of healthy people of serious illness with a new version of the IPQ-R
for healthy people. With this questionnaire, the authors measured perceptions of
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AIDS, tuberculosis, and skin cancer in a sample of 1113 healthy Portuguese sub-
jects. The wording in the questionnaire was adapted for healthy individuals, i.e.
‘this illness’ instead of ‘my illness’. AIDS, tuberculosis, and skin cancer are well-
known illnesses and healthy individuals already have a common sense model of
this illness, independent of the direct experience with this illness. However,
acromegaly is a rare and not well-known disease. It is therefore not possible to ask
a sample of healthy individuals about their illness perceptions concerning
acromegaly without giving them information about the etiology, symptoms, and
treatment of acromegaly beforehand. The provision of information about a rare
and unknown disease would guide the illness perceptions in a certain direction,
which in turn affects the reliability of the questionnaire. Therefore, we decided
not to incorporate a group of healthy controls in the current study.
The illness perceptions of patients are based on various sources, which indicates
that illness perceptions do not necessarily represent the actual medical status of
the disease. This could explain, for example, why patients in long-term remission
of acromegaly believe that a psychological attribution might have caused
acromegaly. Psychological attribution consists of several causes i.e. stress or wor-
ries, family problems or worries, emotional state, mental attitude, own behavior,
overwork, ageing, personality, altered immunity, and poor medical care. It is im-
portant for endocrinologists to explain to the patient what might have caused
acromegaly, and ask the patient what their perceived cause of acromegaly is. 
The current explorative study showed that there is a strong relationship between
illness perceptions and QoL. More affected illness perceptions are correlated with
more impaired QoL parameters. This has also been observed in patients after treat-
ment for Cushing’s syndrome (20) and in patients with various other diseases (23).
This is a relevant observation, since patients with acromegaly suffer from im-
paired QoL even after long-term remission (2;25;26). The somatic and psycho-
logical factors that contribute to decreased QoL are not well-known, but most
likely include  musculoskeletal complaints (2), pituitary insufficiency (27;28) and
the perception of the patients of their disease. A recent study (3) showed that pa-
tients with acromegaly use ineffective coping strategies. Additional research is
necessary to establish whether, and to which extent, these illness perceptions and
ineffective coping strategies can be improved which, in turn, might improve QoL.
A possible limitation of the present study is the fact that only 52% of the initially
invited patients participated. We cannot exclude the possibility that the most dis-
tressed patients were more likely to participate, which might skew the results.
However, this is an explorative study aiming to investigate illness perceptions in
patients after long-term remission of acromegaly. We believe that the present re-
sults give a good first overview of how patients perceive acromegaly. Another
limitation might be the fact that the reference samples differ in age distribution.
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To date, it is unclear whether illness perceptions change with age. Although sev-
eral determinants theoretically could contribute to our observations in these pa-
tients, a detailed analysis of each of these factors is not reliable considering the
relatively small group of acromegaly patients. Future studies examining the dif-
ferences in illness perceptions between patients with various (endocrine) disorders
in larger samples should consider correcting for possible confounders like age.
In summary, in patients with long-term remission of acromegaly, illness percep-
tions are affected and correlate strongly with impaired QoL. Patients reported
more negative illness perceptions than patients with acute illness, but more pos-
itive illness perceptions than patients with chronic diseases. We propose that a tar-
geted self-management intervention might help in improving ineffective coping
strategies and affected illness perceptions, and thereby improve QoL, at least in
part, in patients with long-term remission of acromegaly. 
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Abstract
Context and objective: Coping strategies may affect quality of life (QoL), which is
decreased in patients after treatment for Cushing’s disease, acromegaly, or non-
functioning pituitary macroadenomas (NFMA). We aimed to explore coping
strategies in these patients because this has never been done before. 
Design: This was a cross-sectional study. 
Subjects: We included patients treated for Cushing’s disease (n=42), for
acromegaly (n=80), and for NFMA (n=61). These patients were compared with
three reference populations: an a-select sample from the Dutch population
(n=712), patients with chronic pain (n=59), and patients receiving primary care
psychology services (n=525). Furthermore, the three patient groups were com-
pared with each other. Coping strategies were assessed by the Utrecht Coping
List. 
Results: Compared with the a-select sample, patients with pituitary adenomas re-
ported less active coping (P<0.0001), sought less social support (P<0.0001), and
reported more avoidant coping (P=0.008). In contrast, patients treated for pituitary
adenomas reported somewhat better coping strategies than patients with chronic
pain and those with psychological disease. When patients with different pituitary
adenomas were compared, patients treated for Cushing’s disease sought more so-
cial support than patients treated for NFMA (P=0.035). 
Conclusions: Patients treated for pituitary adenomas display different and less ef-
fective coping strategies compared with healthy controls. A targeted intervention
might help to stimulate patients to use a more active coping strategy and to seek
social support, instead of an avoiding coping strategy. This might, in turn, im-
prove their QoL. 
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Introduction
Pituitary adenomas may result in considerable, chronic comorbidity. Hormone
overproduction results in classical syndromes like Cushing’s disease and
acromegaly. Mass effects of the tumor, especially in non-functioning pituitary
macroadenoma (NFMA) result in visual field defects and hypopituitarism.
Transsphenoidal surgery is an effective therapy for control of tumor mass and
hormone overproduction in the majority of patients. If necessary, additional treat-
ment with medical treatment or incidentally radiotherapy is available. Patients
treated for Cushing’s disease, acromegaly, and NFMA have persistently impaired
quality of life (QoL) despite long-term cure (1-3). The factors causing reduced
QoL in those patients with pituitary adenomas have not been fully elucidated. 
Coping is the way in which someone reacts (behaviorally, cognitively, and emo-
tionally) to situations that require adjustments in dealing with an adverse event
and/or its consequences, for example an illness and its treatment (4). The common
sense model (CSM) of illness cognition conceptualizes the processes involved in
the adaption to threats imposed by illness. According to this CSM, coping strate-
gies are determinants of medical outcomes (5). Furthermore, it is thought that
coping may affect QoL (6). 
At present, there are no studies that report coping strategies in patients with
treated Cushing’s disease, acromegaly or NFMA. Therefore, we aimed to examine
the coping strategies of patients after treatment for pituitary adenomas in com-
parison with reference groups. 
Patients and Methods
Design
We conducted a cross-sectional study in which patients treated for pituitary ade-
nomas were invited to fill out a questionnaire on coping strategies.
Inclusion criteria were age over 18yr and treatment for pituitary adenoma at least
1yr ago. The protocol was approved by the institutional Medical Ethics Commit-
tee.  
Patients
Patients with treated pituitary adenomas were invited to participate in the current
study. These patients suffered from Cushing’s disease, acromegaly, or NFMA. Pa-
tients were asked to complete a questionnaire on coping strategies at home and re-
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turn this questionnaire in a prepaid envelope. Overall, the clinical characteristics
of the non-participants did not differ from those of the participants. 
Cushing’s disease: A clinical chart review of 51 patients who had been treated
by transsphenoidal surgery, if necessary followed by repeated surgery and/or post-
operative radiotherapy was performed. We selected these patients based on their
participation in an earlier study on psychopathology and personality traits (7).
Nine patients (18%) refused to participate for several reasons including old age,
and/or debilitating disease. Forty-two patients (82%) participated in the current
study and completed the questionnaire. 
Acromegaly: A clinical chart review of 156 patients who had been treated for
acromegaly was performed. Fifty six patients (36%) refused to participate and an
additional 20 patients (13%) did not (completely) fill out the measure used to as-
sess coping (see below). Eighty patients (51%) participated in the current study
and completed all questionnaires. 
NFMA: A clinical chart review of 100 patients treated for NFMA was performed.
Twenty five patients (25%) refused to participate and 14 patients (14%) did not
(completely) fill out the measure used to assess coping (see below). Sixty one pa-
tients (61%) participated in the current study and completed all questionnaires. 
Treatment and follow-up
Cushing’s disease  
Cushing’s disease had been diagnosed based on internationally agreed guidelines,
i.e. the clinical manifestations and positive biochemical tests including increased
urinary excretion rates of free cortisol, decreased overnight suppression by dex-
amethasone (1mg) and, since 2004, elevated midnight salivary cortisol values, in
addition to non-suppressed ACTH levels. All patients had been treated by
transsphenoidal surgery, if necessary followed by repeated surgery and/or post-
operative radiotherapy. Cure of Cushing’s disease was defined by normal
overnight suppression of plasma cortisol levels (<50nmol/l) after administration of
dexamethasone (1mg) and normal 24h urinary excretion rates of cortisol
(<220nmol/24h). Hydrocortisone independency was defined as a normal cortisol
response to CRH or insulin-tolerance test (ITT). At the time of the current study,
all patients were in remission of Cushing’s disease.
Acromegaly
The diagnosis of acromegaly had been established by clinical signs and symptoms
and by biochemical tests, including insufficient suppression of GH during glucose
tolerance test and increased IGF-1 levels for age. Cure of acromegaly was defined
by normal serum IGF-1 levels for age and serum GH levels below 1.9µg/l for all
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patients and, in patients without somatostatin analogue treatment, also by normal
suppression of GH levels (<0.38 mcg/l) during glucose tolerance test (8). Remission
was confirmed by repeating the tests at yearly intervals. At the time of the cur-
rent study, all patients were in remission or biochemically controlled. The bio-
chemically controlled patients all had a IGF-I concentration in the normal range
for age.
Non-functioning pituitary adenomas
After surgical treatment for NFMA, which was histopathologically confirmed,
NFMA patients were included. Surgical treatment was performed in case of visual
field defects in the majority of patients. Postoperatively, MRI scans were per-
formed to detect tumor recurrence or regrowth. In case of progression, patients
were referred for radiotherapy or an expectative management was chosen. At the
time of the current study, all patients were free of recurrence of NFMA.
Follow-up
Patients were followed at our outpatient department. Patients were monitored
for (recurrence of) disease, according to appropriate dynamic tests in patients with
functioning adenoma and MRI scans in patients with non-functioning adenoma.
In all patients, pituitary function was monitored and pituitary hormone replace-
ment was prescribed dependent on the results of the yearly evaluation of pitu-
itary functions. In case of corticotrope insufficiency, confirmed by
insulin-tolerance test or CRH test, the average dose of hydrocortisone was 20mg/d
divided into 2 to 3 dosages. Evaluation of GH deficiency was performed by in-
sulin-tolerance test and/or GHRH-arginine test, only in patients under the age of
70yr and only after at least 2yrof remission. Somatotrope insufficiency was treated
with recombinant human GH replacement, aiming at a IGF-I concentration in
the normal range for age. In acromegaly, patients were treated with GH from 2005
onwards during a controlled trial of recombinant human GH replacement (9). In
addition, free T4 and testosterone levels (in male patients) were assessed. If re-
sults were below the lower limit of the respective reference ranges, substitution
with L- T4 and/or testosterone was prescribed. In the case of amenorrhea and low
estradiol levels in premenopausal women, estrogen replacement was provided. 
Utrecht Coping List (UCL)
The UCL is an established Dutch coping scale with well-documented reliability
and validity (10). Although its validity has not been tested for pituitary patients,
the scores on the UCL in various medical samples have been reported in the in-
ternational medical literature (6;11-13). The UCL consists of 47 statements where
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the patients indicate whether they find these applicable to themselves. A four-
point scale was used, ranging from seldom or never to very often. The statements
lead to seven subscales: active coping (score ranging from 7-28), seeking distrac-
tion (score ranging from 8-32), avoiding (score ranging from 8-32), seeking social
support (score ranging from 6-24), passive coping (score ranging from 7-28), ex-
pressing emotions (score ranging from 3-12), and fostering reassuring thoughts
(score ranging from 5-20). 
The subscale active coping refers to the ability to disentangle the situation and
purposefully working to solve the problem. Seeking distraction refers to seeking
distraction not to have to think regarding the problem and trying to feel better by
smoking, drinking, or relaxation. Avoiding refers to leaving the problem for what
it is or running away from it. Seeking social support refers to seeking social sup-
port for comfort and understanding or asking for help. Passive coping refers to
being completely overwhelmed by the problem, a negative view and worrying
about the past. Expressing emotions refers to the ability to show irritation or
anger. Fostering reassuring thoughts refers to optimism (4). 
Dutch population norms are available for nurses and women from the general
population aged 18-65 years (4), as well as for chronic pain patients (10), and pa-
tients receiving primary care psychology services (14).
Reference populations
The a-select sample consisted of 712 women from two groups; the first group con-
sisted of nurses with a mean age 30yr, while the second group was a random se-
lection from the Dutch population with a mean age 47yr (4;14). 
The chronic pain reference group consisted of 59 Dutch patients. This sample con-
sists of 44 women and 15 men with a mean age of 64±6yr. Patients who reported
pain in the hip or knee in the last month on three separate occasions during the
study were classified as chronic pain patients. 
The group of patients receiving primary care psychology services consisted of 525
Dutch patients who were in psychotherapy during the time of study. The group
incorporated 329 women and 196 men, with a mean age of 37±12yr. Most patients
were referred to a primary care psychologist by their general practitioner (37%)
or self-referral (23%). All patients suffered from DSM-IV Axis-1 diagnosis, and an
additional 68% also suffered from a DSM-IV Axis-2 personality disorder (14). 
Statistical analysis
Data were analyzed using PASW Statistics version 17.0.2 (SPSS Inc., Chicago, IL,
USA). All data were presented as mean ± standard deviations, unless mentioned
otherwise. The primary analysis comprised the comparison of the results in pa-
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tients who were treated for pituitary adenoma and of results in various reference
groups. Means were calculated for all subscales of the UCL and compared between
groups using Student’s t-test. The level of significance for this analysis was set at
P≤0.01, because multiple comparisons were performed. The secondary analysis
comprised the comparison of results between patients treated for Cushing’s dis-
ease, patients treated for acromegaly, and patients treated for NFMA. A general
linear model was used to compare the UCL scores,with surgery, postoperative ad-
ditional radiotherapy, and hypopituitarism as fixed factors. A post hoc analysis
with a Bonferroni correction was performed in case of significant differences. The
level of significance for this analysis was set at P≤0.05. 
Results
Sociodemographic and clinical characteristics 
Patients after treatment for Cushing’s disease
Clinical characteristics of the patients are detailed in Table 1. All patients with
Cushing’s disease had been treated by transsphenoidal surgery, and nine patients
(21%) had received additional radiotherapy because of persistent disease after sur-
gery. At the time of the current study, all patients were in remission, with a mean
duration of follow-up after cure of 13±10yr, and 27 patients (64%) were treated
for some degree of pituitary insufficiency. 
Patients after treatment of acromegaly
The clinical characteristics of patients after treatment for acromegaly are detailed
in Table 1. Most of the patients (84%) had been treated by transsphenoidal sur-
gery and 18 patients (23%) had been treated by additional radiotherapy because
of persistent disease after surgery. Twenty eight patients (35%) were treated by so-
matostatin analogs, nine patients (10%) received pegvisomant therapy, and six
patients (8%) received dopamine-agonist therapy. All patients were in remission
or biochemically controlled at the time of study. The mean duration of follow-
up was 16±10yr. At the time of the current study, 30 patients (38%) required treat-
ment for pituitary insufficiency. Since not all patients were surgically cured,
possible differences between surgically cured patients, patients receiving surgery
and additional radiotherapy, and patients receiving chronic injections were ana-
lyzed using a one-way ANOVA with a post hoc Bonferroni correction. However,
there were no significant differences in coping strategies between these groups. 
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Patients after treatment of NFMA
The clinical characteristics of patients after treatment for NFMA are detailed in
Table 1. All patients had been treated by transsphenoidal surgery and 28 patients
(46%) underwent additional radiotherapy because of persistent disease after sur-
gery. At the time of the current study, all patients were free of recurrence of
NFMA, with a mean duration of follow-up of 16±10yr, and all patients were
treated for some degree of pituitary insufficiency. 
Coping strategies in patients after treatment for pituitary adenomas 
Coping strategies in patients after treatment for pituitary adenomas compared
with an a-select sample from the Dutch population 
Patients treated for pituitary adenomas had significantly lower scores on active
coping and seeking social support, and higher scores on the avoiding scale com-
pared with an a-select sample from the Dutch population. 
A lower score on active coping (P<0.0001) indicates that patients with pituitary
adenomas performed worse when it came to disentangling the situation and pur-
posefully working to solve the problem. A lower score on seeking social support
(P<0.0001) suggests that patients with pituitary adenomas sought less comfort and
understanding from others and therefore probably received less social support.
The higher score on avoiding (P=0.008) indicates that they left the problem to
what is was or ran away from it. 
Figure 1 shows the scores of the patients with treated pituitary disease and the ref-
erence groups on the UCL, whereas Figure 2 shows how many patients scored in
the most maladaptive percentile: 95th or higher percentile for avoiding and passive
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Table 1  Clinical characteristics  






Gender (male/female) 6/36 45/35 31/30 
Age in years  54 (12) 60 (12) 63 (12) 









Transsphenoidal surgery (%) 42 (100%) 67 (84%) 61 (100%) 
Additional radiotherapy (%) 9 (21%) 18 (23%) 28 (46%) 
Somatostatin analogue therapy, 
n (%) 
NA 28 (35%) NA 
Pegvisomant therapy, n (%) NA 9 (10%) NA 
Dopa agonist therapy, n (%) NA 6 (8%) NA 
Duration of follow-up (yrs) 13 (10) 16 (10) 16 (10) 
Hypopituitarism (%) Any axis: 27 (64%) 
GH: 19 (45%) 
LH/FSH: 12 (29%) 
TSH: 17 (41%) 
ACTH: 24 (57%) 
Any axis: 30 (38%) 
GH: 12 (15%) 
LH/FSH: 15 (19%) 
TSH: 21 (26%) 
ACTH: 21 (26%) 
Any axis: 61 (100%) 
GH: 46 (75%) 
LH/FSH: 54 (89%) 
TSH: 46 (75%) 
ACTH: 47 (77%) 
Data are mean (SD) unless otherwise stated; NA, not applicable  
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coping, and 5th or lower percentile for active coping, seeking distraction, seeking
social support, expressing emotions, and fostering reassuring thoughts (4). 
Coping strategies in patients after treatment for pituitary adenomas compared
with other diseases 
Coping strategies of patients with pituitary adenomas were compared with pa-
tients who suffered from chronic pain. The latter patient group reported pain in
the hip or knee in the last month on three separate occasions. Compared with
these patients, patients with treated pituitary adenomas scored higher on seeking
social support (P<0.0001), indicating that patients with treated pituitary adenomas
sought more comfort and understanding from others and therefore probably re-
ceived more social support.
Coping strategies of patients with pituitary adenomas were also compared with the
group of patients receiving primary care psychology services. All patients suffered


























Figure 1: Distribution of scores of patients with long-term cure of pituitary adenomas and the refe-
rence groups. Means are displayed in this figure. The coping strategies Avoiding and Passive coping
are negative strategies, which means that a higher score indicates a more maladaptive coping stra-
tegy. The coping strategies Active coping, Seeking distraction, Seeking social support, Expressing
emotions, and Fostering reassuring thoughts are positive strategies, which means that lower scores
indicate a more maladaptive coping strategy. 
Distribution of scores of patients treated pituitary adenomas and the reference groups  
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from a DSM-IV Axis-1 diagnosis, and an additional 68% also suffered from a DSM-
IV Axis-2 personality disorder. Patients with pituitary adenomas scored lower on
avoiding, seeking social support, passive coping, and expressing emotions. 
A lower score on the coping strategy avoiding (P<0.0001) indicates that patients
with pituitary adenomas were less intended to leave the problem to what it was.
Lower scores on seeking social support (P<0.0001) suggest that patients with pi-
tuitary adenomas sought less comfort and understanding from others and there-
fore probably received less social support. Furthermore, a lower score on passive
coping (P<0.0001) suggests that these patients were less overwhelmed by the prob-
lem. A lower score on expressing emotions (P<0.0001) suggests that patients with
pituitary adenomas were less able to show irritation or anger compared with pa-
tients in primary care psychology services.
Patients with pituitary adenomas scored higher on active coping (P=0.0005) com-
pared with patients receiving primary care psychology services, which indicates
that patients with pituitary adenomas work better at disentangling the situation






















Figure 2: Distribution of how many patients scored in the most maladaptive percentile based on the
scores of an a-select sample from the Dutch population. ≥95th percentile for Avoiding and Passive
coping, ≤5th percentile for Active coping, Seeking distraction, Seeking social support, Expressing
emotions, and Fostering reassuring thoughts were used. Percentages are displayed in this figure. 
Distribution of UCL scores in the most maladaptive (<5th or >95th) percentile of patients with tre-
ated Cushing’s disease, acromegaly, or NFMA 
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Comparison of coping strategies in patients with Cushing’s disease, acromegaly,
and NFMA
Because sociodemographic characteristics do not influence coping strategies (14),
we corrected only for surgery, additional radiotherapy, and hypopituitarism in
comparing the patient groups. When the patient groups were compared, just one
significant difference was found in coping strategies. When performing a post hoc
analysis, patients with NFMA appeared to seek less social support compared with
patients with Cushing’s disease (P=0.035). 
In addition, possible differences between short-term (<10yr) and long-term fol-
low-up (≥10yr) in these pituitary patients were analyzed, correcting for diagno-
sis (i.e. Cushing’s disease, acromegaly, or NFMA). In the short term follow-up
group, there were 67 (27 males) patients (age 56±13yr) versus 116 (56 males) pa-
tients (age 61±12yr) in the long-term follow-up group. There was no significant
difference in gender distribution. Age, however, differed between these two
groups, with the long-term follow-up group being slightly older. Nonetheless,
there were no significant differences in coping between these two groups. This
suggests that the duration of follow-up does not influence coping strategies. 
Furthermore, patients who had been treated by transsphenoidal surgery were
compared with patients who had been treated by transsphenoidal surgery and ad-
ditional radiotherapy, correcting for diagnosis (i.e. Cushing’s disease, acromegaly,
or NFMA). The group of patients who had been treated by surgery consisted of
116 subjects (52 males, age 58±13yr), and the group of patients receiving surgery
and radiotherapy consisted of 54 subjects (23 males, age 63±12yr). Thirteen pa-
tients (all with acromegaly) were excluded from this comparison, since they had
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Active coping 17.6 (4) 19 (5)** 16.4 (4) 16.5 (4)** 
Seeking distraction 17.1 (4) 17 (6) 16.8 (4) 17.7 (4) 
Avoiding 15.9 (3) 15 (6)* 16.0 (3) 17.1 (4)** 
Seeking social support 12.2 (4) 15 (5)** 10.2 (3)** 13.5 (4)** 
Passive coping 11.0 (3) 11 (5) 11.7 (4) 15.3 (4)** 
Expressing emotions 5.7 (2) 6 (2) 5.3 (2) 6.3 (2)** 
Fostering reassuring 
thoughts 
12.1 (3) 12 (4) 13.3 (3) 11.6 (3) 
Data are mean (SD), * p<0.01 compared with pituitary patients, ** p<0.001 compared with pituitary patients  
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not been treated by surgery. There were no significant differences in coping
strategies between patients treated by surgery only and by both surgery and ra-
diotherapy. This indicates that the addition of radiotherapy does not influence
coping strategies in our cohort of patients.
Lastly, we also compared coping strategies between patients with hypopituitarism
(i.e. insufficiency of at least one pituitary axis) and without hypopituitarism, cor-
recting for diagnosis (i.e. Cushing’s disease, acromegaly, or NFMA). There were
118 patients (52 males, age 58±13yr) with hypopituitarism and 65 patients (31
males, age 60±12yr) without hypopituitarism. There were no significant differ-
ences in coping strategies between these patient groups. This indicates that hy-
popituitarism also does not affect coping strategies. 
Discussion
This explorative study demonstrates that patients after treatment for pituitary
adenomas report less active coping and more avoidance coping and seek less so-
cial support compared with an a-select sample from the Dutch population. Com-
pared with patients with chronic pain, patients treated for pituitary adenomas
sought more social support. Patients after treatment for pituitary disease were also
compared with patients in primary care psychology services. Patients with pitu-
itary adenomas scored lower on avoiding, seeking social support, passive coping,
and expressing emotions, but higher on active coping. This indicates that patients
treated for pituitary adenomas report less effective coping strategies compared
with the normal population, but apparently use more effective coping strategies
than patients with chronic pain and patients in primary care psychology services.
Furthermore, patients after treatment for Cushing’s disease, acromegaly, and
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Active coping 17.5 (3) 17.4 (4) 18.0 (3) 0.727 
Seeking distraction 17.7 (3) 16.9 (4) 17.1 (4) 0.896 
Avoiding 16.3 (3) 15.5 (4) 16.2 (3.1) 0.546 
Seeking social support 13.3 (4) 12.1 (4) 11.4 (3) 0.016* 
Passive coping 12.0 (3) 10.5 (3) 10.8 (3) 0.730 
Expressing emotions 5.9 (2) 5.6 (2) 5.7 (2) 0.760 
Fostering reassuring 
thoughts 
12.3 (3) 12.1 (3) 12.1 (3) 0.664 
Data are mean (SD), * Post Hoc Bonferroni analysis revealed a significant difference between Cushing’s disease and NFMA (p=0.035) 
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NFMA did not differ from each other with respect to coping strategies, besides the
fact that patients with Cushing’s disease sought more social support than patients
treated for NFMA. This is an interesting difference that might be due to more se-
vere long-term effects of Cushing’s disease compared with NFMA. Patients after
long-term remission of Cushing’s disease suffer from subtle cognitive impairments,
increased prevalence of psychopathology and an increased incidence of maladap-
tive personality traits (7, 17). These impairments could be invalidating in every-
day life, which in turn could lead to a higher need for social support.
This is the first study that explored coping strategies in patients treated for Cush-
ing’s disease, acromegaly, or NFMA. There are, however, two previous studies by
one research group that reported coping strategies in small groups of patients
(Cushing’s disease n=18, acromegaly n=17) during or less than 1yr after treatment
in a developing country (15;16). However, it is not clear whether patients report
different coping strategies compared with controls and whether the coping strate-
gies reported by the patients are negative or positive. 
The present study explored coping strategies in patients treated for Cushing’s dis-
ease, acromegaly, or NFMA. We believe this is valuable information, since these
are chronic diseases with multiple invalidations after cure (1-3;7;17-21), which
are often misunderstood and difficult to treat. Following successful treatment of
hypercortisolism in Cushing’s disease, signs and symptoms of the disease disap-
pear. However, a large number of studies in humans and animal models have doc-
umented that prolonged, increased endogenous or exogenous exposure to
glucocorticoids may have long-lasting adverse effects on behavior and cognition,
due to functional and structural alterations in specific brain target areas
(7;17;22;23). Furthermore, in acromegaly, many of the systemic changes induced
by previous excess of GH and/or IGF-I are not completely reversed upon suc-
cessful biochemical treatment of active acromegaly (20), which may also be true
for the effects of GH and/or IGF-1 on the central nervous system (24). Patients
after treatment for Cushing’s disease, acromegaly, or NFMA suffer from persist-
ently impaired QoL (1-3). Knowledge on coping strategies used by these patients
is of importance, since this information can be used in designing an intervention
based on, for example cognitive behavioural therapy, self-management training,
and information on the negative effects of the disease. We speculate that, with a
targeted intervention, patients could be taught self-management skills and be bet-
ter informed about the consequences of their disease. We believe that this might
lead to an improved QoL. Such self-management and educational interventions
are already offered to, for example, patients with inflammatory bowel disease (24)
and patients after stroke (25). 
A possible limitation of this study might be the fact that the most distressed sub-
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jects may be more likely participate, which is known as the concept of sympto-
matic volunteers. This should be kept in mind when interpreting the conclusions
of this study. However, conversely, it might also be possible that patients who
feel worse are less likely to participate. It is difficult to assess this issue in detail.
Nonetheless, there we no differences in clinical characteristics between patients
who participated and those who decided not to participate in the current study.
In addition, the differences found between pituitary patients and the reference
groups were very large and there is, at least in this cohort of patients, an obvious
need for a self-management intervention. 
In summary, patients treated for Cushing’s disease, acromegaly, or NFMA display
different and less effective coping strategies compared with healthy controls.
Compared with patients with chronic pain and patients receiving primary care
psychology services, patients treated for pituitary adenomas report somewhat bet-
ter coping strategies. These results strongly point towards the need to develop, to
apply and to evaluate coping skills training and self-management in patients with
this condition.
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Abstract
Context and Objective: Active Cushing’s disease is associated with cognitive im-
pairments. We hypothesized that previous hypercortisolism in patients with
Cushing’s disease results in irreversible impairments in cognitive functioning.
Therefore, our aim was to assess cognitive functioning after long-term cure of
Cushing’s disease.
Design: Cognitive assessment consisted of 11 tests, which evaluated global cogni-
tive functioning, memory, and executive functioning.
Patients and Controls: We included 74 patients cured of Cushing’s disease and 74
controls matched for age, gender, and education. Furthermore, we included 54
patients previously treated for nonfunctioning pituitary macroadenomas (NFMA)
and 54 controls matched for age, gender, and education.
Results: Compared with NFMA patients, patients cured from Cushing’s disease
had lower scores on the Mini Mental State Examination (P=0.001), and on the
memory quotient of the Wechsler Memory Scale (P=0.050). Furthermore, patients
cured from Cushing’s disease tended to recall fewer words on the imprinting
(P=0.013), immediate recall (P=0.012), and delayed recall (P=0.003) trials of the
Verbal Learning Test of Rey. On the Rey Complex Figure Test, patients cured
from Cushing’s disease had lower scores on both trials (P=0.002 and P= 0.007)
compared with NFMA patients. Patients cured from Cushing’s disease also made
fewer correct substitutions on the Letter-Digit Substitution Test (P=0.039) and
came up with fewer correct patterns on the Figure Fluency Test (P=0.003) com-
pared with treated NFMA patients.
Conclusions: Cognitive function, reflecting memory and executive functions, is
impaired in patients despite long-term cure of Cushing’s disease. These observa-
tions indicate irreversible effects of previous hypercortisolism on cognitive func-
tion and, thus, on the central nervous system. These observations may also be of
relevance for patients treated with high-dose exogenous glucocorticoids.
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Introduction
Cushing’s disease is characterized by excessive exposure to cortisol. Despite cur-
ative treatment, cardiovascular morbidity and mortality remain increased in these
patients (1, 2). In addition, despite long-term cure of Cushing’s disease, these pa-
tients have persistent physical and psychological complaints, associated with de-
creased quality of life parameters (3).
Patients with active Cushing’s disease and Cushing’s syndrome have cognitive im-
pairments, especially in the memory domain. Previous studies reported impair-
ments in memory, visual and spatial information, reasoning, verbal learning, and
language performance (4 –10). Structures important in cognitive functioning, like
the hippocampus and cerebral cortex, are rich in glucocorticoid receptors and are
therefore particularly vulnerable to the glucocorticoid excess present in Cushing’s
disease (7). Starkman et al. (11) reported that 27% of the patients with active Cush-
ing’s syndrome fell outside the 95% confidence intervals for normal subject hip-
pocampal formation volume and that hippocampal formation volume and
performance on cognitive tests were positively related. In accordance, many other
studies in humans and animal models have documented that prolonged, increased
endogenous or exogenous exposure to glucocorticoids may have long-lasting ad-
verse effects on behavioral, psychiatric, and cognitive functions, due to functional
and, over time, structural alterations in specific brain target areas including the
hippocampus (11–16). After treatment, all patients in the study by Starkman et al.
(17) showed an increase in hippocampal formation volume, and half of the pa-
tients also showed an increase in cognitive function test scores. In contrast, other
studies found no improvements in cognitive functioning within 1yr after treat-
ment (18, 19). Some studies reported impaired cognitive functioning in patients
with treated Cushing’s disease (6, 18–20). However, these studies included only
small numbers of subjects (n=35), and patients were tested relatively shortly (i.e.
within the first 12–18 months) after cure of Cushing’s disease. Therefore, it is
presently unclear to which extent impairments in cognitive functioning remain
present in patients with much longer duration of cure of Cushing’s disease.
We hypothesized that previous hypercortisolism in patients with Cushing’s dis-
ease results in irreversible impairments in cognitive functioning. Therefore, we
evaluated cognitive functioning in patients after long-term cure for Cushing’s dis-
ease and compared these data with those of age- and sex-matched controls as well
as with those of patients treated for nonfunctioning pituitary macroadenomas
(NFMA) and matched controls.
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Subjects and Methods
Subjects
We included four groups of subjects: 1) patients cured from Cushing’s disease and
2) gender-, age-, and education-matched control subjects and 3) patients previ-
ously treated for NFMA and 4) gender-, age-, and education-matched control sub-
jects. The inclusion of these additional control groups was necessary because
patients with Cushing’s disease and NFMA differ with regard to age and gender.
We invited all patients in remission after treatment for Cushing’s disease in our
institution to participate (n=153). Each patient was asked to provide a control per-
son of comparable age, gender, and education. Patients and their controls were
evaluated at the same time. Patients who did not respond were encouraged by
phone to participate. The response rate was 93%. Eighty-five patients were will-
ing to participate, of whom 74 patients actually participated in all cognitive tests.
Fifty-seven patients preferred not to participate, whereas 11 patients did not re-
spond. The characteristics of patients who participated in the tests and those who
did not participate were carefully compared. There were no differences in clinical
characteristics between both groups. Reasons for not participating were distance to
our institution, participation in other studies, old age, and debilitating disease.
The diagnosis of Cushing’s disease had been established by clinical signs and symp-
toms and by biochemical tests including increased urinary excretion rates of free
cortisol, decreased overnight suppression by dexamethasone (1mg) and, since
2004, elevated midnight salivary cortisol values in addition to suppressed ACTH
levels. All patients were treated by Transsphenoidal surgery, if necessary followed
by repeat surgery and/or radiotherapy. Cure of Cushing’s disease was defined by
normal overnight suppression of plasma cortisol levels (<100nmol/l) after admin-
istration of dexamethasone (1mg) and normal 24h urinary excretion rates of cor-
tisol (<220nmol/24h). Hydrocortisone independency was defined as a normal
cortisol response to CRH or insulin tolerance test. Patients were followed at our
department with yearly intervals, and pituitary hormone substitution was pre-
scribed in accordance with the results of yearly evaluation. Persistent cure of
Cushing’s disease was documented by normal values of a dexamethasone (1mg)
suppression test, urinary cortisol excretion rates, and midnight salivary cortisol
levels before participation in the current study.
In addition, we invited 132 patients with NFMA to participate in the study and
to provide a control person (see above). The response rate was 94%. Fifty-four
had undergone Transsphenoidal surgery and participated in all cognitive tests.
There were no differences in clinical characteristics between participants and
nonparticipants.
Pituitary function was assessed at yearly intervals. In patients who were gluco-
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corticoid dependent after treatment, recovery of the pituitary-adrenal axis was
tested twice a year. The dose of hydrocortisone was on average 20 mg/d divided
into two to three dosages. After withdrawal of hydrocortisone replacement for
24h, a fasting morning blood sample was taken for the measurement of serum cor-
tisol concentrations. Patients with serum cortisol concentration less than
120nmol/l were considered glucocorticoid dependent, and hydrocortisone treat-
ment was restarted. Patients with serum cortisol levels of 120–500nmol/l were
tested by ACTH stimulation tests (250µg). A normal response to ACTH stimula-
tion was defined as a stimulated cortisol higher than 550nmol/l. In case the cor-
tisol response to ACTH was normal the patients were tested by insulin tolerance
test or CRH stimulation test. In case the cortisol responses to these tests were less
than 550nmol/l, hydrocortisone treatment was restarted. Evaluation of GH defi-
ciency was done by insulin tolerance test or arginine-GHRH test only in patients
under the age of 70yr and only after at least 2yr of remission. Patients with an in-
adequate stimulation of GH by one of these tests were treated with recombinant
human GH, aiming at IGF-I levels between 0 and +2 SD values. In addition, the
twice-yearly evaluation consisted of measurement of free T4 and testosterone (in
male patients). If results were below the lower limit of the respective reference
ranges, substitution with L-T4 and/or testosterone was started. In the case of
amenorrhea and low estradiol levels in premenopausal women, estrogen replace-
ment was provided. Patient and treatment characteristics were collected from the
patient records. 
Twelve percent of the controls were treated for hypertension with appropriate
blood pressure control (i.e. <140/90 mmHg) without evidence of hypertensive
organ damage. Four percent of the controls were treated for type 2 diabetes mel-
litus with glycosylated hemoglobin levels less than 7% and without evidence of
organ damage.
Inclusion criteria for the current study were age older than 18yr and remission de-
fined by strict biochemical criteria at the time of study. Patients with present or
previous drug or alcohol abuse or with neurological problems, not related to Cush-
ing’s disease or NFMA, were excluded. The protocol was approved by the Med-
ical Ethics Committee, and written informed consent was obtained from all
subjects.
Study design
A single study visit was planned, during which each subject of the two patient
groups and the two control groups underwent anamnesis and performed the cog-
nitive tests.
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Cognitive evaluation
Eleven cognitive tests were to be completed to assess the full spectrum of cogni-
tive functioning. A functional classification was used to subdivide the tests into the
cognitive domains global cognitive functioning, memory, and executive func-
tioning (21).
To measure global cognitive functioning, the Mini Mental State Examination
(MMSE) was used. This is a 30-point questionnaire to assess cognition, with a
higher score reflecting better performance (22). Memory was measured with the
Wechsler Memory Scale, resulting in a memory quotient (MQ) based on scores in
various subscales (23). The Verbal Learning Test of Rey, to measure verbal mem-
ory and learning, consists of three trials. Number of correctly recalled words was
counted for each trial (24). The Rey Complex Figure, which measures drawing
and visual memory, consists of two trials. A higher score indicates better visual
memory (25).
Executive functioning was measured with the Trail Making Test (26), which meas-
ures psychomotor functioning and visuoconceptual tracking. Time used for both
tests and number of mistakes were counted. The Stroop Color-Word Test (27)
measures interference. Number of correct and wrong responses were counted.
The Letter-Digit Substitution Test (28) measures mental flexibility and speed of in-
formation processing. Number of correctly substituted letters and errors within 60
sec were counted. The Digit-Deletion Test measures selective attention and con-
centration. Number of correctly deleted digits and the number of missed digits in
3 min were counted. The Figure Fluency Test measures the ability to produce
new figures and assesses nonverbal mental flexibility and fluency (29). The num-
ber of correct figures, percentage of repeats, and percentage of wrong figures were
counted. The FAS Test employs the letters F, A, and S and measures verbal men-
tal flexibility and fluency (30). The number of correctly produced words and per-
centage of repeats and errors were counted. Furthermore, the Synonyms Subtest
of the Groninger Intelligence Test-2 was used, with a higher score indicating bet-
ter performance (31).
The Hospital Anxiety and Depression Scale (HADS) was used to measure anxiety
and depression. The HADS consists of 14 items on a 4-point scale. Both anxiety
and depression subscale scores range from 0–21 points. Higher scores indicate
more severe anxiety and/or depression. A total score higher than 13 points on
both subscales together is used to characterize subjects as anxious or depressed
(32, 33).
Statistical analysis
Data were analyzed using SPSS for Windows version 16.0.2 (SPSS Inc., Chicago,
IL, USA). All data are reported in tabular form, expressed as mean ± SD. The pri-
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mary analysis comprised the comparison of the results between patients cured
from Cushing’s disease and their matched controls and between the patients with
NFMA and their matched controls. Groups were compared using a general linear
mixed model, with the matched patient-control couples as random factor. Sec-
ondary analysis comprised the comparison of results in relation to patient and
treatment characteristics. To compare patients treated for Cushing’s disease and
for NFMA, mean and SD scores for each cognitive test were calculated for each
control group, and subsequently, Z-scores were calculated for each patient group
in relation to their appropriate control group. A general linear model was used to
compare the Z-scores, with postoperative additional radiotherapy, hydrocorti-
sone usage, and hypopituitarism as fixed factors. Independent variables affecting
cognitive functioning in patients cured from Cushing’s disease were explored by
stepwise linear regression analysis. The standardized β-coefficients of this analy-
sis were reported. To check the appropriateness of assumptions for each statisti-
cal analysis, we used Levene’s test, Durbin-Watson test, histograms, and scatter
plots. All assumptions were met, except for the independence assumption for para-
metric data. We therefore used nonparametric tests to analyze the clinical char-
acteristics of patients versus controls (McNemar test, Friedman ANOVA, and
Wilcoxon signed-ranks test). The level of significance was set at P≤0.05.
Results
Patient characteristics
Patients treated for Cushing’s disease 
All 74 patients were treated by transsphenoidal surgery, and 20 patients (27%)
received additional radiotherapy because of persistent disease after surgery. The
mean duration of remission was 13 ± 13 yr (range 1–51yr). The number of years
in remission was calculated from the date of curative transsphenoidal surgery or,
in case of persistent postoperative disease, from the date of the normalization of
the biochemical tests after postoperative radiotherapy. Any degree of hypopitu-
itarism was present in 43 patients (58%), and hydrocortisone replacement was
given to 38 patients (51%). There were no differences between patients and con-
trols with respect to age, gender, and education. We asked all patients whether
they experienced limitations with respect to memory and/or executive function-
ing. Sixty-two percent reported memory problems, and 47% reported problems in
executive functioning.
All patients with Cushing’s disease also completed the HADS questionnaire. The
mean scores for the depression subscale were 5.6±4.7 and for the anxiety subscale
5.0±4.7, resulting in total HADS scores of 10.5±8.8. This is well below the cutoff
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score of 13 (32, 33), which indicates that there is, on average, no clinical depres-
sion or anxiety in this cohort of Cushing’s disease patients.
Patients treated for nonfunctioning pituitary macroadenomas 
All patients (n=54) were treated by transsphenoidal surgery, and 24 patients (44%)
received postoperative radiotherapy. Fifty patients (93%) required treatment for
pituitary insufficiency, and hydrocortisone replacement therapy was given to 31
patients (57%). There were no differences between patients and controls with re-
spect to age, gender, and education. Thirty-nine percent reported memory prob-
lems, and 24% reported problems in executive functioning.
Cognitive function
Patients with Cushing’s disease versus matched controls
Patients with long-term cure of Cushing’s disease did not perform worse on meas-
ures of global cognitive functioning. However, these patients showed a lower MQ
on the Wechsler Memory Scale compared with controls (P=0.015), especially in
the subtests concentration (P=0.023), visual memory (P=0.013), and associative
learning (P=0.023). Furthermore, patients recalled fewer words than controls in
the immediate and delayed recall trials of the Verbal Learning Test of Rey
(P<0.001 on both trials). In accordance, patients scored lower than controls in the
delayed trial of the Rey Complex Figure (P=0.040). 
In tests assessing the executive functioning domain, the Letter-Digit Substitution
Test showed that patients substituted fewer letters than controls (P=0.026). Fur-
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Gender (male/female) 13/61 13/61 1.00 
Age (yrs) 52 ± 13 52 ± 13 0.26 







Transsphnoidal surgery, n (%) 74 (100%) NA NA 
Postoperative radiotherapy, n (%) 20 (27%) NA NA 
Duration of remission (yr) 13 (13) NA NA 
Duration of follow-up (yr) 16 (12) NA NA 
Hypopituitarism, n (%) Any axis: 43 (58%) 
GH: 26 (35%) 
LH/FSH: 19 (26%) 
TSH: 24 (32%) 
ADH: 11 (15%) 
NA NA 
Hydrocortisone substitution, n(%) 38 (51%) NA NA 
Data are mean ± SD, NA; not applicable 
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thermore, patients deleted fewer digits (P=0.035) on the Digit-Deletion Test and
produced more repeated patterns on the Figure Fluency Test (P=0.045) when com-
pared with controls.
When patients with short-term (<10 yr, mean 4±2 yr, range 1–8 yr) and long-
term (≥10 yr, mean 24±11 yr, range 11–51yr) remission were compared, only a
single test result was significantly different between these two groups. Patients
with short-term remission had a higher percentage of errors on the FAS than those
in the long-term remission group (3.1 vs. 0.9%, P=0.012).
Patients treated for NFMA vs. matched controls
Patients treated for NFMA did not perform worse on measures of global cognitive
functioning. In tests assessing the memory domain, there were some differences
between patients and controls. Patients scored lower on the subtest associative
learning of the Wechsler Memory Scale (P=0.032) when compared with controls.
In tests assessing executive functioning, there was a difference between patients
and controls on the Trail Making Test. Patients needed more time on Trail A and
B and made more errors on Trail A when compared with controls (P=0.001,
P=0.035, and P=0.019, respectively). Furthermore, patients had a lower total score
on the Stroop Color-Word Test (P=0.045).
When patients with short-term (<10 yr) and long-term (≥10 yr) duration of fol-
low-up were compared, patients with long-term follow-up scored worse on the
Groninger Intelligence Test (P=0.003) and made more errors on the first trail of
the Trail Making Test (P< 0.001).
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Gender (male/female) 30/24 30/24 1.00 
Age (yrs) 61± 11 59 ± 11 0.06 







Operation, n (%) 54 (100%) NA NA 
Postoperative radiotherapy, n (%) 24 (44 %) NA NA 
Duration of follow up (yr) 15 (12) NA NA 
Hypopituitarism, n (%) 
 
Any axis: 50 (93%) 
GH: 40 (74%) 
LH/FSH: 32 (59%) 
TSH: 33 (61%) 
ADH: 6 (11%) 
NA NA 
Hydrocortisone substitution, n(%) 31 (57%) NA NA 
Data are mean ± SD, NA; not applicable 
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Table 3 Cognitive outcomes: patients cured from Cushing’s disease vs matched controls 













    
MMSE Score  27.9 (1.9) 28.3 (2.0) 0.173 
 
Memory 
    
Wechsler Memory Scale Memory Quotient  109.0 (16.8) 115.6 (15.6) 0.015 
 Information 5.8 (0.4) 5.9 (0.4) 0.677 
 Orientation 4.9 (0.2) 5.0 (0.2) 0.701 
 Concentration 7.0 (2.0) 7.7 (1.4) 0.023 
 Logical memory 6.3 (3.2) 7.1 (3.2) 0.118 
 Digit span 9.9 (1.9) 10.3 (1.8) 0.231 
 Visual memory 8.1 (3.0) 9.2 (3.4) 0.013 
 Associative learning 16.0 (3.4) 17.2 (2.8) 0.023 
Verbal Learning Test of Rey Imprinting, total 5.8 (2.1) 6.3 (2.2) 0.154 
 Immediate, total 9.4 (2.7) 11.0 (2.3) 0.000 
 Delayed, total 7.5 (3.0) 9.4 (3.2) 0.000 
Rey Complex Figure test Immediate  17.2 (6.0) 18.9 (6.7) 0.063 
 Delayed  16.7 (6.3) 18.6 (6.8) 0.040 
 
Executive functioning 
    
Trail making test Trail A, time 0.4 (0.3) 0.4 (0.4) 0.889 
 Trail A, errors 0.1 (0.3) 0.2 (0.4) 0.111 
 Trail B , time 1.3 (1.3) 1.2 (0.9) 0.415 
 Trail B, errors 0.7 (1.7) 0.7 (2.2) 0.911 
Stroop color-word test Interference, total 39.8 (11.0) 42.0 (10.6) 0.220 
 Interference, 
mistakes 
0.3 (0.8) 0.2 (0.5) 0.297 
Letter-digit substitution test # correct 31.6 (8.0) 34.2 (7.9) 0.026 
 # errors 0.1 (0.2) 0.1 (0.3) 0.555 
Digit-deletion test # correct 376.5 (102.2) 409.7 (91.3) 0.035 
 # missed 5.0 (5.2) 4.3 (4.8) 0.385 
Figure Fluency # patterns 62.0 (23.4) 66.9 (22.7) 0.164 
 % repeats 9.0 (11.3) 6.2 (5.7) 0.045 
 % errors 17.2 (12.3) 16.9 (13.1) 0.866 
FAS # correct 33.1 (14.8) 36.2 (13.3) 0.168 
 % repeats 1.8 (2.8) 1.2 (2.5) 0.131 
 % errors 2.1 (3.8) 1.5 (4.8) 0.391 
Synonyms subtest of the 
Groninger Intelligence test 
Synonyms score 4.5 (1.9) 4.5 (1.8) 0.134 
Data are mean (SD) 
 
Tiemensma hfd 5:Layout 1  23-01-2012  16:33  Pagina 88
Coping strategies in pituitary patients 89
Table 4 Cognitive outcomes: patients cured from NFMA vs matched controls 











    
MMSE Score  28.9 (1.1) 28.4 (1.4) 0.053 
 
Memory 
    
Wechsler Memory Scale Memory Quotient  118.2 (16.9) 118.1 (13.9) 0.965 
 Information 5.9 (0.3) 5.9 (0.3) 0.693 
 Orientation 4.9 (0.2) 5.0 (0.2) 0.651 
 Concentration 7.6 (1.8) 7.3 (1.8) 0.526 
 Logical memory 7.4 (3.3) 7.5 (2.6) 0.884 
 Digit span 10.0 (1.6) 10.0 (1.9) 0.869 
 Visual memory 8.9 (3.5) 8.6 (3.1) 0.618 
 Associative learning 15.7 (3.0) 16.9 (2.6) 0.032 
Verbal Learning Test of Rey Imprinting, total 5.2 (1.9) 5.0 (1.9) 0.550 
 Immediate, total 9.2 (2.9) 9.8 (2.2) 0.163 
 Delayed, total 6.9 (3.4) 7.5 (2.7) 0.278 
Rey Complex Figure test Immediate  19.6 (6.6) 19.4 (5.8) 0.850 
 Delayed  19.2 (6.4) 19.1 (5.8) 0.911 
 
Executive functioning 
    
Trail making test Trail A, time 0.6 (0.39) 0.4 (0.18) 0.001 
 Trail A, errors 0.3 (0.5) 0.1 (0.3) 0.019 
 Trail B , time 1.4 (0.69) 1.2 (0.6) 0.035 
 Trail B, errors 0.5 (0.9) 0.4 (0.9) 0.724 
Stroop color-word test Interference, total 36.2 (9.1) 38.9 (8.8) 0.045 
 Interference, 
mistakes 
0.1 (0.4) 0.1 (0.4) 1.00 
Letter-digit substitution test # correct 31.2 (8.5) 32.7 (6.7) 0.230 
 # errors 0.0 (0.2) 0.1 (0.4) 0.309 
Digit-deletion test # correct 366.3 (88.7) 389.2 (76.9) 0.148 
 # missed 3.9 (4.3) 3.7 (4.1) 0.771 
Figure Fluency # patterns 47.9 (22.9) 53.0 (22.1) 0.597 
 % repeats 9.2 (9.8) 8.5 (9.3) 0.840 
 % errors 19.8 (11.4) 20.5 (16.3) 0.780 
FAS # correct 33.6 (13.4) 34.6 (11.7) 0.680 
 % repeats 1.1 (2.0) 1.9 (2.6) 0.082 
 % errors 2.3 (6.0) 2.2 (3.3) 0.919 
Synonyms subtest of the 
Groninger Intelligence test 
Synonyms score 5.0 (1.9) 5.0 (1.8) 0.958 
Data are mean (SD) 
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Table 5 Cognitive function: comparison between patients with Cushing’s disease and patients with NFMA 
by Z-scores, calculated for each patient group by comparison with their own matched control groups 














    
MMSE Score  -0.21 (-0.4 to 0.0) 0.34 (0.1-0.5) 0.001 
 
Memory 
    
Wechsler Memory Scale Memory Quotient -0.42 (-0.7 to -0.2) 0.01 (-0.3 to 0.3) 0.050 
 Information -0.07 (-0.3 to 0.2) 0.07 (-0.2 to 0.4) 0.109 
 Orientation -0.07 (-0.3 to 0.2) -0.10 (-0.4 to 0.2) 0.960 
 Concentration -0.47 (-0.8 to -0.1) 0.12 (-0.2 to 0.4) 0.017 
 Logical memory -0.26 (-0.5 to 0.0) -0.03 (-0.4 to 0.3) 0.073 
 Digit span -0.21 (-0.5 to 0.1) 0.03 (-0.2 to 0.3) 0.230 
 Visual memory -0.31 (-0.5 to -0.1) 0.09 (-0.2 to 0.4) 0.006 
 Associative learning -0.41 (-0.7 to -0.1) -0.43 (-0.7 to -0.1) 0.293 
Verbal Learning Test of Rey Imprinting, total -0.23 (-0.5 to 0.0) 0.11 (-0.2 to 0.4) 0.013 
 Immediate, total -0.70 (-1.0 to -0.4) -0.27 (-0.6 to 0.1) 0.012 
 Delayed, total -0.60 (-0.8 to -0.4)  -0.21 (-0.6 to 0.1) 0.003 
Rey Complex Figure test Immediate  -0.25 (-0.5 to 0.0) 0.03 (-0.3 to 0.3) 0.002 
 Delayed  -0.27 (-0.5 to -0.1) 0.02 (-0.3 to 0.3) 0.007 
 
Executive function 
    
Trail making test Trail A, time 0.02 (-0.2 to 0.2) 1.16 (0.6-1.8) 0.081 
 Trail A, errors -0.21 (-0.4 to -0.1) 0.49 (0.1 to 0.9) 0.167 
 Trail B , time 0.14 (-0.2 to 0.5) 0.36 (0.0-0.7) 0.939 
 Trail B, errors 0.02 (-0.2 to 0.2) 0.06 (-0.2 to 0.3) 0.480 
Stroop color-word test Interference, total -0.21 (-0.4 to 0.0) -0.31 (-0.6 to 0.0) 0.823 
 Interference, 
mistakes 
0.21 (-0.1 to 0.6) 0.00 -0.3 to 0.2) 0.270 
Letter-digit substitution test # correct -0.33 (-0.6 to -0.1) -0.22 (-0.6 to 0.1) 0.039 
 # errors -0.08 (-0.3 to 0.1) -0.15 (-0.3 to 0.0) 0.722 
Digit-deletion test # correct -0.37 (-0.6 to -0.1) -0.30 (-0.6 to 0.0) 0.359 
 # missed 0.15 (-0.1 to 0.4) 0.05 (-0.2 to 0.3) 0.053 
Figure Fluency # patterns -0.22 (-0.5 to 0.0) -0.10 (-0.4 to 0.2) 0.003 
 % repeats 0.49 (0.0-0.1) 0.04 (-0.2 to 0.3) 0.215 
 % errors 0.03 (-0.2 to 0.2) -0.04 (-0.2 to 0.2) 0.757 
FAS # correct -0.24 (-0.5 to 0.0) -0.09 (-0.4 to 0.2) 0.423 
 % repeats 0.26 (-0.1 to 0.3) 0.03 (-0.5 to 0.5) 0.067 
 % errors 0.13 (0.0 - 0.3) 0.03 (-0.5 to 0.5) 0.735 
Synonyms subtest of the 
Groninger Intelligence test 
Synonyms score -0.24 (-0.5 to 0.0) 0.01 (-0.3 to 0.3) 0.215 
Data are Z-scores mean (95% CI) 
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Comparison of Z-scores between patients cured from Cushing’s disease and
patients treated for nonfunctioning pituitary macroadenomas 
Patients cured from Cushing’s disease performed worse on the MMSE, which
measures global cognitive functioning, compared with patients treated for NFMA
(P=0.001). The observed difference between the two patient groups in the MMSE
is most likely clinically not very relevant. Apparently, patients with long-term
cure of Cushing’s disease do not suffer from impaired global cognitive function-
ing, because there were no differences compared with their matched controls.
In the memory domain, patients cured from Cushing’s disease had a lower MQ
measured with the Wechsler Memory Scale compared with patients with NFMA
(P=0.050) in the subscales concentration (P=0.017) and visual memory (P=0.006).
On the Verbal Learning Test of Rey, patients cured from Cushing’s disease re-
called fewer words in the imprinting (P=0.013), the immediate recall (P=0.012),
and the delayed recall trials (P=0.003) compared with NFMA patients. Further-
more, on the Rey Complex Figure, patients with cured Cushing’s disease scored
worse on both trials (P= 0.002 and P=0.007, respectively) when compared with
NFMA patients.
In tests measuring executive function, patients cured from Cushing’s disease made
fewer correct substitutions on the Letter-Digit Substitution Test (P=0.039) and
came up with fewer correct patterns on the Figure Fluency Test (P=0.003) com-
pared with treated NFMA patients.
Factors associated with cognitive function in patients with Cushing’s disease
As expected, age and educational level were associated with the outcomes of al-
most all cognitive tests, whereas gender was not. Potential factors of influence, in-
cluding hypopituitarism, hydrocortisone dependency, duration of remission, and
additional radiotherapy, were added in the stepwise linear regression model with
adjustments for age and education. We calculated regression coefficients for test
outcomes that were associated with duration of remission, which might indicate
the potential for improvement.
Global cognitive functioning was not associated with any of the variables. In the
memory domain, the Wechsler Memory Scale MQ was positively associated with
duration of remission (β=0.276; P=0.017). In the executive function domain, the
number of missed digits on the Digit-Deletion Test was positively associated with
duration of remission (β=0.245; P=0.041) and additional radiotherapy (β=0.361;
P=0.002). Furthermore, the number of correct patterns in the Figure Fluency Test
was negatively associated with hypopituitarism (β=-0.278; P=0.012) and hydro-
cortisone dependency (β=-0.230; P=0.040). The percentage of mistakes in the Fig-
ure Fluency Test was positively associated with hydrocortisone dependency
(β=0.224; P=0.048). The percentage of mistakes on the FAS Test was inversely as-
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sociated with duration of remission (β=-0.254; P=0.034). 
There was a significant correlation between the outcome on the Wechsler Mem-
ory Scale (MQ) and duration of remission (r=0.236; P=0.049). There was also a
significant correlation between the number of missed digits on the Digit-Dele-
tion Test and duration of remission (r=0.245; P=0.041), and the percentage of mis-
takes on the FAS and duration of remission (r=-0.254; P=0.034).
Discussion
This study demonstrates that cognitive function is impaired in patients despite
long-term cure of Cushing’s disease. These patients reported impairments in mem-
ory in daily life, which was confirmed by cognitive functioning tests. The per-
formance was decreased in certain aspects of executive functioning and several
memory tasks compared with matched controls. These impairments were not
merely related to pituitary disease in general, because these patients with long-
term cure of Cushing’s disease also revealed impaired cognitive function com-
pared with patients previously treated for NFMA. These observations indicate
irreversible effects of previous hypercortisolism on cognitive function and, thus,
on the central nervous system.
The outcomes of the cognitive tests are in general affected by many factors, in-
cluding age, gender, and educational level. Because the controls and patients were
perfectly matched, these potentially confounding factors did not influence our
results or conclusions. We do not think that our results can be explained to a large
extend by the difference in gender distribution between both patient groups. First,
patients with long-term cure of Cushing’s disease had impaired cognition com-
pared with gender-matched controls. Second, we used Z-scores derived from the
comparisons between patients and appropriately matched controls to compare the
patients with cured Cushing’s disease with patients treated for NFMA, because
the gender differences were too large between these two patients groups to jus-
tify a direct comparison.
Several clinical characteristics influenced outcome parameters. Hypopituitarism
was associated with mildly impaired executive functioning. Hydrocortisone de-
pendency and additional radiotherapy were negatively associated with memory
and executive functioning, whereas the duration of remission positively influ-
enced memory and executive functioning. These findings do not invalidate our
conclusions, because these factors were also present in patients treated for NFMA,
who in general had better performances compared with the patients cured from
Cushing’s disease.
Table 6 summarizes all studies on the effect of Cushing’s disease and syndrome on
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cognitive functions, including the effects of treatment. Our observations extend
those of previous studies. Four previous studies studied cognitive functioning in
treated Cushing’s disease patients, with a total of 98 patients and 77 controls. In
the first study, patients with treated Cushing’s disease (n=27) showed improve-
ment of verbal fluency and recall within 18 months of follow-up, whereas brief
attention did not change. This indicates that some but not all of the effects of pre-
vious glucocorticoid excess are reversible (20). The second study showed that
there were no differences between patients (n=33) and matched controls in IQ
during active disease and 12 months after treatment. There was, however, a pos-
itive relation for some subscales of the IQ test and recovery of the hypothalamic-
pituitary-adrenal axis. There was also a negative association between some IQ
subscales and duration of disease (18). The third study showed that 1yr after sur-
gical treatment, high levels of cortisol caused long-lasting impairments in atten-
tion, visuospatial processing, memory, reasoning, and verbal fluency in patients
with Cushing’s syndrome (n=13) (19). Furthermore, the last study observed that
patients with Cushing’s disease (n=25) showed selective impairments in memory
functions. After treatment, the eight patients who were retested showed amelio-
ration of these memory impairments (6). Our study indicates that patients with
long-term cure of Cushing’s disease have impaired scores of memory and to a
lesser extent in executive functions compared with both matched controls and
treated NFMA patients. Our study differs in several respects from the previous
studies. First, the number of patients included in our study was relatively large
compared with the previous studies. Second, the duration of cure was very long
in our study compared with previous studies. Third, we compared the patients
with long-term cure of Cushing’s disease both with matched controls and with pa-
tients previously operated for NFMA. From the studies summarized in Table 6, in-
cluding our present study, the notion emerges that active Cushing’s disease is
associated with cognitive impairment and that treatment of Cushing’s disease re-
sults in some but not complete recovery of cognitive impairment.
Several other studies evaluated the effects of pituitary adenomas, including
ACTH-producing adenomas, on executive functioning and memory but did not
specify the differences between different pituitary adenomas (34–36). Therefore,
these studies do not permit any conclusion with respect to the specific effects of
Cushing’s disease compared with the effects of other pituitary adenomas on cog-
nitive function.
Prolonged glucocorticoid excess modifies neurotransmitter function and neuronal
structure of the central nervous system (7, 11). In rodents, chronic exposure to
high levels of glucocorticoids impairs hippocampal long-term potentiation (12)
and decreases hippocampal synaptic plasticity (13). In humans, endogenous ac-
tive Cushing’s disease is associated with cognitive impairment (6, 7, 20). The hip-
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pocampus is one of the most sensitive structures in the brain for glucocorticoids
and is crucial in cognitive function (37). The persistent impairments in cognitive
function in patients with previous Cushing’s disease might be explained by irre-
versible effects of previous glucocorticoid excess on the central nervous system,
especially the hippocampus. Additional studies, including functional magnetic
resonance imaging and postmortem analyses of the central nervous system, are
required to evaluate the effects of previous glucocorticoid excess on brain areas of
interest. Patients with long-term cure of Cushing’s disease are a unique, mono-
factorial model to study the long-term effects of glucocorticoid exposure. The re-
sults of the current study may also apply to patients previously treated with
high-dose glucocorticoids for nonendocrine diseases. In addition, the results might
also be of relevance for patients with chronically increased glucocorticoid levels
in conditions like depression (38, 39).
In the review process of the manuscript, there was concern with respect to the
presentation of the data without adjustments for multiple comparisons. Simply
defined, these adjustments test for no effects in all the primary endpoints under-
taken vs. an effect in one or more of those endpoints. This is a difficult method-
ological issue because there are divergent views on the need for statistical
adjustment for multiplicity. This is also reflected in the Lancet papers by Schulz
and Grimes (40, 41), who advocate a restrictive approach toward adjustments for
multiple comparisons. If we consider our own data and if we assume that the dif-
ferences would mostly reflect false-positive results, it is to be expected that the
positive significant results would have been randomly distributed among the dif-
ferent variables. However, this is not the case, as shown in Tables 3 and 4. More-
over, there are several arguments that cortisol excess can indeed cause irreversible
effects on the central nervous system (see above). We designed this study in our
patients cured from Cushing’s disease with the primary aim to evaluate cognitive
function in detail, in view of the documented abnormalities in previous studies
and those observed in experimental animal studies. Indeed, the main results of
our study point toward similar adverse effects of previous Cushing’s disease doc-
umented in previous studies, although these had a different study design. Ac-
cording to Schulz and Grimes (40, 41), statistical adjustments somewhat rescue
the positive results of scattershot analyses. However, we performed a targeted
evaluation and analysis focused on cognitive function related to previous Cush-
ing’s disease rather than a scattershot analysis of cognitive functions in general.
Therefore, in our opinion, our data should not be neglected merely because of the
absence of adjustments for multiple comparisons. Moreover, this would carry the
serious risk of missing an important association between previous Cushing’s dis-
ease and cognitive impairments.
A limitation of the present study was the cross-sectional study design. Conse-
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quently, we do not have any information on premorbid functions, the effects of
active Cushing’s disease, and the extent of reversibility of the disturbed parame-
ters. Nonetheless, these limitations do not invalidate our observations that pa-
tients with long-term cure have subtle impairments in cognitive function
compared with matched controls and with patients treated similarly for NFMA.
It might be argued that potential bias may have been introduced by the selection
of the controls by the patients. In previous studies, we used similarly selected con-
trols and compared the responses of these matched controls with those obtained
from published Dutch control populations for several questionnaires (including
HADS, Nottingham Health Profile, Multidimensional Fatigue Index, and Short
Form) (3, 42, 43). In general, the conclusions obtained in the matched control
subjects were in agreement with the literature-based reference data. In the pres-
ent study, the self-selection of controls enabled a perfect match for an additional
parameter, i.e. socioeconomic status, an important determinant of the outcomes
of the questionnaires, in addition to age, gender, and education. Moreover, we
used the same method of selection of controls for both groups of patients. Even
though the selection procedure may have induced some, but unknown, bias, the
data indicate that there were differences in outcome parameters between both
groups of patients with the similar selection method of controls. Therefore, the
outcomes are not a consequence of the study design or the selection procedure of
the control subjects but, rather, of the long-term consequences of Cushing’s dis-
ease.
In summary, there are subtle impairments in cognitive function in patients dur-
ing long-term follow-up after cure of Cushing’s disease compared with NFMA pa-
tients and matched controls. The greatest impairment was present in memory,
although executive functioning was also affected. This impairment in cognitive
function after treatment of Cushing’s disease is not merely the result of pituitary
disease in general and/or its treatment but includes specific elements most likely
caused by the irreversible effects of previous glucocorticoid excess on the central
nervous system. 
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Abstract
Context and Objective: Psychopathology and maladaptive personality traits are
often observed during the active phase of Cushing’s disease (CD). We hypothe-
sized that patients with long-term cure of CD show persistent psychopathology
and maladaptive personality traits.
Design: Four questionnaires on frequently occurring psychopathology in somatic
illnesses were used, including the Apathy Scale, Irritability Scale, Hospital Anxi-
ety and Depression Scale, and Mood and Anxiety Symptoms Questionnaire short-
form. Personality was assessed using the Dimensional Assessment of Personality
Pathology short-form (DAPPs).
Patients and Controls: We included 51 patients cured of CD (16% men, 53±13 yr)
and 51 matched controls. In addition, we included 55 patients treated for non-
functioning pituitary macroadenomas (55% men, 62±10 yr), and 55 matched con-
trols.
Results: Mean duration of remission was 11 yr (range 1–32yr). Compared with
matched controls, patients cured from CD scored significantly worse on virtually
all questionnaires. Compared with nonfunctioning pituitary macroadenoma pa-
tients, patients treated for CD scored worse on apathy (P<0.001), irritability
(P<0.001), anxiety (P<0.001), negative affect and lack of positive affect (P<0.001
on both scales), somatic arousal (P<0.001), and 11 of 18 subscales of the Dimen-
sional Assessment of Personality Pathology short-form (P<0.05).
Conclusions: Patients with long-term cured CD show an increased prevalence of
psychopathology and maladaptive personality traits. These observations suggest ir-
reversible effects of previous glucocorticoid excess on the central nervous system
rather than an effect of pituitary tumors and/or their treatment in general. This
may also be of relevance for patients treated with high doses of exogenous gluco-
corticoids.
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Introduction
Patients with active Cushing’s disease are exposed to excessive endogenous glu-
cocorticoid levels, caused by ACTH-producingpituitaryadenomas.In these pa-
tients, psychopathology is often observed with major depression being the most
common comorbid disorder, although mania and anxiety disorders have also been
reported (1). After successful treatment of hypercortisolism, both physical and
psychiatric signs and symptoms improve substantially (2, 3). However, these pa-
tients do not completely return to their premorbid level of functioning, and per-
sistently impaired quality of life has been reported despite long-term cure (4).
Furthermore, maladaptive personality traits were documentedafter treatment for
Cushing’s disease insome,but not all, studies (3, 5–7). Table 1 gives an overview of
the current literature on psychopathology and personality traits in patients with
Cushing’s disease. Alarge number of studies in humans and animal models have
documented that prolonged, increased endogenous or exogenous exposure to glu-
cocorticoids may have longlasting adverse effects on behavioral and cognitive
functions due to functional and, over time, structural alterations in specific brain
target areas (8, 9). An important question is to what extent these adverse effects
of glucocorticoids are reversible after withdrawal of glucocorticoid excess. At pres-
ent, it is not clear whether, and to what extent, psychopathology and maladaptive
personality traits persist after long-term cure of Cushing’s disease. Therefore, our
aim was to investigate psychopathology that is frequently present in patients with
somatic illnesses and personality traits among long-term cured Cushing’s disease
patients, and compare them with matched controls. To exclude the possibility
that pituitary adenomas and/or their treatment in general are associated with in-
creased psychopathology or maladaptive personality traits, we also studied these
parameters in patients previously treated for nonfunctioning pituitary macroade-
nomas (NFMA).
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Patients and Methods
Patients 
We included four groups of subjects: 1) patients with long-term cure of Cushing’s
disease, and 2) gender-, age-, and education level-matched control subjects for
these patients with previous Cushing’s disease, 3) patients previously treated for
NFMA, and 4) age-, gender-, and education level-matched control subjects for
these patients previously treated for NFMA. The inclusion of these two separate
control groups was necessary because patients with Cushing’s disease and NFMA
patients differ considerably with respect to age and gender distribution. We per-
formed a clinical chart review of 85 patients who had been treated by transsphe-
noidal surgery if necessary followed by repeated surgery and/or postoperative
radiotherapy. All were in remission of Cushing’s disease at the time of the cur-
rent study for at least 1yr. The long-term treatment outcome of these patients has
been characterized and described in detail (10). We invited these patients to par-
ticipate in the current study. Each patient was asked to provide a control person
of comparable gender, age, and education level. Gender and education had to be
the same, and age was allowed to differ maximally by 10 yr. Patients who did not
respond were encouraged by phone to participate. Thirty-four patients (40%) re-
fused to participate for several reasons including living outside The Netherlands,
which implicated that the patients were not able to use the prepaid answer enve-
lope to return the questionnaires. The other reasons were old age and/or debili-
tating disease. Fifty-one patients (60%) participated in the current study and
completed all questionnaires. The clinical characteristics of the nonparticipants
did not differ from those of the participants.
Cushing’s disease had been diagnosed based on the clinical manifestations and
positive biochemical tests including increased urinary excretion rates of free cor-
tisol; decreased overnight suppression by dexamethasone (1mg); and, since 2004,
elevated midnight salivary cortisol values in addition to non-suppressed ACTH
levels. All patients had been treated by transsphenoidal surgery, if necessary, fol-
lowed by repeated surgery and/or postoperative radiotherapy. Cure of Cushing’s
disease was defined by normal overnight suppression of plasma cortisol levels
(<50nmol/l) after administration of dexamethasone (1mg) and normal 24h uri-
nary excretion rates of cortisol (<220nmol/24h). Hydrocortisone independency
was defined as a normal cortisol response to CRH or insulin-tolerance test (ITT).
In addition, we invited 132 patients with NFMA treated previously by transsphe-
noidal surgery to participate in the study. The response rate was 94%. Fifty-five
patients (42%) completed all questionnaires. There were no differences in clini-
cal characteristics between participants and nonparticipants. Each patient was
asked to provide a control person of comparable gender, age, and education level.
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Pituitary function was assessed at yearly intervals in both patient groups. In pa-
tients cured of Cushing’s disease who were glucocorticoid dependent after treat-
ment, recovery of the pituitary-adrenal axis was tested twice a year. The dose of
hydrocortisone was on average 20 mg/d divided into two to three dosages. After
withdrawal of hydrocortisone replacement for 24h, a fasting morning blood sam-
ple was taken for the measurement of serum cortisol concentrations. Patients with
serum cortisol concentration less than 120 nmol/l (blood samples obtained be-
tween 0800 and 0900 h) were considered to be glucocorticoid dependent, and hy-
drocortisone treatment was restarted. Patients with serum cortisol levels between
120 and 500 nmol/l were tested by ITT or CRH stimulation. In case the cortisol
responses to these tests were less than 550 nmol/l, hydrocortisone treatment was
restarted. In patients under the age of 70yr, GH-deficiency was assessed by ITT or
combined GHRH-arginine test, after at least 2yr of remission of Cushing’s dis-
ease. Patients with inadequate stimulation of GH by one of these tests were treated
with recombinant human GH, aiming at IGF-I levels between 0 and +2 SD values.
In addition, free T4 and testosterone levels (in male patients) were assessed. If re-
sults were below the lower limit of the respective reference ranges, substitution
with L-T4 and/or testosterone was prescribed. In the case of amenorrhea and low
estradiol levels in premenopausal women, estrogen replacement was provided.
Inclusion criteria for the current study were age older than 18yr and remission de-
fined by strict biochemical criteria for at least 1yr. Patients with present or pre-
vious drug or alcohol abuse or with neurological disorders not related to Cushing’s
disease or NFMA were excluded. The protocol was approved by the Medical
Ethics Committee and written informed consent was obtained from all subjects.
Questionnaires
Patients and controls were asked to complete questionnaires on psychopathology
and personality at home and to return them in a prepaid envelope.
Apathy scale
Apathy was assessed using the Apathy Scale, which was designed at the Johns
Hopkins School of Medicine (Baltimore, MD). The Apathy Scale consists of 14
questions on a four-point scale measuring the different features of apathy in the
2 wk before. The score for each item ranges from 0 (no apathetic behavior) to 3
(maximum intensity of apathetic behavior). The total score ranges from 0 to 42
points, with higher scores indicating greater apathy. A total score of 14 points or
more is being used to characterize subjects as apathetic (11, 12).
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Irritability scale
Irritability was assessed using the irritability scale that consists of 14 items on a
four-point scale measuring different features of irritability in the 2 previous weeks.
The total score ranges from 0 to 42 points, with higher scores indicating greater
irritability. A total score of 14 points or more is being used to characterize subjects
as irritable (12).
Hospital Anxiety and Depression Scale (HADS)
Anxiety and depression were assessed using the HADS that consists of 14 items on
a four-point scale. Both anxiety and depression subscale scores range from 0 to 21
points. Higher scores indicate more severe anxiety and/or depression. A score
greater than 8 points on one of the subscales is being used to characterize subjects
as being anxious or depressed respectively (13, 14).
Mood and Anxiety SymptomsQuestionnaire shortform (MASQ-30)
The MASQ-30 consists of 30 items assessing symptoms that occur in mood and
anxiety disorders subdivided into the three subscales of negative affect, lack of
positive affect, and somatic arousal. The scores for each subscale ranges from 10
to 50, with higher scores indicating more severe negative affect, more lack of pos-
itive affect, or more somatic arousal. There are no formal cutoff scores (15).
Dimensional Assessment of Personality Pathology short-form (DAPPs)
The DAPPs consists of 136 items to assess personality traits, which are subdivided
into 18 subscales: submissiveness, cognitive distortion, identity problems, affective
lability, stimulus seeking, compulsivity, restricted expression, callousness, oppo-
sitionality, intimacy problems, rejection, anxiousness, conduct problems, suspi-
ciousness, social avoidance, narcissism, insecure attachment, and self-harm. The
score for each subscale differs with a maxima of 30–40 and higher scores indicat-
ing more pronounced maladaptive personality traits. There are no formal cut-off
scores (16). 
Statistical analysis
Data were analyzed using PASW Statistics version 17.0.2 (SPSS Inc., Chicago, IL,
USA). All data were presented as mean ± SD, unless mentioned otherwise. When
data were missing, multiple imputation was used to impute the missing values. In
the present study, this was not a major issue because only approximately 0.5% of
the data were missing and therefore imputed. Ten different imputations were cal-
culated and the pooled descriptives and P-values were used. The primary analy-
sis comprised the comparison of the results between patients cured of Cushing’s
disease and their matched controls and between the patients with NFMA and
their matched controls. Groups were compared using an independent-samples t
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test. A χ2 test was used in case of categorical data. Secondary analysis comprised
the comparison of results of patients treated for Cushing’s disease and patients
treated for NFMA. Mean and SD scores for each questionnaire subscale were cal-
culated for each control group, and subsequently Z-scores were calculated for
each patient group in relation to their appropriate control group. Independent
variables affecting psychopathology and personality in patients cured of Cush-
ing’s disease were explored by stepwise linear regression analysis. The standard-
ized β-coefficients of this analysis were reported. The level of significance was set
at P≤0.05.
Results
Sociodemographic and clinical characteristics
Patients cured of Cushing’s disease and their matched controls 
All patients (n=51) had been treated by transsphenoidal surgery, and 11 patients
(22%) had been treated by additional radiotherapy because of persistent disease
after surgery (Table 2). At the time of the current study, all patients were in re-
mission and the mean duration of remission was 11±9yr (range 1–32yr, mode 3
and 5yr). Thirty-one patients (61%) were treated for some degree of pituitary in-
sufficiency. Twenty-seven patients (53%) were substituted with hydrocortisone.
Patients treated for NFMA and their matched controls
All patients (n=55) had been treated by transsphenoidal surgery and 24 of these
(43%) also by additional radiotherapy (Table 3). Mean duration of follow-up was
14±11yr (range 1–51yr, mode 4, 7, and 12yr). At the time of the current study, 51
patients (93%) were treated for pituitary insufficiency. Hydrocortisone substitu-
tion was used by 33 patients (60%).
Psychopathology
Patients cured of Cushing’s disease versus their matched controls 
Patients with long-term cure of Cushing’s disease had a higher total score on the
Apathy Scale (t (85)=4.6, P<0.001) and on the Irritability Scale (t (77)=4.1,
P<0.001), compared with matched controls (Table 4). Patients also showed higher
scores on the anxiety and depression subscales of the HADS (t (82)=3.9, P<0.001,
and t (78)=4.8, P<0.001, respectively). On the MASQ-30, patients with long-term
cured Cushing’s disease scored higher on negative affect (t (91)=3.5, P<0.001) and
somatic arousal (t (78)=4.1, P<0.001) and lower on positive affect (t (95)=-3.7,
P<0.001). On the Apathy scale, 57% of the patients with Cushing’s disease had a
score of 14 or greater, and on the Irritability Scale, 31% of the patients had a score
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of 14 or greater, indicative for the presence of clinically significant apathy and ir-
ritability, respectively. On the HADS, 26% of the patients with cured Cushing’s
disease scored greater than 8 on the depression subscale and 20% of the patients
scored greater than 8 on the anxiety subscale. This is indicative for the presence
of clinically relevant depression or anxiety, respectively. In particular, depression
is evident in a substantial amount of the patients. Significantly more patients than
controls had clinically relevant scores on these questionnaires (Apathy P<0.001;
Irritability P<0.001; anxiety subscale HADS P=0.014; and depression subscale
HADS P=0.002).
When patients with short-term (<10 yr, 28 patients (six males), aged 54±14yr) and
long-term (≥10 yr, 23 patients (two males), aged 52±13yr) remission were com-
pared, several differences were found. After a remission duration of more than
10yr, the patients scored significantly worse on the Apathy Scale (P=0.002), the
depression subscale of the HADS (P=0.033), and the positive affect subscale of the
MASQ-30 (P<0.001).
Patients treated for NFMA vs. their matched controls
Patients treated for NFMA had a higher total score on the Apathy Scale (t
(108)=3.0, P=0.003) and higher mean scores on the anxiety and depression subscale
of the HADS compared with their matched controls (t (108)=-2.4, P=0.017, and t
(108)=-4.7, P<0.001, respectively), but the scores for the other scales (Irritability
Scale and MASQ-30) were not different (Table 5). In patients treated for NFMA,
a score of 14 or greater on the Apathy Scale was observed in 40%, a score of 14 or
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Gender (male/female) 8/43 8/43 1.00 
Age in yrs 53 (13) 54 (13) 0.70 
Educational level (n) Low: 20 
Medium: 13  
High: 18 
Low: 18 
Medium: 16  
High: 17 
0.80 
Surgery, n (%) 51 (100%) NA NA 
Postoperative radiotherapy, n (%) 11 (22%) NA NA 
Duration of remission in yrs 11 (9) NA NA 
Duration of follow-up in yrs 14 (10) NA NA 
Hypopituitarism, n (%) Any axis: 31 (61%) 
GH: 20 (39%) 
LH/FSH: 14 (28%) 
TSH: 21 (41%) 
ADH: 10 (20%) 
NA NA 
Hydrocortisone substitution, n (%) 27 (53%) NA NA 
Data are mean ± SD or number and %; NA=not applicable  
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greater on the Irritability Scale in 27%, a score greater than 8 on the HADS anx-
iety scale in 15%, and a score greater than 8 on the depression scale in 13%. There
were significantly more patients than controls with a clinically relevant score on
the HADS depression scale (P=0.026). There were no differences between patients
with short-term (<10yr) and long-term (≥10yr) duration of follow-up. 
Chapter 6114













   
   Total score 14.8 (6.5) 9.8 (4.2) 0.000 
   Score !14, n (%) 29 (57%) 7 (14%) 0.000 
 
Irritability Scale 
   
   Total score 11.5 (7.7) 6.6 (4.2) 0.000 
   Score !14, n (%) 16 (31%) 2 (4%) 0.000 
 
HADS 
   
   Anxiety 6.2 (4.2) 3.5 (2.5) 0.000 
   Depression 5.6 (4.5) 2.1 (2.5) 0.000 
   Anxiety score >8, n (%) 10 (20%) 2 (4%) 0.014 
   Depression score >8, n (%) 13 (26%) 2 (4%) 0.002 
 
MASQ-30 
   
   Negative Affect 18.2 (6.7) 14.2 (4.8) 0.001 
   Positive Affect 25.7 (9.6) 32.1 (7.6) 0.000 
   Somatic Arousal 17.4 (6.6) 13.1 (3.7) 0.000 
 
DAPP 
   
   Submissiveness 19.0 (7.7) 15.4 (5.5) 0.008 
   Cognitive distortion 11.5 (5.6) 8.4 (2.6) 0.001 
   Identity problems 13.0 (6.6) 8.7 (3.3) 0.000 
   Affective lability 21.7 (7.8) 13.9 (4.7) 0.000 
   Stimulus seeking 14.6 (4.8) 13.6 (4.3) 0.260 
   Compulsivity 23.8 (6.6) 20.1 (6.1) 0.004 
   Restricted expression 21.2 (7.3) 18.0 (6.0) 0.016 
   Callousness 16.1 (4.5) 15.3 (4.4) 0.392 
   Oppositionality 22.9 (8.8) 17.2 (5.5) 0.000 
   Intimacy problems 18.8 (6.4) 20.5 (7.0) 0.188 
   Rejection 17.2 (5.7) 17.1 (6.0) 0.959 
   Anxiousness 15.3 (6.2) 11.1 (4.2) 0.000 
   Conduct problems 9.0 (1.8) 9.0 (1.6) 0.953 
   Suspiciousness 12.6 (5.9) 10.8 (3.0) 0.061 
   Social avoidance 12.3 (6.3) 9.8 (3.2) 0.014 
   Narcissism 15.0 (5.5) 13.3 (5.0) 0.091 
   Insecure attachment 13.3 (6.6) 10.7 (4.5) 0.025 
   Self-harm 7.3 (2.9) 6.5 (1.8) 0.110 
Data are mean (SD), unless otherwise mentioned 
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Factors associated with psychopathology in patients cured of Cushing’s disease
Stepwise linear regression analysis was performed using the absolute test scores of
the patients with long-term cure of Cushing’s disease as dependent variables and
gender, age, education, hypopituitarism, hydrocortisone dependency, additional
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   Total score 12.8 (4.7) 10.2 (4.1) 0.003 
   Score !14, n (%) 22 (40%) 13 (24%) 0.065 
 
Irritability Scale 
   
   Total score 10.0 (5.8) 8.9 (5.1) 0.289 
   Score !14, n (%) 15 (27%) 10 (18%) 0.255 
 
HADS 
   
   Anxiety 5.0 (3.6) 3.5 (3.0) 0.017 
   Depression 4.6 (3.9) 1.7 (2.1) 0.000 
   Anxiety score >8, n (%) 8 (15%) 3 (6%) 0.105 
   Depression score >8, n (%) 7 (13%) 1 (2%) 0.026 
 
MASQ-30 
   
   Negative Affect 15.6 (5.8) 14.9 (5.8) 0.492 
   Positive Affect 29.3 (8.3) 30.4 (8.0) 0.491 
   Somatic Arousal 15.0 (5.7) 13.5 (4.4) 0.137 
 
DAPP 
   
   Submissiveness 16.5 (5.6) 17.1 (6.1) 0.636 
   Cognitive distortion 9.5 (3.9) 9.8 (4.9) 0.747 
   Identity problems 10.2 (4.5) 9.6 (4.3) 0.454 
   Affective lability 18.8 (5.6) 16.1 (5.6) 0.013 
   Stimulus seeking 14.5 (4.4) 14.2 (5.1) 0.748 
   Compulsivity 22.3 (6.9) 21.9 (6.6) 0.746 
   Restricted expression 21.9 (4.5) 20.2 (5.2) 0.080 
   Callousness 16.9 (4.6) 15.9 (4.3) 0.222 
   Oppositionality 20.3 (6.5) 19.1 (6.7) 0.378 
   Intimacy problems 20.1 (6.7) 19.3 (6.6) 0.566 
   Rejection 18.3 (5.8) 17.0 (5.9) 0.260 
   Anxiousness 12.8 (4.7) 12.9 (4.8) 0.905 
   Conduct problems 9.7 (2.8) 9.5 (2.4) 0.690 
   Suspiciousness 11.0 (3.5) 10.9 (4.0) 0.995 
   Social avoidance 11.3 (3.9) 10.7 (4.0) 0.374 
   Narcissism 15.6 (4.9) 15.4 (5.9) 0.902 
   Insecure attachment 13.0 (5.2) 13.1 (5.3) 0.928 
   Self-harm 6.9 (2.4) 6.4 (1.7) 0.228 
Data are mean (SD), unless otherwise mentioned 
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radiotherapy, and duration of remission as independent variables. The total score
on the Apathy Scale was negatively influenced by educational level (β=-0.380,
P=0.009), which means that a higher education level predicts a lower score on the
Apathy Scale in these patients. The total score on the Irritability Scale was posi-
tively associated with additional radiotherapy (β=0.314, P=0.034), which indicates
that patients who had additional radiotherapy scored higher on the Irritability
Scale. The depression subscale of the HADS was positively influenced by the du-
ration of remission (β=0.358, P=0.015), meaning that a longer duration of remis-
sion indicates a higher score on the depression subscale of the HADS. On the
MASQ-30, the positive affect subscale was positively influenced by gender
(β=0.410, P=0.003), with females scoring higher, and education (β=0.338, P=0.012),
with higher educational level predicting higher scores. The positive affect sub-
scale was negatively associated with duration of remission (β=-0.332, P=0.014),
with longer duration of remission indicating lower scores on this subscale. The
negative affect subscale was negatively associated with gender (β=-0.361, P=0.014),
with females scoring lower, and positively influenced by duration of remission
(β=0.311, P=0.032), with longer duration of remission indicating higher scores on
the negative affect subscale.
Personality
Patients cured of Cushing’s disease versus their matched controls 
Patients with long-term cure of Cushing’s disease scored worse compared with
matched controls on the DAPPs personality traits submissiveness (t (90)=2.7,
P=0.008), cognitive distortion (t (71)= 3.6, P<0.001), identity problems (t (74)=4.2,
P<0.001), affective lability (t (82)=6.1, P<0.001), compulsivity (t (100)=2.9,
P=0.004), restricted expression (t (97)=2.5, P=0.016), oppositionality (t (84)=4.0,
P<0.001), anxiousness (t (89)=4.0, P<0.001), social avoidance (t (74)=2.5, P=0.014),
and insecure attachment (t (88)=2.3, P=0.025), see also Table 4. When using de-
pression and anxiety as covariates, only two traits remained statistically different
between patients and controls: affective lability (F (1)=16.3, P<0.001) and anx-
iousness (F (1)=5.2, P=0.024). This observation increases the likelihood of the pres-
ence of these premorbid traits. The traits identity problems (F (1)=3.1, P=0.081),
compulsivity (F (1)=2.9, P=0.092), and intimacy problems (F (1)=2.9, P=0.094]
showed trend significance. When only co-varying for depression, the traits af-
fective lability (F (1)=15.5, P<0.001) and anxiousness (F (1)=5.7, P=0.019) remained
significantly different between patients and controls, whereas the traits identity
problems (F (1)=3.5, P=0.064), compulsivity (F (1)=3.3, P=0.071), oppositionality
(F (1)=3.0, P=0.087), and intimacy problems (F (1)=3.1, P=0.079) showed trend
significance. When patients with short-term (<10yr, 24 patients (17 men), aged
58±11yr) and long-term (≥10yr, 31 patients (13 men), aged 65±7yr) remission were
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compared, only minor differences were found. After a remission duration of more
than 10yr, the patients scored significantly worse only on the identity problems
subscale (P=0.045) and the intimacy subscale (P=0.003) of the DAPPs.
Patients treated for NFMA vs. their matched controls
Patients treated for NFMA scored worse on the trait affective lability (t (108)=2.5,
P=0.013) of the DAPPs compared with controls but not on other traits.
When patients with short-term (<10yr) and long-term (≥10yr) duration of fol-
low-up were compared, patients with long-term follow-up scored higher on the
intimacy subscale of the DAPPs (P=0.020), see also Table 5.
Factors associated with personality in patients cured of Cushing’s disease
On the DAPPs questionnaire, several subscales were associated with the inde-
pendent variables: the cognitive distortion subscale was negatively associated with
education (β=-0.391, P=0.007), with higher education indicating lower scores on
the cognitive distortion subscale. The identity problems subscale was positively in-
fluenced by additional radiotherapy (β=0.329, P=0.021) and hydrocortisone de-
pendency (β=0.278, P=0.049), with additional radiotherapy and hydrocortisone
dependency predicting higher scores. The rejection subscale was positively asso-
ciated with education (β=0.426, P=0.003), with higher education being associated
with higher scores on this subscale. The conduct problems subscale was nega-
tively associated with gender (β=-0.331, P=0.024), with females scoring lower.
The suspiciousness subscale was positively associated with hypopituitarism
(β=0.302, P=0.042), which indicates that hypopituitarism is associated with higher
scores on the suspiciousness subscale. Finally, the self-harm subscale was posi-
tively affected by duration of remission (β=0.370, P=0.011), with longer duration
of remission being associated with higher scores on the self-harm subscale.
Comparison of  Z-scores between patients cured of Cushing’s disease and
patients treated for NFMA
In comparison with patients treated for NFMA, patients with long-term cure of
Cushing’s disease had higher scores on the Apathy Scale (P<0.001), the Irritabil-
ity Scale (P<0.001), and on the anxiety subscale of the HADS (P<0.001). Further-
more, patients with cured Cushing’s disease scored higher on the negative affect
(P<0.001) and on the somatic arousal (P<0.001) subscales of the MASQ-30,
whereas they scored lower on the positive affect subscale (P<0.001). On the
DAPPs, patients with cured Cushing’s disease scored worse when compared with
patients treated for NFMA on submissiveness (P=0.002), cognitive distortion
(P<0.001), identity problems (P<0.001), affective lability (P<0.001), compulsivity
(P=0.010), oppositionality (P<0.001), anxiousness (P<0.001), conduct problems
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(P<0.001), suspiciousness (P=0.049), social avoidance (P=0.049), and insecure at-
tachment (P=0.019). This is also shown in Figure 1 and Figure 2. 
Discussion
This study demonstrates that patients with long-term cure of Cushing’s disease
suffer from more psychopathology and maladaptive personality traits compared
with matched controls. In addition, patients with long-term cure of Cushing’s dis-
ease had significantly more psychopathology and maladaptive personality traits
than patients previously treated for NFMA, indicating that the presence of psy-
chopathology and maladaptive personality traits was not merely related to pitu-
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Figure 1: Figure 1: Z-scores of patients cured from Cushing’s disease and of patients treated for
NFMA, calculated for each patient group by comparison with their own matched control groups. Z-
scores with 95% confidence intervals are shown in this figure. The zero Z-line indicates the scores
of the matched controls. On the apathy scale, irritability scale, anxiety subscale of the HADS, and
all three subscales of the MASQ-30 patients with long-term cured Cushing’s disease scored worse
when compared with patients with treated NFMA. 
Comparison of psychopathology of patients with Cushing’s disease and patients with NFMA by Z-
scores
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itary tumors and/or their treatment in general. Therefore, the long-term effects of
cured Cushing’s disease on psychopathology and personality traits are more likely
to be the consequence of previous glucocorticoid excess. These observations point
to irreversible effects of previous glucocorticoid excess on the central nervous sys-
tem. Psychopathology is reported to be present in the majority of patients with ac-
tive Cushing’s disease (17). Major depression, atypical depression, or at least one
other psychiatric diagnosis, is present in more than 50% of these patients (18–23).
Appropriate treatment of hypercortisolism results in improvement of these symp-
toms in many of these patients (2, 3, 24), and the prevalence of overall psy-
chopathology decreases to 24% of the patients within 1yr after appropriate
treatment of active Cushing’s disease (21, 22). Therefore, appropriate treatment of
Cushing’s disease results in improvement of the psychiatric manifestations asso-
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Figure 2: Z-scores of patients cured from Cushing’s disease and of patients treated for NFMA. Pa-
tients with long-term cured Cushing’s disease scored worse when compared with patients with tre-
ated NFMA on the DAPP subscales submissiveness, cognitive distortion, identity problems, affective
lability, compulsivity, oppositionality, anxiousness, conduct problems, suspiciousness, social avoi-
dance, and insecure attachment.
Comparison of personality traits (DAPPs) of patients with Cushing’s disease and patients with NFMA
by Z-scores  
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ciated with this disease.
Several previous studies evaluated the effects of Cushing’s disease and Cushing’s
syndrome on psychopathology and personality traits. These studies are summa-
rized in Table 1. Several previous studies in patients with active Cushing’s disease
concluded that patients had a higher tendency for anxiety than controls (6, 19, 25).
In contrast, Kelly et al. (3) concluded that patients with active Cushing’s syn-
drome and control patients scored equally on personality traits (neuroticism and
extraversion). When patients with Cushing’s syndrome were reassessed after ap-
propriate treatment, there was a significant decrease in neuroticism score but not
extraversion. However, another recent study concluded that were no differences
in personality traits between patients with Cushing’s syndrome in remission and
controls (7). Therefore, maladaptive personality traits are documented after treat-
ment of Cushing’s disease in some, but not all, studies. However, these studies in-
cluded only limited numbers of patients with heterogeneous clinical characteristics.
Moreover, the long-term effects of cure of Cushing’s disease have not been studied
in detail.
A limitation of the present study was the cross-sectional study design instead of
a longitudinal design. Consequently, we do not have any information on pre-
morbid functions, the effects of active Cushing’s disease, and the extent of re-
versibility of the disturbed parameters. Nonetheless, these observations do not
invalidate our observations that patients with long-term cure show an increased
prevalence of psychopathology and maladaptive personality traits compared with
matched controls and with patients treated similarly for NFMA. It might be ar-
gued that the use of mailed self-rating scales for depression and anxiety is a limi-
tation. However, self-reported scales provide a valuable tool to measure the
patients’ perception of their illness, which is not possible with observer ratings
(26). Furthermore, we intended to screen for symptoms of possible psy-
chopathology, not to establish psychopathology. Another possible limitation is
the fact that the most distressed subjects are the ones who are more likely partic-
ipate. Unselected series (3, 7, 22) reported a prevalence of psychopathology of 24–
32% in patients cured from Cushing’s disease, which is in accordance with data of
the present study.
Patients with long-term cure of Cushing’s disease provide a unique human model
to study the effects of prolonged, but transient (endogenous), glucocorticoid ex-
cess. Furthermore, the results of the current study may be relevant for patients
who have previously been treated with prolonged high doses of glucocorticoids
(27, 28).
In summary, patients with long term cure of Cushing’s disease report a high preva-
lence of psychopathology, compared with both matched controls and patients
previously treated for NFMA. Furthermore, patients with long-term cure of Cush-
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ing’s disease have a greater degree of maladaptive personality traits. The results
suggest that these observations reflect irreversible effects of previous glucocorti-
coid excess on the central nervous system rather than an effect of pituitary tu-
mors and/or their treatment in general.
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Abstract 
Glucocorticoids are crucial in the initiation and consolidation of the stress re-
sponse. Patients with active Cushing’s syndrome (CS) are exposed to excessive en-
dogenous glucocorticoid levels. In these patients, psychopathology is often being
observed. The most common co-morbid disorder is major depression, but to a
lesser extent mania and anxiety disorders have also been reported. A severe clin-
ical presentation of CS often also includes depression. Reduction of glucocorticoid
synthesis or action, either with metyrapone, ketoconazole, or mifepristone, rather
than treatment with antidepressant drugs, is generally successful in relieving de-
pressive symptoms, as well as other disabling symptoms. Following successful sur-
gical treatment of hypercortisolism, both physical and psychiatric signs and
symptoms improve substantially. However, it appears that patients do not com-
pletely return to their premorbid level of functioning and persistent impairment
of quality of life and cognitive function has been reported despite long-term cure.
At present, it is not clear whether, and to which extent, psychopathology still af-
fects general well-being after long-term cure of CS.
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Introduction
Cushing’s syndrome (CS) is associated with psychopathology. The spectrum of
behavioral abnormalities observed in patients with CS ranges from severe de-
pression to mania and can be present in both endogenous CS and in patients ex-
posed to exogenous corticosteroids, which strongly suggests a causal role for
corticosteroid excess in the initiation and consolidation of psychopathology. In
this concise review, we will address the pathophysiology of the neuropsychiatric
disorders observed in CS. In order to emphasize the crucial role of corticosteroid
excess in the control of mood and behavior and cognitive function, we will first
discuss the data on psychopathology observed in active CS, then the effects of re-
duction of corticosteroid synthesis or action on psychopathology in CS, and, fi-
nally, the reversibility of psychopathology after remission of glucocorticoid excess.
Physiology and pathophysiology of the control of behavior in response to stress
In order to put the behavioral abnormalities observed in CS into the right per-
spective, it is important to realize that cortisol (or corticosterone in the rodent) is
the main mediator of the stress response (1) . When an individual is exposed to a
stressor, rapid changes occur within seconds to minutes through stimulation of the
sympathetic nervous system via catecholamines (CRH, AVP) and via nongenomic
actions of cortisol. These mediators increase excitability, resulting in behavioral
changes characterized by increased vigilance, alertness, arousal, and attention. In
addition, the stress response is characterized by slower changes that occur within
minutes to hours via stimulation of both the mineralocorticoid (MR) and gluco-
corticoid (GR) receptor. All these changes, in the end, occur only with the pur-
pose to induce the required behavioral adaptations for the individual to be able to
adequately cope with the stressor. However, when the stressor becomes chronic,
a so-called vulnerable phenotype develops, characterized by neurodegenerative
changes within the central nervous system and cognitive impairment (1). Thus, it
is not surprising that CS, that can be considered the clinical human equivalent for
severe chronic stress, is associated with behavioral abnormalities.
Psychopathology in active Cushing’s syndrome
Active, untreated CS is associated with a high prevalence of psychopathology. The
frequencies of psychiatric symptoms have been evaluated since the late 1970s
using different criteria in a total of approximately 500 patients with CS, mostly
comprising small patient groups. A subset of these studies that evaluated psy-
chopathology and personality traits are summarized in Table 1 . 
An early study on personality traits in 53 patients with CS reported that 60% of
these subjects had personality changes (2). However, it is not clear from the data
Neuropsychiatric disorders in Cushing’s syndrome 127
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Tiemensma hfd 7:Layout 1  23-01-2012  16:34  Pagina 128






























































































































































































































































































































































































































































































Tiemensma hfd 7:Layout 1  23-01-2012  16:34  Pagina 129
in that study whether these patients still had active Cushing’s disease. Another
study in 9 patients with active Cushing’s disease concluded that patients had a
higher tendency for anxiety than controls (3). In contrast, Kelly et al. (4) con-
cluded that patients with active CS and control patients scored equally on per-
sonality traits (neuroticism and extraversion). Starkman and Schteingart (5)
evaluated the prevalence of psychiatric symptoms in 35 patients with active CS
and found that irritability, depressed mood, and anxiety were present in the ma-
jority of the patients. Intriguingly, an increased overall psychiatric disability,
measured by and indicated by a specific score, was associated with increased cor-
tisol secretion. Among another consecutive unselected series of 29 patients with
untreated CS, 25 (86%) were significantly depressed. In this study, the severity of
the depression was not related to circulating cortisol levels, but the depression
was rapidly relieved when the tumor or adrenal glands were removed (6). Kelly
et al. (7) compared in another study 15 patients with active CS both with 15 other
patients who had been treated successfully for CS and with 13 patients with other
pituitary tumors. Depression was the main psychiatric diagnosis using the CAT-
EGO program after Present State Examinations. Patients with active CS were sig-
nificantly more depressed (Hamilton Rating Scores) than were the other patients.
Another study (8) compared 20 patients with Cushing’s disease with 20 patients
with major depressive disorder using the Structured Clinical Interview for DSM-
III-R (SCID) and Research Diagnostic Criteria. A diagnosis of generalized anxiety
disorder, major depressive disorder, or panic disorder, either alone or in combi-
nation, was present in approximately two thirds of the patients with Cushing’s
disease. Interestingly, behavioral symptoms usually first occurred at or after the
onset of the first physical symptoms. However, the onset of panic disorder was as-
sociated with more chronic stages of active Cushing’s disease. In agreement with
the studies that involved small patient numbers, psychopathology was highly
prevalent in a large cohort of 162 patients with Cushing’s disease reported by
Sonino et al. (9). Major depression, according to DSM-IV criteria, was present in
more than 50% of the patients. Interestingly, the presence of psychopathology
was significantly associated with older age, female gender, higher pretreatment
24-hour urinary cortisol levels, a more severe clinical condition, and absence of
pituitary adenoma (Table 2). This has led to the inclusion of mood disorders in a
clinical index for rating the severity of CS (10).
Effects of reduction of corticosteroid synthesis or action on psychopathology in
Cushing’s syndrome
Only a few studies with a limited number of patients have reported the effects of
successful reduction of corticosteroid excess on psychopathology. These studies
demonstrate that both reduction of corticosteroid synthesis with ketoconazole or
Chapter 7130
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metyrapone and blockade of the glucocorticoid receptor with mifepristone posi-
tively affect psychopathology. The first study that reported the effects of medical
treatment of patients with CS was published in 1979 (11). In this study, in 38 pa-
tients with CS, 65% were diagnosed with depression of different clinical severity.
The majority of the patients were treated with metyrapone which resulted in re-
mission of psychiatric symptoms in virtually all of them (11). This impressive
treatment efficacy was later confirmed in another study with 53 patients with
Cushing’s disease pretreated with metyrapone and 24 patients who had been given
pituitary irradiation for a median duration of 27 months (12). In contrast to
metyrapone, a total of only 20 patients with CS have been reported that were
treated with the GR antagonist mifepristone. The clinical applicability and effec-
tivity of mifepristone in these CS patients was reviewed recently (13). Treatment
with mifepristone resulted in a dramatic improvement of clinical signs in 15/20
patients. In parallel, in 3 of the 4 patients with psychopathology a significant im-
provement was reported. It is important to note that the beneficial effects of
mifepristone on psychopathology already occur within a few days after the initi-
ation of treatment.
Reversibility of psychopathology after remission of Cushing’s syndrome
The literature is even scarcer when the potential reversibility of psychopathology
after successful surgical treatment of CS is considered. The paucity of data after
treatment indicates that a significant improvement occurs within the first year
after treatment. Starkman et al. (14) reported significant improvement in both
the depressed mood score and the modified Hamilton depression score in 23 pa-
tients with pituitary-dependent CS after treatment, which were also significantly
correlated to decreases in urinary cortisol excretion. The longitudinal course of
psychopathology in CS after correction of hypercortisolism was evaluated in 33
patients with active CS before and 3, 6 and 12 months after successful surgery.
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Table 2 Demographic and clinical correlates of major depression in pituitary-dependent Cushing’s 








Mean age (± SD), years 34.5 ± 13.5 40.0 ± 11.4 <0.01 
Sex, male/female 26/48 12/76 <0.01 
Urinary cortisol, nmol/day 1,076 ± 786 1,694 ± 1,170 <0.001 
Plasma ACTH, pmol/l 15.9 ± 9.4 18.8 ± 12.2 NS 
Clinical presentation, mild/severe 62/12 12/76 <0.001 
Pituitary lesion2, adenoma/no 
adenoma 
45/8 41/21 <0.05 
NS, not significant; 1, by !2 or t test; 2, data available in 115 cases 
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Before cure, 67% of the patients had significant psychopathology, predominantly
atypical depressive disorder and/or major affective disorder. After cure, overall
psychopathology decreased significantly to 54% at 3 months, 36% at 6 months,
and 24% at 12 months, when there was a parallel recovery of the hypothalamic-
pituitary-adrenal axis (Figure 1). The authors also found an inverse correlation
between psychological recovery and baseline morning cortisol. Intriguingly, even
after correction of hypercortisolism, atypical depressive disorder continued to be
the prevailing diagnosis, whereas the frequency of suicidal ideation and panic dis-
order increased (15). In our Leiden series of patients treated for Cushing’s disease,
we have documented persistent psychopathology in CS even after long-term re-
mission for a mean of 13 years using general health-related questionnaires, like the
Hospital Anxiety and Depression Scale (HADS) and the Nottingham Health Pro-
file (NHP) (16). Noteworthy, some but not all items were no longer significant
when corrected for hypopituitarism, indicating that hypopituitarism per se also
importantly influences psychological well-being. The general clinical impression,
however, is that the final outcomes of treatment of CS are far from satisfactory
(17). In agreement, we recently documented in our Leiden cohort of 74 patients
treated for Cushing’s disease that cognitive function, reflecting memory and ex-
ecutive functions, was persistently impaired despite long-term cure. Compared
with patients that had been treated for nonfunctioning pituitary macroadenomas
(NFMA), patients cured from Cushing’s disease had lower scores on the Mini
Mental State Examination, and on the memory quotient of the Wechsler Mem-
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Figure 1 Significant changes in mean T-scores of subscales of the Symptom Checklist-90R for pa-
tients with CS during CS (time 1) and 3, 6, and 12 months after treatment. 
Dorn et al. (15); copyright 1997, The Endocrine Society, with permission. 
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ory Scale. Furthermore, patients cured from Cushing’s disease tended to recall
fewer words on the imprinting, immediate recall, and delayed recall trials of the
Verbal Learning Test of Rey. Patients cured from Cushing’s disease also had lower
scores on the Rey Complex Figure Test on both trials compared with NFMA pa-
tients. Finally, patients cured of Cushing’s disease also made fewer correct substi-
tutions (on the Letter-Digit Substitution Test) and came up with fewer correct
patterns (on the Figure Fluency Test)  compared with treated NFMA patients (18).
These observations indicate irreversible effects of previous hypercortisolism on
cognitive function and, thus, on the central nervous system.
Furthermore, in some, but not all, studies (2, 4, 19–21) maladaptive personality
traits were documented after treatment for Cushing’s disease. When patients with
CS were re-assessed after appropriate treatment, there was a significant decrease
in neuroticism score but no change in extraversion (4). However, another recent
study concluded that there were no differences in personality traits between pa-
tients with CS in remission and controls (19). Therefore, maladaptive personality
traits are documented after treatment of Cushing’s disease in some, but not all,
studies. However, definite conclusions on the extent of normalisation of mood and
behavior cannot be drawn from these studies because they included only limited
numbers of patients with heterogeneous clinical characteristics. Moreover, the
long-term effects of cured Cushing’s disease have not been studied in detail.
Conclusion
Active CS is associated with a high prevalence of psychopathology, mainly atyp-
ical depression. Treatments with glucocorticoid reducing or blocking agents can
rapidly relief symptoms. After successful surgery, psychopathology decreases but
mood and behavior do not seem to normalize. After long-term remission, patients
with Cushing’s disease still show decreased quality of life and impaired cognitive
function. Future studies should aim at further investigating if and how CS longi-
tudinal changes affect (subclinical) psychopathology.
Neuropsychiatric disorders in Cushing’s syndrome 133
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Abstract
Objective: Active acromegaly is associated with psychopathology, personality
changes, and cognitive dysfunction. It is unknown whether, and to what extent,
these effects are present after long-term cure of acromegaly.
Aim: The aim of the study was to assess psychopathology, personality traits, and
cognitive function in patients after long-term cure of acromegaly.
Design: This was a cross-sectional study.
Patients and Methods: We studied 68 patients after long-term cure (13±1yr) of
acromegaly and 68 matched controls. We compared these data with 60 patients
treated for nonfunctioning pituitary macroadenomas (NFMAs) and 60 matched
controls. Psychopathology was assessed using the Apathy Scale, Irritability Scale,
Hospital Anxiety and Depression Scale, and Mood and Anxiety Symptoms Ques-
tionnaire short-form, and personality was assessed by the Dimensional Assess-
ment of Personality Pathology short-form (DAPPs). Cognitive function was
assessed by 11 tests.
Results: Compared with matched controls, patients cured from acromegaly scored
significantly worse on virtually all psychopathology questionnaires and on several
subscales of the DAPPs. Compared with NFMA patients, patients cured from
acromegaly scored worse on negative affect (P=0.050) and somatic arousal
(P=0.009) and seven of 18 subscales of the DAPPs (P<0.05). Cognitive function in
patients cured from acromegaly did not differ from matched controls or patients
treated for NFMA.
Conclusion: Patients with long-term cure of acromegaly show a higher preva-
lence of psychopathology and maladaptive personality traits but not cognitive
dysfunction, compared with matched controls and patients treated for NFMA.
These results suggest irreversible effects of previous GH excess, rather than ef-
fects of pituitary adenomas per se and/or their treatment, on the central nervous
system.
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Introduction
Acromegaly is associated with typical signs and symptoms caused by excess of GH
and IGF-I. Almost 60yr ago, Bleuler (1, 2) reported that patients with active
acromegaly and acromegalic patients after radiotherapy were often dull and apa-
thetic and sometimes had an irritable mood. Subsequently other studies docu-
mented that patients with active acromegaly suffer from cognitive dysfunction,
personality changes, and various forms of psychopathology (3–7). These observa-
tions suggest that the central nervous system is also involved in the clinical syn-
drome of active acromegaly. This notion is supported by the presence of GH
receptors in various brain areas outside the classical pathways of the GH-IGF-I
axis (8). Some of these structures are crucial for cognitive function and influence
mental status and personality through connections with the limbic system and
frontal lobe (9).
Many of the systemic changes induced by previous excess of GH and/or IGF-I are
not completely reversed on successful biochemical treatment of active acromegaly
(10), which may also be true for the effects of GH and/or IGF-I on the central
nervous system. For instance, 36% of the patients with long-term cure of
acromegaly showed elevated scores for anxiety and depression (11). We hypoth-
esized that some of the effects of GH and/or IGF-I excess on the central nervous
system might be irreversible. Therefore, the aim of the present study was to as-
sess whether previous GH and/or IGF-I excess is associated with psychopathology,
maladaptive personality traits, and cognitive dysfunction. We compared psy-
chopathology, personality traits, and cognitive function between patients with
long-term cure of acromegaly and gender-, age-, and education-matched controls.
To assess to what extent treatment of pituitary adenomas per se affected our pa-
rameters, we additionally compared patients with long-term cure of acromegaly
to patients treated for nonfunctioning pituitary macroadenomas (NFMAs).
Patients and Methods
Patients
We included four groups of subjects: 1) patients with long-term cure of
acromegaly, and 2) age-, gender-, and education-matched control subjects for
these patients with previous acromegaly, 3) patients previously treated for NFMA,
and 4) age-, gender-, and education-matched control subjects for the patients pre-
viously treated for NFMA. The inclusion of two separate control groups was nec-
essary because patients with acromegaly and patients treated for NFMA differ
with respect to age and distribution of level of education.
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Inclusion criteria were a history of acromegaly or NFMA, treatment by transsphe-
noidal surgery, age above 18yr, and remission of acromegaly defined by strict bio-
chemical criteria (12). Exclusion criteria were a low Mini-Mental State
Examination (MMSE) score, present or previous drug or alcohol abuse, and neu-
rological disorders, not related to acromegaly or NFMA, because of potential in-
terference with mental status, personality, and cognition.
We asked all eligible patients followed up in our institution to participate. Each
patient was asked to provide a control subject of comparable gender, age, and ed-
ucational level. When patients did not respond to our invitation within 3 wk, we
encouraged them by phone to participate. The response rate was 93%. Of all pa-
tients (n=164) who were contacted to participate in this study, 92 patients were
interested, of whom 68 completed all questionnaires and cognitive tests. Sixty pa-
tients preferred not to participate, and 12 patients did not respond. The clinical
characteristics of the patients who did not participate were not different from
those of the participating patients. Reasons for not participating were remote dis-
tance to our institution, participation in other studies, old age, and debilitating
disease. None of the subjects stopped participation during the study at a later stage.
The diagnosis of acromegaly had been established by clinical signs and symptoms
and biochemical tests, including impaired suppression of GH during glucose tol-
erance test and increased IGF-I levels for age. Cure of acromegaly was defined by
normal serum IGF-I levels for age and serum GH levels less than 1.9µg/l for all pa-
tients and, in patients without somatostatin analog treatment, also by normal sup-
pression of GH levels (<0.38µg/liter) during a glucose tolerance test (13). Remission
was confirmed by repeating the tests at yearly intervals. Patients were followed
up at our outpatient department, and pituitary hormone replacement was pre-
scribed dependent on the results of the yearly evaluation of pituitary functions
(see below).
In addition, we invited 133 patients previously treated by transsphenoidal sur-
gery for nonfunctioning pituitary macroadenomas to participate. Each patient was
asked to provide a control of comparable gender, age, and educational level, who
was evaluated on the same day as the patient. The response rate was 96%. Eighty-
four patients agreed to participate in this study, of whom 60 filled out all ques-
tionnaires and completed all cognitive tests. Forty-three patients preferred not to
participate, and six patients did not respond. There were no differences in clini-
cal characteristics between the patients who decided to participate and those who
decided not to participate. None of the subjects stopped participation during the
study at a later stage.
Pituitary function was assessed in patients treated for acromegaly or NFMA at
yearly intervals by experienced clinical endocrinologists. This evaluation con-
sisted of measurement of free T4 and testosterone/SHBG (male patients) levels. If
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these laboratory results were below the lower limit of the respective reference
ranges, substitution with L-T4 and/or testosterone was prescribed. In the case of
amenorrhea and low estradiol levels in premenopausal women, estrogen replace-
ment was prescribed. Corticotrope function was assessed by appropriate stimula-
tion tests, including a CRH stimulation test or an insulin tolerance test. Normal
cortisol reserve was defined by stimulated cortisol concentrations greater than
550nmol/l. In cortisol-deficient patients, the hydrocortisone dose was on average
20mg/d divided into two to three dosages. Evaluation of GH deficiency was per-
formed by an insulin tolerance test and/or a GHRH-arginine test, only in patients
under the age of 70yr and only after at least 2yr of remission. In NFMA patients
with inadequate stimulation of GH levels by one of these tests, treatment with
recombinant human (rh) GH was prescribed, aiming at IGF-I levels between 0
and +2 SD values. Patients previously treated for acromegaly were tested with the
same tests (14), but in case of GH deficiency, these patients were treated with
rhGH from 2005 onward during a controlled trial of rhGH replacement (15).
The protocol was approved by the Medical Ethics Committee of the Leiden Uni-
versity Medical Center, and written informed consent was obtained from all sub-
jects.
Study design
The study consisted of a single study visit, during which each participant partic-
ipated in a structured interview and performed the cognitive tests. Furthermore,
patients and controls were asked to complete five questionnaires on psy-




Apathy was assessed by the Apathy Scale that consists of 14 questions on a 4-point
scale measuring different features of apathy in the 2 previous weeks. The total
score of this scale ranges from 0 to 42 points, with higher scores indicating greater
apathy. Apathy is defined by a total score of 14 points or more (16, 17).
Irritability Scale
Irritability was assessed by the Irritability Scale that consists of 14 items on a 4-
point scale, which assesses different features of irritability in the 2 previous weeks.
The total score ranges from 0 to 42 points, with higher scores indicating greater
irritability. Irritability is defined by a total score of 14 points or more (17).
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Hospital Anxiety and Depression Scale (HADS)
Anxiety and depression were assessed by the HADS that consists of 14 items on a
4-point scale. Both anxiety and depression subscale scores range from 0 to 21
points. Higher scores indicate more severe anxiety and/or depression. Anxiety or
depression is defined by total scores more than 13 points on the respective sub-
scales (18, 19).
Mood and Anxiety Symptoms Questionnaire short-form (MASQ-30)
The MASQ-30 consists of 30 items to assess symptoms of mood and anxiety dis-
orders subdivided into the three subscales: negative affect, lack of positive affect,
and somatic arousal. The scores of each subscale range from 10 to 50, with higher
scores indicating more severe negative affect, more positive affect, or more so-
matic arousal. There are no formal cutoff scores for these subscales (20, 21).
Dimensional Assessment of Personality Pathology short-form (DAPPs)
The DAPPs consists of 136 items assessing personality subdivided into 18 sub-
scales: submissiveness, cognitive distortion, identity problems, affective lability,
stimulus seeking, compulsivity, restricted expression, callousness, oppositional-
ity, intimacy problems, rejection, anxiousness, conduct problems, suspiciousness,
social avoidance, narcissism, insecure attachment, and self-harm. The score for
each subscale differs with maxima of 30–40, and higher scores indicate more pro-
nounced maladaptive personality traits. There are no formal cutoff scores for these
subscales (22, 23).
Cognitive evaluation
Cognitive tests were used to assess the full spectrum of cognitive functioning. A
functional classification was used to subdivide the 11 tests into the cognitive do-
mains global cognitive functioning, memory, and executive functioning (24). The
psychological evaluation took approximately 1.5handwasperformed in a prede-
fined order. None of the patients required more than one session to complete all
tests. The following tests were used: MMSE, Wechsler Memory Scale, Verbal
Learning Test of Rey, Rey Complex Figure Test, Trail-Making Test, Stroop Color-
Word Test, Letter-Digit Substitution Test, Digit-Deletion Test, Figure Fluency
Test, FAS test, and the synonyms subtest of the Groninger Intelligence Test-2 (32–
41).The description of these tests is included as an online supplement, published
on The Endocrine Society’s Journals Online web site at http://jcem.endojour-
nals.org.
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Statistical analysis
Data were analyzed using PASW Statistics version 17.0.2 (SPSS Inc., Chicago, IL,
USA). All data were presented as mean ± SD, unless mentioned otherwise. The pri-
mary analysis comprised the comparison of the results between patients cured of
acromegaly and their matched controls and between the patients with NFMA and
their matched controls. Groups were compared using a linear mixed model, with
the matched patient-control pairs as random factor. For the clinical characteristics,
a nonparametric χ2 test was used in case of categorical data, and the Mann-Whit-
ney test was used in case of continuous variables. Secondary analysis comprised
the comparison of results in relation to patient and treatment characteristics. To
compare patients treated for acromegaly and patients treated for NFMA, mean and
SD scores for each questionnaire subscale were calculated for each control group,
and subsequently Z-scores were calculated for each patient group in relation to
their appropriate control group. The Z-scores were compared using a general lin-
ear model, with additional radiotherapy and hypopituitarism as fixed factors. Odds
ratios were calculated using the (ad)/(bc) formula. The odds ratios represent the
odds of a score above the cutoff score in a specific questionnaire in the acromegaly
or NFMA group to the odds of a score above the cutoff score in the matched con-
trols. Independent variables affecting psychopathology and personality in patients
cured of acromegaly were explored by stepwise linear regression analysis. The
standardized β-coefficients of this analysis were reported. The level of significance
was set at P≤0.05.
Results
Patient characteristics
Patients with long-term cure of acromegaly 
All patients (n=68) had been treated by transsphenoidal surgery and 15 patients
(22%) had been treated by additional radiotherapy. Eleven patients (16%) were
treated by somatostatin analogs, and two patients (3%) received pegvisomant ther-
apy. All patients were in biochemical remission. Twenty-one percent of the pa-
tients had suffered from a microadenoma, 54% from a noninvasive
macroadenoma, and 21% from an invasive macroadenoma. The mean duration of
active disease before treatment was 7.4±0.7yr, whereas the mean duration of re-
mission was 13.1±1.0yr. Mean GH levels before operation were 96±16µg/liter and
mean IGF-I SD adjusted for gender and age was 8.5±0.8. The GH concentrations
preoperatively are derived from the mean of four samples obtained with 30-min
intervals during 2h (Table 1). 
At the time of the current study, 29 patients (43%) required treatment for pitu-
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itary insufficiency, and 16 patients (24%) were treated for GH deficiency with
rhGH. There were no differences between patients and controls in gender, age,
and education level. During the interview, 44% of the patients reported memory
problems in daily life, and 25% reported problems in executive functioning. 
Patients treated for nonfunctioning pituitary macroadenomas
All patients (n=60) had previously been treated by transsphenoidal surgery and 27
patients (45%) also by postoperative radiotherapy. Fifty-six patients (93%) re-
quired treatment for pituitary insufficiency, and 46 NFMA patients (77%) were on
rhGH replacement therapy. There were no differences between patients and con-
trols in gender, age, and education level (Table 1). During the interview, 37% of
the patients reported memory problems in daily life, and 27% reported problems
in executive functioning.
Psychopathology, personality traits, and cognitive function
Patients with long-term cure of acromegaly versus their matched controls 
Patients with long-term cure of acromegaly scored worse compared with matched
controls on the Apathy Scale (P=0.001), the Irritability Scale (P=0.006), the anx-
iety and depression subscales of the HADS (P=0.031, and P=0.003, respectively),
and the somatic arousal subscale of the MASQ-30 (P=0.042). There were no dif-
ferences on the negative and positive affect subscales of the MASQ-30 between pa-
Chapter 8144
Table 1  Clinical characteristics of patients with long term cure of acromegaly and of patients previously 
treated for NFMA 
 
 Acromegaly patients 
(n=68) 
NFMA patients   
(n=60) 
Gender (male/female) 35/33 34/26 
Age in years  59 (11) 62 (10) 






Transsphenoidal surgery, n (%) 68 (100%) 60 (100%) 
Additional radiotherapy, n (%) 15 (22%) 27 (45%) 
Somatostatin analogue therapy, n (%) 11 (16%) NA 
Pegvisomant therapy, n (%) 2 (3%) NA 
Duration active disease, yr (se) 7.4 (0.7) NA 
Duration of remission/follow-up, yr 
(se) 
13.1 (1.0) 13.5 (1.4) 
Hypopituitarism, n (%) Any axis: 29 (43%) 
GH: 16 (24%) 
LH/FSH: 13 (19%) 
TSH: 17 (25%) 
ACTH: 21 (31%) 
Any axis: 56 (93%) 
GH: 46 (77%) 
LH/FSH: 34 (57%) 
TSH: 40 (67%) 
ACTH: 40 (67%) 
GH level before operation (se) 96 µg/liter (16) NA 
Data are mean ± SD unless otherwise mentioned, NA; not applicable, se; standard error of the mean 
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tients and controls. Furthermore, patients with cured acromegaly scored worse
on the affective lability (P=0.003), oppositionality (P=0.012), anxiousness
(P=0.030), and self-harm (P=0.042) subscales of the DAPPs (see also Table 2). 
On the Apathy Scale, 47% of the patients with acromegaly (odds ratio 3.3) had a
score of 14 or more, indicative for the presence of clinically significant apathy,
whereas 35% of the patients (odds ratio 2.0) had a score of 14 or more on the Ir-
ritability Scale, indicative for the presence of clinically significant irritability. On
the HADS, 19% of the patients with cured acromegaly (odds ratio 2.1) scored
greater than 13, indicative for the presence of clinically relevant depression or
anxiety. There were significantly more patients than controls with clinically rel-
evant scores on the Apathy Scale (P=0.001) but not on the other questionnaires.
The data on cognitive function are included as a supplemental table (Supplemen-
tal Table 1). There were a few significant differences between patients and con-
trols in cognitive functioning. Patients with long-term cure of acromegaly scored
significantly worse on only one verbal memory test, in which they remembered
fewer words than controls in two of three trials (P=0.017 and P=0.012). Further-
more, patients performed worse on all aspects of a verbal fluency test (P=0.020).
Patients treated for NFMA versus their controls
Patients treated for NFMA scored worse only on the Apathy scale (P=0.001) and
on the depression subscale of the HADS compared with their matched controls
(P<0.001). On the DAPPs, NFMA patients scored worse on the trait affective la-
bility (P=0.011), compared with controls (Table 3).
On the apathy scale, 40% of the NFMA patients (odds ratio 2.4) scored 14 or more
and 27% of the patients (odds ratio 1.8) scored 14 or more on the Irritability Scale.
Twenty-five percent of the patients (odds ratio 4.4) scored greater than 13 on the
HADS. There were significantly more patients than controls with a clinically rel-
evant score on the Apathy Scale and the HADS (P=0.034 and P=0.005, respec-
tively).
The data on cognitive function are included as a supplemental table (Supplemen-
tal Table 2). There were hardly any differences between patients and controls in
tests of cognitive function. Patients treated for NFMA scored better on the MMSE
(P=0.013) but could remember fewer words on one of three trials measuring ver-
bal memory (P=0.043). Furthermore, patients made more errors on one of two
trials of the Trail-Making Test (P=0.007).
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   Total score 13.8 (6.1) 10.5 (4.8) 0.001 
   Score !14, n(%) 32 (47%) 14 (21%) 0.001 
 
Irritability Scale 
   
   Total score 12.7 (7.7) 9.5 (5.7) 0.006 
   Score !14, n(%) 24 (35%) 14 (21%) 0.056 
 
HADS 
   
   Anxiety 5.0 (3.7) 3.8 (3.1) 0.031 
   Depression 4.3 (4.2) 2.4 (2.8) 0.003 
   Score >13, n(%) 13 (19%) 7 (10%) 0.146 
 
MASQ-30 
   
   Negative Affect 16.6 (6.0) 15.1 (5.1) 0.126 
   Positive Affect 28.4 (8.8) 30.6 (8.2) 0.089 
   Somatic Arousal 14.6 (5.4) 12.9 (4.3) 0.042 
 
DAPP 
   
   Submissiveness 17.1 (6.2) 15.8 (5.0) 0.160 
   Cognitive distortion 9.9 (3.8) 8.8 (2.7) 0.055 
   Identity problems 11.0 (4.9) 9.8 (4.1) 0.128 
   Affective lability 19.2 (6.5) 16.0 (5.8) 0.003 
   Stimulus seeking 13.9 (4.0) 14.9 (5.0) 0.218 
   Compulsivity 22.3 (6.8) 21.8 (6.6) 0.653 
   Restricted expression 20.5 (6.3) 20.1 (5.7) 0.680 
   Callousness 16.5 (5.4) 16.0 (5.2) 0.558 
   Oppositionality 22.2 (7.4) 19.2 (6.4) 0.012 
   Intimacy problems 20.2 (7.4) 18.2 (5.6) 0.084 
   Rejection 18.9 (6.0) 18.7 (5.9) 0.776 
   Anxiousness 14.0 (5.3) 12.2 (4.3) 0.030 
   Conduct problems 9.8 (2.5) 9.6 (2.7) 0.616 
   Suspiciousness 11.2 (3.8) 12.1 (4.7) 0.206 
   Social avoidance 12.1 (5.3) 11.5 (4.5) 0.455 
   Narcissism 15.5 (5.8) 14.6 (4.9) 0.306 
   Insecure attachment 13.1 (6.0) 13.0 (5.6) 0.940 
   Self-harm 7.6 (3.8) 6.6 (2.0) 0.042 
Data are mean (SD), unless otherwise mentioned  
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Supplementary Table 1 Cognitive outcomes: patients cured from acromegaly vs matched controls 













    
MMSE Score  28.3 (1.7) 28.2 (1.8) 0.722 
 
Memory 
    
Wechsler Memory Scale Memory Quotient  112.7 (17.2) 113.7 (15.8) 0.694 
 Information 5.8 (0.4) 5.9 (0.3) 0.618 
 Orientation 4.9 (0.3) 4.9 (0.3) 1.00 
 Concentration 7.4 (1.7) 7.2 (1.8) 0.466 
 Logical memory 6.8 (4.0) 6.8 (3.0)  
 Digit span 9.6 (1.9) 9.9 (1.9) 0.350 
 Visual memory 8.6 (2.8) 8.5 (3.3) 0.744 
 Associative learning 15.0 (3.6) 16.2 (2.8) 0.017 
Verbal Learning Test of Rey Imprinting, total 5.1 (1.9) 5.2 (2.2) 0.608 
 Immediate, total 9.0 (2.6) 9.8 (2.5) 0.027 
 Delayed, total 6.6 (3.1) 7.7 (3.2) 0.012 
Rey Complex Figure test Immediate  17.8 (5.4) 18.3 (6.9) 0.602 
 Delayed  17.6 (5.5) 17.8 (7.0) 0.887 
 
Executive functioning 
    
Trail making test Trail A, time 0.4 (0.3) 0.4 (0.2) 0.537 
 Trail A, errors 0.1 (0.4) 0.2 (0.4) 0.621 
 Trail B , time 1.3 (0.8) 1.2 (0.9) 0.625 
 Trail B, errors 0.6 (1.7) 0.8 (2.4) 0.649 
Stroop color-word test Interference, total 38.1 (10.0) 40.1 (10.0) 0.251 
 Interference, 
mistakes 
1.4 (5.7) 0.3 (0.7) 0.105 
Letter-digit substitution test # correct 31.2 (7.7) 31.7 (7.7) 0.657 
 # errors 0.1 (0.3) 0.6 (3.9) 0.305 
Digit-deletion test # correct 376.1 (89.0) 395.0 (85.5) 0.188 
 # missed 4.7 (4.2) 4.5 (5.5) 0.766 
Figure Fluency # patterns 58.0 (24.0) 57.6 (22.3) 0.906 
 % repeats 11.3 (12.5) 8.3 (9.0) 0.120 
 % errors 18.4 (15.2) 17.7 (14.8) 0.751 
FAS # correct 32.0 (13.3) 37.3 (13.9) 0.019 
 % repeats 1.1 (1.9) 2.1 (3.1) 0.015 
 % errors 4.0 (5.1) 1.7 (3.0) 0.002 
Groninger Intelligence test Synonyms score 4.5 (2.0) 4.9 (1.8) 0.132 
Data are mean (SD) 
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Comparison of Z-scores between patients cured from acromegaly and patients
treated for NFMA
Patients with long-term cure of acromegaly had higher scores on the negative af-
fect subscale (P=0.05) and the somatic arousal subscale (P=0.009) of the HADS
compared with treated NFMA patients. Furthermore, in comparison with NFMA
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   Total score 13.1 (5.0) 10.4 (3.7) 0.001 
   Score !14, n(%) 24 (40%) 13 (22%) 0.034 
 
Irritability Scale 
   
   Total score 9.9 (5.7) 8.5 (5.3) 0.175 
   Score !14, n(%) 16 (27%) 10 (17%) 0.200 
 
HADS 
   
   Anxiety 4.5 (3.6) 3.6 (3.1) 0.131 
   Depression 4.1 (3.9) 1.9 (2.2) 0.000 
   Score >13, n(%) 15 (25%) 4 (7%) 0.005 
 
MASQ-30 
   
   Negative Affect 15.5 (5.7) 15.1 (5.6) 0.739 
   Positive Affect 29.6 (8.5) 30.5 (8.2) 0.562 
   Somatic Arousal 14.7 (5.2) 14.3 (4.8) 0.715 
 
DAPP 
   
   Submissiveness 16.7 (5.8) 16.9 (6.2) 0.832 
   Cognitive distortion 9.6 (4.0) 9.9 (4.8) 0.647 
   Identity problems 10.2 (4.9) 9.3 (4.3) 0.310 
   Affective lability 18.3 (5.7) 15.7 (5.7) 0.011 
   Stimulus seeking 14.6 (4.7) 14.7 (5.4) 0.861 
   Compulsivity 21.9 (6.8) 21.0 (5.8) 0.441 
   Restricted expression 21.6 (4.6) 20.5 (5.6) 0.227 
   Callousness 16.6 (4.6) 15.8 (4.3) 0.369 
   Oppositionality 20.6 (6.7) 19.2 (6.1) 0.242 
   Intimacy problems 20.0 (6.5) 20.3 (6.2) 0.810 
   Rejection 19.0 (11.1) 17.2 (5.7) 0.258 
   Anxiousness 12.8 (4.6) 12.3 (4.8) 0.542 
   Conduct problems 9.6 (2.7) 9.4 (2.3) 0.765 
   Suspiciousness 10.9 (3.4) 11.2 (4.0) 0.590 
   Social avoidance 11.1 (3.9) 10.3 (3.9) 0.232 
   Narcissism 15.5 (5.0) 14.7 (5.0) 0.378 
   Insecure attachment 12.9 (5.1) 12.6 (5.3) 0.827 
   Self-harm 6.9 (2.4) 6.4 (1.7) 0.199 
Data are mean (SD), unless otherwise mentioned  
 
Tiemensma hfd 8:Layout 1  23-01-2012  16:35  Pagina 148
Psychopathology and personality traits in acromegaly 149
Supplementary Table 2 Cognitive outcomes: patients cured from NFMA vs matched controls 












    
MMSE Score  28.9 (1.1) 28.3 (.8) 0.013 
 
Memory 
    
Wechsler Memory Scale Memory Quotient  119.0 (16.7) 119.2 (14.2) 0.999 
 Information 5.9 (0.3) 5.9 (0.3) 0.721 
 Orientation 4.9 (0.3) 4.9 (0.2) 0.788 
 Concentration 7.6 (1.8) 7.5 (1.4) 0.812 
 Logical memory 7.4 (3.2) 7.5 (2.7)  
 Digit span 10.1 (1.6) 10.0 (1.6) 0.818 
 Visual memory 8.9 (3.4) 8.7 (3.4) 0.686 
 Associative learning 15.8 (2.9) 16.4 (3.2) 0.250 
Verbal Learning Test of Rey Imprinting, total 5.1 (1.8) 5.3 (1.9) 0.546 
 Immediate, total 9.1 (2.9) 9.8 (2.1) 0.122 
 Delayed, total 6.6 (3.4) 7.8 (2.8) 0.043 
Rey Complex Figure test Immediate  19.5 (6.8) 19.5 (6.1) 0.889 
 Delayed  19.3 (6.4) 19.3 (6.3) 0.902 
 
Executive functioning 
    
Trail making test Trail A, time 0.6 (0.4) 0.5 (0.4) 0.109 
 Trail A, errors 0.3 (0.5) 0.1 (0.3) 0.007 
 Trail B , time 1.5 (0.7) 1.3 (0.7) 0.072 
 Trail B, errors 0.6 (1.3) 0.5 (0.9) 0.641 
Stroop color-word test Interference, total 36.0 (8.4) 37.2 (8.0) 0.407 
 Interference, 
mistakes 
0.2 (0.4) 0.2 (0.5) 0.953 
Letter-digit substitution test # correct 30.7 (8.3) 31.1 (7.0) 0.721 
 # errors 0.0 (0.2) 0.1 (0.4) 0.126 
Digit-deletion test # correct 358.4 (77.9) 382.2 (74.9) 0.054 
 # missed 3.8 (4.2) 4.7 (4.6) 0.222 
Figure Fluency # patterns 48.1 (21.3) 54.6 (21.9) 0.083 
 % repeats 8.9 (8.8) 6.6 (6.3) 0.107 
 % errors 20.3 (11.3) 22.2 (15.4) 0.376 
FAS # correct 33.4 (12.9) 32.7 (11.4) 0.779 
 % repeats 1.1 (2.0) 1.1 (2.0) 0.619 
 % errors 2.2 (5.7) 1.8 (3.0) 0.873 
Groninger Intelligence test Synonyms score 5.2 (1.9) 4.9 (1.8) 0.395 
Data are mean (SD) 
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patients, acromegaly patients scored worse on the submissiveness (P=0.049), cog-
nitive distortion (P=0.001), identity problems (P=0.036), affective lability
(P=0.044), oppositionality (P=0.025), anxiousness (P=0.005), and self-harm
(P=0.008) subscales of the DAPPs. This is depicted in Figure 1 and Figure 2.
Patients with long-term cure of acromegaly scored worse on two aspects of exec-
utive functioning tests measuring attention, compared with NFMA patients, on
which they worked more slowly (P=0.015) and made more mistakes (P=0.042).
The memory tests were not different between the patient groups. The data on

































Figure 1: Z-scores of patients cured of acromegaly and patients treated for NFMA, calculated for
each patient group by comparison with their own matched control groups. Z-scores with standard
errors are given in this figure. On the negative affect subscale and somatic arousal subscale of the
MASQ-30 patients with long-term cured acromegaly scored worse when compared with patients
with treated NFMA. 
Comparison of psychopathology of patients with long-term cure of acromegaly and patients with
NFMA by Z-scores, calculated for each patient group by comparison with their own matched con-
trol groups (i.e. Z-score of 0.0).
Tiemensma hfd 8:Layout 1  23-01-2012  16:35  Pagina 150
Psychopathology and personality traits in acromegaly 151
Figure 2: Z-scores of patients cured of acromegaly and patients treated for NFMA, calculated for
each patient group by comparison with their own matched control groups. Z-scores with standard
errors are given in this figure. Patients with long-term cured acromegaly scored worse on the DAPP
subscales submissiveness, cognitive distortion, identity problems, affective lability, oppositionality,
anxiousness, and self-harm when compared with patients with treated NFMA. 
Comparison of personality of patients treated for acromegaly and patients treated for NFMA by Z-
scores, calculated for each patient group by comparison with their own matched control groups (i.e.
Z-score of 0.0). 
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Supplementary Table 3.  Cognitive function: comparison between patients with acromegaly and 
patients with NFMA by Z-scores, calculated for each patient group by comparison with their own 
matched controls 











    
MMSE Score  0.06 (-0.2 to 0.3) 0.35 (0.2 – 0.5) 0.236 
 
Memory 
    
Wechsler Memory Scale Memory Quotient -0.06 (-0.3 to 0.2) -0.01 (-0.3 to 0.3) 0.446 
 Information -0.09 (-0.4 to 0.2) -0.04 (-0.4 to 0.3) 0.915 
 Orientation 0.00 (-0.2 to 0.2) -0.05 (-0.3 to 0.2) 0.794 
 Concentration 0.11 (-0.1 to 0.3) 0.05 (-0.2 to 0.4) 0.652 
 Logical memory 0.00 (-0.3 to 0.3) -0.06 (-0.3 to 0.3) 0.828 
 Digit span -0.15 (-0.4 to 0.1) 0.04 (-0.2 to 0.3) 0.511 
 Visual memory 0.05 (-0.2 to 0.2) 0.05 (-0.2 to 0.3) 0.417 
 Associative learning -0.41 (-0.7 to 0.1) -0.19 (-0.4 to 0.1) 0.117 
Verbal Learning Test of Rey Imprinting, total -0.07 (-0.3 to 0.1) -0.11 (-0.4 to 0.2) 0.411 
 Immediate, total -0.34 (-0.6 to -0.1) -0.34 (-0.7 to 0.1) 0.145 
 Delayed, total -0.36 (-0.6 to -0.1) -0.41 (-0.7 to -0.1) 0.092 
Rey Complex Figure test Immediate  -0.07 (-0.3 to 0.1) 0.01 (-0.2 to 0.3) 0.051 
 Delayed  -0.02 (-0.2 to 0.2) 0.00 (-0.2 to 0.3) 0.243 
 
Executive function 
    
Trail making test Trail A, time 0.09 (-0.2 to 0.4) 0.28 (0.0 – 0.5) 0.967 
 Trail A, errors -0.09 (-0.3 to 0.2) 0.75 (0.3 – 1.2) 0.406 
 Trail B , time 0.07 (-0.2 to 0.3) 0.31 (0.0 – 0.6) 0.831 
 Trail B, errors -0.07 (-0.2 to 0.1) 0.11 (-0.3 to 0.5) 0.824 
Stroop color-word test Interference, total -0.20 (-0.4 to 0.0) -0.15 (-0.4 to 0.2) 0.345 
 Interference, 
mistakes 
1.55 (-0.3 to 3.5) 0.00 (-0.2 to 0.2) 0.355 
Letter-digit substitution test # correct -0.07 (-0.3 to 0.2) -0.06 (-0.3 to 0.3) 0.018 
 # errors -0.14 (-0.2 to -0.1) -0.22 (-0.3 to -0.1) 0.325 
Digit-deletion test # correct -0.22 (-0.5 to 0.0) -0.32 (-0.6 to 0.0) 0.229 
 # missed 0.05 (-0.1 to 0.2) -0.19 (-0.4 to 0.0) 0.042 
Figure Fluency # patterns 0.02 (-0.2 to 0.3) -0.30 (-0.5 to 0.0) 0.094 
 % repeats 0.33 (0.0 – 0.7) 0.37 (0.0 – 0.6) 0.828 
 % errors 0.05 (-0.2 to 0.3) -0.13 (-0.3 to 0.0) 0.258 
FAS # correct -0.38 (-0.6 to -0.1) 0.06 (-0.2 to 0.4) 0.148 
 % repeats -0.32 (-0.5 to -0.2)  0.03 (-0.2 to 0.3) 0.610 
 % errors 0.77 (0.3 – 1.1) 0.14 (-0.4 to 0.4) 0.194 
Groninger Intelligence test Synonyms score -0.22 (-0.5 to 0.0) 0.17 (0.0 – 0.5) 0.347 
Data are Z-scores mean (95% CI) 
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Factors associated with psychopathology and personality traits in patients with
cured acromegaly
Stepwise linear regression analysis was performed using the absolute test scores of
the patients with long-term cure of acromegaly as dependent variables and pre-
surgical GH level, pre-surgical IGF-I SD value, rhGH replacement therapy, so-
matostatin therapy, hypopituitarism, additional radiotherapy, duration of active
disease, and duration of remission as independent variables.
The negative affect subscale of the MASQ-30 was negatively associated with hy-
popituitarism (β=-0.380, P=0.011), with hypopituitarism being associated with
lower scores. The positive affect subscale of the MASQ-30 was negatively associ-
ated with radiotherapy (β=-0.348, P=0.022), which indicates that radiotherapy is
associated with lower scores. However, only a small percentage of the patients
received radiotherapy (22%, n=15), which makes it difficult to draw solid con-
clusions on the association between our parameters of interest and radiotherapy.
Furthermore, the subscales compulsivity of the DAPPs (β=-0.334, P=0.027), re-
stricted expression (β=-0.336, P=0.026), and insecure attachment (β=-0.307,
P=0.043) were all negatively associated with rhGH replacement therapy, which
means that patients who receive rhGH have a tendency to score lower on these
subscales. The subscale oppositionality was positively associated with pre-surgi-
cal IGF-I SD value (β=0.323, P=0.033), which indicates that higher pre-surgical
IGF-I SD values are associated with higher scores on oppositionality. The rejec-
tion subscale was negatively associated with pre-surgical GH level (β=-0.333,
P=0.027), with higher preoperative GH levels being associated with a lower score.
Anxiousness was negatively associated with duration of remission (β=-
0.311,P=0.040), with longer duration of remission being associated with lower
anxiousness.
Discussion
This study demonstrates that patients with long-term cure of acromegaly suffer
from increased psychopathology and maladaptive personality traits, but hardly
from increased cognitive dysfunction, compared with matched controls. Patients
with long-term cure of acromegaly also showed more psychopathology, and es-
pecially more maladaptive personality traits, compared with patients treated for
NFMA. These observations indicate that the increased psychopathology and mal-
adaptive personality traits observed in patients with long-term cure of acromegaly
are not merely caused by pituitary adenomas per se and/or their treatment, but
rather by previous GH excess.
A direct comparison of parameters of interest between patients with long-term
Psychopathology and personality traits in acromegaly 153
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cure of acromegaly and patients treated for NFMA is confounded by relevant dif-
ferences in other clinical characteristics. Therefore, we included matched control
subjects for each patient group. We calculated Z-scores for each patient group in
comparison with their own matched controls. Subsequently we compared these
Z-scores to detect possible differences between patients with acromegaly and
NFMA patients. By using these Z-scores, we have carefully corrected for the dif-
ferences in clinical characteristics between both groups of patients. We have used
this approach for similar problems in the comparison of patients with Cushing’s
disease versus patients with NFMA (25, 26).
Table 4 summarizes the previous studies on psychopathology in patients with
acromegaly. Previous studies on psychopathology in patients with active
acromegaly reported affective disorders, fatigue, and loss of drive causing irri-
tability and impatience (3). Most patients cured of acromegaly notice an increase
in physical well-being (6), but they still have a high prevalence of psychological
distress, especially anxiety disorders and major depression (27, 28), although an-
other study found only increased prevalence of affective disorders (29). Limita-
tions of those studies are the limited number of included patients, and
heterogeneous clinical characteristics. Moreover, the effects of long-term cure of
acromegaly have not been studied in detail.
Several previous studies assessed the effects of acromegaly on personality (Table
4). Patients with active acromegaly were characterized by industriousness, con-
scientiousness, and compulsiveness and sometimes lack of self-confidence (3).
Furthermore, in patients with active acromegaly, a high need for sociability, high
self-assuredness, and industry have been reported (4). After treatment, patients
with acromegaly show a pattern of increased anxiety-related personality traits
with reduced impulsivity and novelty-seeking behavior (30). Thus, those previ-
ous studies indicate that maladaptive personality traits are present in active and
treated acromegaly patients. 
Our study extends these results by indicating that maladaptive personality traits
remain present after very long-term cure of acromegaly. Our study differs in sev-
eral respects from previous studies. First, the number of patients included is rel-
atively large in the present study compared with earlier studies. Second, the
duration of cure was very long in our study compared with previous studies.
Third, we compared patients with long-term cure of acromegaly both with
matched controls and with patients previously treated for NFMA. From the cur-
rent study, in addition to the studies summarized in Table 4, the notion emerges
that patients with active acromegaly suffer from increased prevalence of psy-
chopathology and maladaptive personality traits, and that long-term treatment of
acromegaly results in some, but not complete, recovery of these parameters.
Patients with long-term cure of Cushing’s disease suffer from impaired cognitive
Chapter 8154
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functioning (25). This is in contrast to the current observations in patients with
long-term cure of acromegaly. We speculate that these differences in cognitive
function between patients with long-term cure of acromegaly and patients with
long-term cure of Cushing’s disease are explained by glucocorticoid specific irre-
versible effects on the central nervous system on structures involved in cognitive
function, which are apparently not affected by previous GH and IGF-I excess.
In the present study, the outcomes of the questionnaires in patients with long-
term cure of acromegaly were still well within the normal reference ranges of -2
SD and +2 SD (Figs. 1 and 2). Anecdotal reports have documented patients with
pituitary disease and an apathy syndrome who had been incorrectly diagnosed as
major depression and who had been treated accordingly with antidepressants for
a long time (31). Our own subjective experiences in routine clinical practice sug-
gest that there are subtle differences between the personalities of patients cured
from acromegaly and those of patients with other pituitary diseases. However,
clinical endocrinologists are not trained to detect subtle manifestations of psy-
chopathology and maladaptive personality traits. We speculate that the results of
our study confirm the clinical impression that patients cured from acromegaly
have different and more serious complaints than patients with NFMA, even
though patients treated for NFMA have a higher incidence of hypopituitarism.
In summary, patients with long-term cure of acromegaly have a high prevalence
of psychopathology, compared with matched controls. Furthermore, patients with
long-term cure of acromegaly have a greater degree of maladaptive personality
traits, compared with both matched controls and patients treated for NFMA.
These results suggest irreversible effects of previous GH excess on the brain, rather
than effect of pituitary adenomas and/or their treatment in general. 
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163General discussion and summary
1. Introduction   
In the present thesis, we explored the long-term consequences of pituitary diseases
from a psychological perspective. Pituitary and adrenal adenomas can be treated
quite adequately from a medical perspective, but these patients suffer from im-
paired quality of life (QoL) despite long-term remission or cure. This decreased
QoL is assumed to originate mostly from physical complaints, but psychological
problems might also contribute. 
2. Illness perceptions
Although decreased QoL may originate from persisting limitations due to irre-
versible effects of previous excessive hormone exposure, an alternative hypothe-
sis is that the psychological impact of suffering from this disease reduces QoL. The
aim of the study described in Chapter 2 was to explore the illness perceptions of
patients after long-term remission of Cushing’s syndrome. This is the first time
that illness perceptions are addressed in endocrine diseases in general. We used
several validated QoL questionnaires and the Illness Perception Questionnaire
Revised to assess QoL and illness perceptions. The results indicate that affected ill-
ness perceptions and reduced QoL parameters are strongly related. Moreover, pa-
tients after long-term remission of Cushing’s syndrome reported more negative
illness perceptions compared with several reference groups with acute and chronic
conditions. In addition, patients with hydrocortisone dependency had stronger
beliefs regarding the chronic nature and the cyclical nature of Cushing’s syndrome
than patients without hydrocortisone dependency. Furthermore, hypopituitarism
was associated with the number of symptoms attributed to Cushing’s syndrome,
chronicity and fluctuations of the disease, and the perceived consequences of
Cushing’s syndrome. Therefore, hydrocortisone dependency and hypopituitarism
both influence illness perceptions. 
The perceptions of patients depend on information from different sources. There-
fore, these illness perceptions do not necessarily represent the actual medical sta-
tus of the disease. This might explain why patients in remission of Cushing’s
syndrome perceive their illness as chronic or cyclical and believe that psycholog-
ical attributions might have caused Cushing’s syndrome. 
The current study also demonstrates that there is a strong relationship between ill-
ness perceptions and QoL. This has already been observed in multiple other med-
ical conditions (1). This relationship is a relevant observation, since patients with
long-term cure of Cushing’s syndrome have persistent complaints reflected in im-
paired QoL (2-4). These complaints are often misunderstood and difficult to treat.
Tiemensma hfd 9:Layout 1  23-01-2012  16:35  Pagina 163
164 Chapter 9
Therefore, awareness of how these patients perceive their disease and its conse-
quences could lead to a better understanding of Cushing’s syndrome and its long-
term effects. 
In Chapter 3 we aimed to explore illness perceptions in patients after long-term
biochemical control of acromegaly. We used several validated QoL questionnaires
and the Illness Perception Questionnaire Revised to assess QoL and illness per-
ceptions. The results indicated that patients with long-term remission of
acromegaly have a good understanding of their disease, but they experience a lack
of personal control and are not very likely to seek medical care. Interestingly,
there are clear differences between illness perceptions in acromegaly and other
diseases. For example, acromegalic patients reported more negative illness per-
ceptions than patients with acute pain or vestibular schwannoma, but more pos-
itive illness perceptions than patients with chronic conditions, like chronic
obstructive pulmonary disease. In addition, patients with long-term remission of
acromegaly perceived impaired QoL. The illness perceptions in patients with
acromegaly correlated strongly with QoL parameters, in accordance with our ob-
servations in patients with long-term cure of Cushing’s disease and in other con-
ditions (Chapter 2, (1)).  
Patients in long-term remission of acromegaly reported somewhat more positive
illness perceptions than patients after long-term remission of Cushing’s syndrome.
It is tempting to speculate that there are disease-specific characteristics in illness
perceptions in addition to more general influences related to complaints or
chronicity. Additional research is needed to see whether these findings can be
extended to other endocrine diseases. 
It is important for endocrinologists to explain to the patients what might have
caused acromegaly, and ask the patient what their perceived cause of acromegaly
is. The illness perceptions of patients, including those pertaining to the perceived
cause of acromegaly, are based on various sources which indicates that illness per-
ceptions do not necessarily represent the actual medical status or cause of
acromegaly.
The current explorative study is important, since patients with acromegaly suffer
from impaired QoL even after long-term remission (5-7). The somatic and psy-
chological factors that contribute to decreased QoL are not well-known, but most
likely include musculoskeletal complaints (5), pituitary insufficiency (8;9) and the
perception of the patients of their disease. 
In conclusion, there is a strong correlation between illness perceptions and de-
creased QoL in patients with long-term remission of Cushing’s syndrome as well
as in patients after long-term remission of acromegaly. Patients after long-term re-
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mission of Cushing’s syndrome reported more negative illness perceptions com-
pared with various reference samples with acute and chronic diseases. Patients
with long-term remission of acromegaly reported more negative illness percep-
tions than patients with acute illness, but more positive illness perceptions than
patients with chronic diseases including Cushing’s syndrome. 
In the studies described above, the Common Sense Model of self-regulation (CSM)
by Leventhal et al. was used as starting point to understand the relation between
illness, illness perceptions, coping strategies, and outcome (10-13). Based on the
performed studies described in this thesis and a recent meta-analytic review of
the CSM (14), we postulate that the CSM should incorporate a new arm that rep-
resents QoL. The studies described in Chapter 2 and Chapter 3 show that illness
perceptions and QoL are strongly correlated. We revised the existing CSM, which
is depicted in Figure 1. We should note that further research is necessary to es-
tablish the correctness of the proposed addition of QoL in the CSM, and whether
QoL is involved in the feedback loop of the CSM. 
Stimuli  
(Illness) 
Cognitive response  
to health threat  
Emotional response  















Emotional outcomes  
Feedback loop 
Figure 1. The revised Common Sense Model, partially based on Hagger & Orbell (2003)
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In addition, the CSM does not encompass contextual factors. These contextual
factors are, however, embedded in the Chronic Care Model (CCM) (15). The CCM
incorporates self-management into a social context and characteristics of the
healthcare system. Both the CSM and the CCM revolve around the central posi-
tion of the patient in medical care for chronic illnesses. An important difference
between the models is that the CCM focuses on beliefs about the target behavior,
while the CSM includes beliefs about the illness. Therefore, Fischer et al. (16) de-
veloped the Trilevel Model of Self-Management and Chronic Care that ties to-
gether the CSM and the CCM (see Figure 2). 
Based on this Trilevel Model and our findings, we strongly encourage the devel-
opment of a self-management intervention for (treated) pituitary patients. This in-
tervention should incorporate self-management (17) and should intervene in
illness perceptions, which is a dynamic process. Another important aspect to take
into account in this intervention is self-efficacy (18;19), which might also play a
role in the willingness of patients to change their illness perceptions and/or cop-
ing strategies.
We believe that the proposed intervention will ultimately lead to a better QoL,
since illness perceptions and QoL are closely related in pituitary diseases. The
CSM implies that changing illness perceptions may lead to changes in relevant
self-management behaviors. Previous studies have already shown that psycho-
Figure 2. Trilevel Model of Self-Management and Chronic Care, adapted from Fischer et al. (2007)
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education interventions can indeed change negative illness perceptions (13;20)
and thereby self-management and, consequently, outcome (i.e. QoL). 
3. Coping strategies
In Chapter 4, we aimed to investigate coping strategies of patients after treatment
for pituitary adenomas. We used the Utrecht Coping Lijst to assess coping. The
study demonstrated that patients after appropriate treatment for pituitary adeno-
mas report less active coping, more avoidance coping and seek less social support
compared with an a-select sample from the Dutch population. Compared with
patients with chronic pain, patients treated for pituitary adenomas sought more
social support. Patients after treatment for pituitary disease were also compared
with patients in primary care psychology services. Patients with pituitary adeno-
mas scored lower on avoiding, seeking social support, passive coping, and ex-
pressing emotions, but higher on active coping. This indicates that patients treated
for pituitary adenomas report less effective coping strategies compared with the
normal population, but apparently use more effective coping strategies than pa-
tients with chronic pain and patients in primary care psychology services. Fur-
thermore, patients after treatment for Cushing’s disease, acromegaly, and NFMA
did not differ from each other with respect to coping strategies, besides the fact
that patients with Cushing’s disease sought more social support than patients
treated for NFMA. 
This is the first study that explored coping strategies in patients treated for Cush-
ing’s disease, acromegaly, or NFMA. We believe that information on coping strate-
gies of these patients is important, since they suffer from chronic and multiple
disabilities despite long term cure of their initial pituitary adenoma (2-5;21-25),
which are often misunderstood and difficult to treat. Knowledge of the coping
strategies can be used in designing an intervention based on e.g. cognitive be-
havioural therapy, self-management training, and information on the negative ef-
fects of the disease. 
In conclusion, patients treated for Cushing’s disease, acromegaly, or NFMA dis-
play different and less effective coping strategies compared with healthy controls.
Compared with patients with chronic pain and patients receiving primary care
psychology services, patients treated for pituitary adenomas report somewhat bet-
ter coping strategies. Therefore, there is a need to develop, to apply and to eval-
uate coping skills training and self-management in patients with this condition. 
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4. Cognitive functioning
In Chapter 5, we aimed to assess cognitive function in patients after long-term
remission of Cushing’s disease. We used eleven cognitive tests to assess the entire
spectrum of cognition. We compared patients after long-term remission of Cush-
ing’s disease with matched controls, and with patients after treatment for NFMA
using Z-scores. This study demonstrated that cognitive function is impaired in
patients despite long-term cure of Cushing’s disease. These patients reported im-
pairments in memory in daily life, which was confirmed by cognitive function-
ing tests. The performance was decreased in certain aspects of executive
functioning and several memory tasks, compared with matched controls. These
impairments were not merely related to pituitary disease in general, since these
patients with long-term cure of Cushing’s disease also revealed impaired cognitive
function compared with patients previously treated for NFMA. These observa-
tions indicate irreversible effects of previous hypercortisolism on cognitive func-
tion and, thus, on the central nervous system.
Several clinical characteristics influenced outcome parameters. Hypopituitarism
was associated with mildly impaired executive functioning. Hydrocortisone de-
pendency and additional radiotherapy were negatively associated with memory
and executive functioning, whereas the duration of remission positively influ-
enced memory and executive functioning.
Prolonged glucocorticoid excess modifies neurotransmitter function and neuronal
structure of the central nervous system (26;27). In rodents, chronic exposure to
high levels of glucocorticoids impairs hippocampal long-term potentiation (28),
and decreases hippocampal synaptic plasticity (29). In humans, endogenous active
Cushing’s disease is associated with cognitive impairment (27;30;31). The hip-
pocampus is one of the most sensitive structures in the brain for glucocorticoids
and is crucial in cognitive function (32). The persistent impairments in cognitive
function in patients with previous Cushing’s disease might be explained by irre-
versible effects of previous glucocorticoid excess on the central nervous system,
especially the hippocampus. Additional studies, including functional MRI and
postmortem analyses of the central nervous system, are required to evaluate the
effects of previous glucocorticoid excess on brain areas of interest.
In Chapter 8, we described a cross-sectional study in which we assessed cognitive
functioning in patients after long-term remission of acromegaly. We compared
these patients with matched controls, and with patients after treatment for NFMA
using Z-scores. 
We found no differences in cognitive functioning between patients after long-
term remission of acromegaly and matched controls or NFMA patients. However,
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in contrast, patients with long-term cure of Cushing’s disease suffered from im-
paired cognitive functioning (Chapter 5, (3)). We speculate that these differences
in cognitive function between patients with long-term cure of acromegaly and
patients with long-term cure of Cushing’s disease are explained by glucocorti-
coid-specific, irreversible effects on the central nervous system on structures in-
volved in cognitive function, which are apparently not affected by previous
GH/IGF-I excess.  
In summary, there are subtle impairments in cognitive function in patients during
long-term follow up after cure of Cushing’s disease compared with NFMA patients
and matched controls. The greatest impairment was present in memory, although
executive functioning was also affected. This impairment in cognitive function
after treatment of Cushing’s disease is not merely the result of pituitary disease in
general and/or its treatment, but includes specific elements most likely caused by
the irreversible effects of previous glucocorticoid excess on the central nervous
system. However, there were no differences in cognitive functioning between pa-
tients after long-term remission of acromegaly and matched controls or NFMA pa-
tients. We postulate that previous GH/IGF-I excess does not cause irreversible
effects on parts of the central nervous system important in cognitive functioning. 
5. Prevalence of psychopathology
We analyzed the prevalence of psychopathology and maladaptive personality traits
in patients after long-term remission of Cushing’s disease in Chapter 6. We used
several validated questionnaires to assess psychopathology, i.e. the Apathy Scale,
Irritability Scale, Hospital Anxiety and Depression Scale, and the Mood and Anx-
iety Symptoms Questionnaire (short-form). We used the Dimensional Assessment
of Personality Pathology (short-form) to evaluate personality traits. This study
demonstrated that patients with long-term cure of Cushing’s disease suffer from
more psychopathology and maladaptive personality traits compared with matched
controls. In addition, patients with long-term cure of Cushing’s disease had signif-
icantly more psychopathology and maladaptive personality traits than patients pre-
viously treated for NFMA, indicating that the presence of psychopathology and
maladaptive personality traits was not merely related to pituitary tumors and/or
their treatment in general. Therefore, the long-term effects of cured Cushing’s dis-
ease on psychopathology and personality traits are more likely to be the conse-
quence of previous glucocorticoid excess. These observations point to irreversible
effects of previous glucocorticoid excess on the central nervous system. 
In Chapter 7, we reviewed the current literature on psychopathology and Cush-
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ing’s disease. Active Cushing’s disease is associated with a high prevalence of psy-
chopathology, mainly atypical depression. Treatments with glucocorticoid re-
ducing or blocking agents can rapidly relief symptoms. After successful surgery,
prevalence of psychopathology decreases, whereas mood and behavior do not
seem to normalize. After long-term remission, patients with Cushing’s disease still
show decreased QoL and impaired cognitive function. 
In Chapter 8, we described the prevalence of psychopathology and maladaptive
personality traits –as well as cognitive functioning (see section IV. Cognitive func-
tioning)– in patients after long-term remission of acromegaly. We used the same
validated questionnaires as the study described in Chapter 6, i.e. the Apathy Scale,
Irritability Scale, Hospital Anxiety and Depression Scale, and the Mood and Anx-
iety Symptoms Questionnaire (short-form). We used the Dimensional Assessment
of Personality Pathology (short-form) to evaluate personality traits. The study
demonstrated that patients with long-term cure of acromegaly suffer from an in-
creased prevalence of psychopathology and maladaptive personality traits com-
pared with matched controls. Patients with long-term cure of acromegaly also
showed more psychopathology, and especially more maladaptive personality
traits, compared with patients treated for NFMA. These observations indicate that
the increased psychopathology and maladaptive personality traits observed in pa-
tients with long-term cure of acromegaly are not merely caused by pituitary ade-
nomas per se and/or their treatment, but rather by previous GH excess. We
speculate that the results of our study confirm the clinical impression that pa-
tients cured from acromegaly have different and more serious complaints than
patients with NFMA, even though patients treated for NFMA have a higher inci-
dence of hypopituitarism.  
In summary, patients with long-term cure of Cushing’s disease report a high
prevalence of psychopathology, compared with both matched controls and pa-
tients previously treated for NFMA. Furthermore, patients with long-term cure of
Cushing’s disease have a greater degree of maladaptive personality traits. In addi-
tion, patients with long-term cure of acromegaly also have a high prevalence of
psychopathology, compared with matched controls. Patients with long-term cure
of acromegaly have a greater degree of maladaptive personality traits, both com-
pared with matched controls and to patients treated for NFMA. The results sug-
gest that these observations reflect irreversible effects of previous glucocorticoid
or GH/IGF-I excess on the central nervous system rather than an effect of pitu-
itary tumors and/or their treatment in general. Future studies should aim at fur-
ther investigating if and how glucocorticoids and GH/IGF-I changes (subclinical)
psychopathology.
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6. Summary and concluding remarks
The present thesis describes the long-term psychological consequences of pitu-
itary diseases. From the studies described in this thesis we can conclude that:
• Patients after long-term remission of Cushing’s syndrome have more
negative illness perceptions compared with patients with acute and
chronic conditions.
• Patients after long-term remission of acromegaly have more negative illness
perceptions than patients with acute conditions.
• Illness perceptions and QoL are strongly correlated in patients after long-term
remission of Cushing’s syndrome, as well as in patients after long-term remis-
sion of acromegaly. 
• Patients treated for a (non)functioning pituitary adenoma display different and
less effective coping strategies compared with healthy controls. 
• Patients after long-term remission of Cushing’s disease show subtle impair-
ments in cognitive functioning compared with matched controls and NFMA
patients. 
• There were no differences in cognitive functioning between patients after long-
term remission of acromegaly and matched controls or NFMA patients.
• Patients after long-term remission of Cushing’s disease or acromegaly have a
higher prevalence of psychopathology and maladaptive personality traits than
both matched controls and NFMA patients. 
Nowadays, pituitary adenomas can be appropriately treated, but patients continue
to report impaired QoL despite long-term remission or cure. 
In patients with Cushing’s disease, Cushing’s syndrome or acromegaly, doctors
should be aware of subtle cognitive impairments and the increased prevalence of
psychopathology and maladaptive personality traits after long-term remission. In
addition, these patients use ineffective coping strategies and have negative illness
perceptions that are not always correct. Patients are labeled ‘cured’, but still ex-
perience chronic and persisting impairments due to their pituitary disease. Doc-
tors should consider informing patients better about the long-term consequences
and act as a guide in this ‘acceptance process’ of the patient. In addition, a multi-
disciplinary team of endocrinologists, psychologists, and community health work-
ers might also help patients in accepting and dealing with the consequences of
their pituitary disease.
We strongly encourage the development of a self-management intervention, in-
cluding coping skills training, for patients with pituitary diseases. This intervention
might help these patients to cope with their impairments and change illness per-
ceptions. We postulate that this approach might ultimately lead to a better QoL. 
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1. Inleiding
In dit proefschrift hebben we de lange termĳn effecten van hypofysaire ziekten
onderzocht vanuit een psychologisch perspectief. Hypofyse adenomen kunnen
vanuit medisch perspectief goed worden behandeld. Toch behouden hypofyse pa-
tiënten een verminderde kwaliteit van leven terwĳl zĳ al langdurig in remissie of
genezen zĳn. Er wordt verondersteld dat deze vermindering in kwaliteit van leven
voornamelĳk wordt veroorzaakt door lichamelĳke klachten, maar psychische pro-
blemen kunnen hierbĳ ook een rol spelen. 
2. Ziektepercepties 
De verminderde kwaliteit van leven zou veroorzaakt kunnen worden door be-
perkingen ten gevolge van eerdere excessieve hormoonoverproductie. Een alter-
natieve hypothese is dat de psychische impact van het hebben van een hypofysaire
ziekte zou kunnen leiden tot een verminderde kwaliteit van leven. 
Het doel van de studie beschreven in Hoofdstuk 2 was om de ziektepercepties van
patiënten in remissie van het syndroom van Cushing in kaart te brengen. Dit was
de eerste keer dat ziektepercepties onderzocht werden in endocriene ziekten. We
hebben hiervoor een aantal gevalideerde vragenlĳsten gebruikt om de kwaliteit
van leven te meten en de Illness Perception Questionnaire Revised (IPQ-R) om
de ziektepercepties te onderzoeken. De resultaten laten zien dat ziektepercepties
en kwaliteit van leven sterk met elkaar correleren. Bovendien rapporteren pa-
tiënten na langdurige remissie van het syndroom van Cushing meer negatieve
ziektepercepties in vergelĳking met een aantal referentie groepen met acute en
chronische aandoeningen. Daarnaast hebben patiënten die hydrocortison afhan-
kelĳk zĳn het idee dat hun ziekte chronischer en cyclischer van aard was dan pa-
tiënten die geen hydrocortison gebruiken. Hypofysaire uitval werd verder
geassocieerd met een aantal symptomen die werden toegeschreven aan het syn-
droom van Cushing, de chroniciteit en schommelingen van de ziekte, en de waar-
genomen gevolgen van het syndroom van Cushing. We concluderen dat zowel
hydrocortison afhankelĳkheid als hypofysaire uitval van invloed zĳn op de ziek-
tepercepties van deze patiënten.
Omdat de percepties van patiënten afhankelĳk zĳn van informatie uit verschil-
lende bronnen, is het niet noodzakelĳkerwĳs zo dat deze ziektepercepties de me-
dische status van de ziekte representeren. Dit zou kunnen verklaren waarom
patiënten in remissie van het syndroom van Cushing hun ziekte toch als chro-
nisch of cyclisch beschouwen en denken dat een psychologische attributie het
syndroom van Cushing zou hebben veroorzaakt.
De huidige studie toont ook aan dat er een sterke relatie is tussen ziektepercep-
ties en kwaliteit van leven. Dit is reeds waargenomen in verschillende andere me-
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dische aandoeningen. Deze relatie is relevant, aangezien patiënten na langdurige
genezing van het syndroom van Cushing aanhoudende klachten hebben die ge-
reflecteerd worden in een verminderde kwaliteit van leven. Deze klachten wor-
den vaak niet goed begrepen en zĳn moeilĳk te behandelen. Het is daarom van
belang dat artsen zich bewust zĳn hoe deze patiënten hun ziekte en de gevolgen
daarvan ervaren. Dit zal leiden tot een beter begrip van het syndroom van Cus-
hing en de lange termĳn effecten ervan.
In Hoofdstuk 3 hebben we ons gericht op de ziektepercepties van patiënten na bi-
ochemische controle van acromegalie. We hebben een aantal gevalideerde kwa-
liteit van leven vragenlĳsten en de IPQ-R gebruikt om kwaliteit van leven en
ziektepercepties te meten. De resultaten laten zien dat patiënten na langdurige
remissie van acromegalie een goed begrip van hun ziekte hebben, maar een gebrek
aan persoonlĳke controle ervaren en niet snel om medische hulp vragen. Het is in-
teressant dat er duidelĳke verschillen in ziektepercepties waar te nemen zĳn bĳ
patiënten met acromegalie en andere ziekten. Acromegalie patiënten rapporteer-
den bĳvoorbeeld meer negatieve ziektepercepties dan patiënten met acute pĳn of
vestibularis schwannoom, maar meer positieve ziektepercepties dan patiënten met
chronische aandoeningen zoals COPD. Daarnaast ervaren patiënten in langdu-
rige remissie van acromegalie een verminderde kwaliteit van leven. De ziekte-
percepties van acromegalie patiënten zĳn sterk gecorreleerd aan de kwaliteit van
leven parameters, zoals we eerder ook al zagen bĳ patiënten in remissie van het
syndroom van Cushing (Hoofdstuk 2).
Acromegalie patiënten in remissie rapporteerden meer positieve ziektepercepties
dan patiënten in remissie van het syndroom van Cushing. Het is verleidelĳk om
te speculeren dat er ziektespecifieke kenmerken bestaan bĳ ziektepercepties, naast
meer algemene invloeden met betrekking tot klachten of chroniciteit. Verder is
het ook verleidelĳk te speculeren dat wellicht bĳ sommige andere endocriene
ziekten dergelĳke verstoringen in ziektepercepties bestaan. 
Het is belangrĳk dat endocrinologen aan patiënten uitleggen wat de oorzaak van
acromegalie is. Ook zou de endocrinoloog feedback aan de patiënt moeten vragen
naar diens overtuiging met betrekking tot de oorzaak van acromegalie. De ziek-
tepercepties van patiënten, waaronder die met betrekking tot de vermeende oor-
zaak van acromegalie, zĳn gebaseerd op verschillende bronnen. Dit betekent dat
ziektepercepties niet noodzakelĳkerwĳs de feitelĳke medische status of oorzaak
van acromegalie weergeven.
De beschreven studie is belangrĳk, omdat patiënten met acromegalie een ver-
minderde kwaliteit van leven hebben, zelfs na langdurige remissie. De somati-
sche en psychologische factoren die bĳdragen tot een vermindering van de
kwaliteit van leven zĳn niet bekend, maar waarschĳnlĳk spelen klachten aan het
bewegingsapparaat, hypofysaire insufficiëntie en ziektepercepties een rol.
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We concluderen dat er een sterke correlatie bestaat tussen ziektepercepties en
kwaliteit van leven bĳ patiënten in remissie van het syndroom van Cushing en bĳ
patiënten in biochemische remissie van acromegalie. Patiënten in remissie van
het syndroom van Cushing rapporteren meer negatieve ziektepercepties dan de
verschillende referentie groepen met acute en chronische ziekten uit de litera-
tuur. Patiënten in remissie van acromegalie rapporteerden meer negatieve ziek-
tepercepties dan patiënten met een acute aandoening, maar meer positieve
ziektepercepties dan patiënten met chronische aandoeningen, waaronder het syn-
droom van Cushing. We postuleren dat een gerichte zelfmanagement interventie
zou kunnen helpen bĳ het verbeteren en bĳsturen van negatieve ziektepercepties.
Dit zou kunnen leiden tot een verbeterde kwaliteit van leven, althans ten dele, bĳ
patiënten in remissie van het syndroom van Cushing of acromegalie.
3. Copingstrategieën
In Hoofdstuk 4 hebben we de copingstrategieën van patiënten na de behandeling
van hypofysaire adenomen onderzocht. We hebben de Utrechtse Coping Lĳst ge-
bruikt om de verschillende copingstrategieën in kaart te brengen. De resultaten
van deze studie laten zien dat patiënten na behandeling voor een hypofyse ade-
noom minder actieve copingstrategieën gebruiken, meer problemen proberen te
vermĳden en minder sociale steun zoeken in vergelĳking met een aselecte steek-
proef uit de Nederlandse bevolking. In vergelĳking met patiënten met chronische
pĳn zochten hypofyse patiënten meer sociale steun. Behandelde hypofyse pa-
tiënten werden ook vergeleken met patiënten die onder behandeling zĳn bĳ een
eerstelĳns psycholoog en met patiënten met chronische pĳn. Hypofyse patiënten
scoorden lager op vermĳden, het zoeken van sociale steun, passieve coping en het
uiten van emoties, maar hoger op actieve coping. Dit betekent dat patiënten die
werden behandeld voor een hypofyse adenoom, minder effectieve copingstrate-
gieën gebruiken in vergelĳking met de normale bevolking, maar blĳkbaar ge-
bruiken zĳ wel effectiever copingstrategieën dan patiënten met chronische pĳn en
patiënten onder behandeling bĳ een eerstelĳns psycholoog. Een tweede analyse
toonde aan dat patiënten na behandeling voor de ziekte van Cushing, acromega-
lie, en niet-functionerend hypofyse adenoom (NFA) bĳna niet van elkaar ver-
schilden met betrekking tot copingstrategieën. Het enige verschil was op het
gebied van sociale steun: patiënten behandeld voor de ziekte van Cushing zoch-
ten meer sociale steun dan de patiënten behandeld voor NFA.
Dit is de eerste studie die zich richt op copingstrategieën bĳ patiënten behandeld
voor een hypofyse adenoom. Wĳ zĳn van mening dat informatie over de co-
pingstrategieën van deze patiënten erg belangrĳk is, omdat zĳ lĳden aan chroni-
sche beperkingen ondanks genezing van hun initiële hypofyse adenoom. Deze
beperkingen zĳn vaak onbegrepen en moeilĳk te behandelen. Kennis over het ge-
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bruik van bepaalde copingstrategieën kan worden gebruikt bĳ het ontwerpen van
een interventie op basis van bĳvoorbeeld cognitieve gedragstherapie, zelfma-
nagement en de verstrekking van informatie over de negatieve effecten van de
ziekte. We denken dat een dergelĳke gerichte interventie kan leiden tot een be-
tere kwaliteit van leven.
Concluderend kunnen we zeggen dat patiënten die behandeld zĳn voor de ziekte
van Cushing, acromegalie, of NFA andere en minder effectieve copingstrategieën
gebruiken dan gezonde controles. Vergeleken met patiënten met chronische pĳn
en patiënten onder behandeling bĳ een eerstelĳns psycholoog, rapporteren pa-
tiënten met een hypofyse adenoom iets beter copingstrategieën. Het zou belang-
rĳk kunnen zĳn om een training gericht op ziektepercepties, copingstrategieën
en zelfmanagement vaardigheden te ontwikkelen, toe te passen en te evalueren
voor hypofyse patiënten.
4. Cognitief functioneren
In Hoofdstuk 5 hebben we ons gericht op het cognitief functioneren van patiën-
ten in remissie van de ziekte van Cushing. We hebben elf cognitieve testen ge-
bruikt om het gehele spectrum van cognitie te onderzoeken. We hebben patiënten
in remissie van de ziekte van Cushing met gematchte controles en met patiënten
na de behandeling voor NFA vergeleken door middel van Z-scores. De resultaten
toonden aan dat cognitief functioneren verminderd is bĳ patiënten na curatie van
de ziekte van Cushing. Deze patiënten rapporteerden beperkingen in het dagelĳks
leven met betrekking tot geheugen, wat ook bevestigd werd door de cognitieve
testen die we afnamen. Ook werden er beperkingen in bepaalde aspecten van het
executief functioneren gevonden vergeleken met gematchte controles. Deze be-
perkingen zĳn niet alleen gerelateerd aan hypofyse ziekte in het algemeen. Pa-
tiënten in remissie van de ziekte van Cushing bleken ook een verminderde
cognitieve functie te vertonen in vergelĳking met patiënten die behandeld zĳn
voor NFA. Deze waarnemingen geven aan dat er waarschĳnlĳk onomkeerbare ef-
fecten zĳn die het gevolg zĳn van eerder hypercortisolisme op het cognitief func-
tioneren, en dus op het centrale zenuwstelsel. 
Verschillende klinische kenmerken beïnvloedden de uitkomstparameters. Hypo-
fyse uitval werd geassocieerd met verminderd executief functioneren. Verder
waren hydrocortison afhankelĳkheid en aanvullende radiotherapie negatief ge-
associeerd met het geheugen en executief functioneren, terwĳl de duur van de
remissie geheugen en executief functioneren positief beïnvloedde.
Langdurige blootstelling aan een overmaat van glucocorticoïden kan het functi-
oneren van neurotransmitters en de neuronale structuur van het centrale ze-
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nuwstelsel beïnvloeden. Bĳ knaagdieren werden schade aan de hippocampus en
lange termĳn potentiatie en een afname van hippocampale synaptische plastici-
teit vastgesteld ten gevolge van chronische blootstelling aan hoge niveaus van glu-
cocorticoïden. Bĳ de mens is een endogene actieve ziekte van Cushing
geassocieerd met cognitieve stoornissen. De hippocampus is een van de meest ge-
voelige structuren voor glucocorticoïden in de hersenen en is cruciaal in het cog-
nitief functioneren. De aanhoudende stoornissen in het cognitief functioneren bĳ
patiënten met een behandelde ziekte van Cushing kunnen verklaard worden door
de onomkeerbare effecten van het eerdere glucocorticoïd overschot op het cen-
trale zenuwstelsel, met name de hippocampus. Verder onderzoek, waaronder
functionele MRI en post-mortem analyses van het centrale zenuwstelsel zĳn nodig
om de gevolgen van eerdere glucocorticoïden blootstelling op belangrĳke her-
sengebieden te evalueren.
In Hoofdstuk 8 hebben we een cross-sectionele studie beschreven waarin we cog-
nitief functioneren onderzochten bĳ patiënten in langdurige biochemische re-
missie van acromegalie. We hebben deze patiënten vergeleken met gematchte
controles en met patiënten na behandeling voor NFA door middel van Z-scores.
We vonden geen verschillen in cognitief functioneren tussen patiënten in remis-
sie van acromegalie en gematchte controles of NFA patiënten. Dit is in tegenstel-
ling tot patiënten in remissie van de ziekte van Cushing, die wel last hebben van
verminderd cognitief functioneren (Hoofdstuk 5). Gezien de design van de studie,
is het waarschĳnlĳk dat deze verschillen in cognitieve functioneren tussen de pa-
tiënten na behandeling van acromegalie en patiënten na behandeling van de
ziekte van Cushing worden verklaard door glucocorticoïd-specifieke onomkeer-
bare effecten op bepaalde hersenstructuren die betrokken zĳn bĳ cognitieve func-
ties, die blĳkbaar niet beïnvloed worden door eerdere blootstelling aan GH/IGF-I
overproductie.
Samenvattend zĳn er subtiele stoornissen in het cognitief functioneren bĳ pa-
tiënten in remissie van de ziekte van Cushing in vergelĳking met NFA patiënten
en controles. De grootste problemen waren aanwezig in het geheugen, hoewel er
ook problemen waren met het executief functioneren. Deze vermindering van de
cognitieve functie na behandeling van de ziekte van Cushing is niet alleen het ge-
volg van een hypofyse aandoening in het algemeen en/of de behandeling daar-
van, maar heeft ook te maken met specifieke elementen die waarschĳnlĳk worden
veroorzaakt door de onomkeerbare effecten van het eerdere glucocorticoïd over-
schot op het centrale zenuwstelsel. Echter, er waren geen verschillen in cognitief
functioneren toen patiënten in remissie van acromegalie werden vergeleken met
gematchte controles en NFA patiënten. We postuleren dat het eerdere GH/IGF-
I overschot geen onomkeerbare effecten heeft op delen van het centrale zenuw-
stelsel die belangrĳk zĳn voor het cognitief functioneren.
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5. Prevalentie van psychopathologie
In Hoofdstuk 6 hebben we de prevalentie van psychopathologie en maladaptieve
persoonlĳkheidstrekken bĳ patiënten in remissie van de ziekte van Cushing be-
studeerd. We hebben een aantal gevalideerde vragenlĳsten gebruikt om psycho-
pathologie te meten: de Apathie Schaal, de Prikkelbaarheid Schaal, de Hospital
Anxiety and Depression Scale, en de Mood and Anxiety Symptom Questionnaire
(verkorte vorm). We hebben de Dimensional Assessment of Personality Pathology
(verkorte vorm) gebruikt om persoonlĳkheidstrekken in kaart te brengen. 
De studie liet zien dat patiënten in remissie van de ziekte van Cushing een hogere
prevalentie van psychopathologie en maladaptieve persoonlĳkheidstrekken heb-
ben in vergelĳking met gematchte controles. Daarnaast hebben patiënten in re-
missie van de ziekte van Cushing een hogere prevalentie van psychopathologie en
maladaptieve persoonlĳkheidstrekken dan patiënten die behandeld zĳn voor NFA.
Dit geeft aan dat de aanwezigheid van psychopathologie en maladaptieve per-
soonlĳkheidstrekken niet alleen gerelateerd is aan hypofyse tumoren en/of de be-
handeling in het algemeen. Het is aannemelĳk dat de lange termĳn effecten van
de ziekte van Cushing op psychopathologie en persoonlĳkheidskenmerken het
gevolg zĳn van het eerdere glucocorticoïd overschot. Deze waarnemingen wĳzen
op de onomkeerbare effecten van eerder glucocorticoïd overschot op het centrale
zenuwstelsel.
In Hoofdstuk 7 hebben we de huidige literatuur over psychopathologie en de
ziekte van Cushing bekeken. Een actieve ziekte van Cushing gaat gepaard met
een hoge prevalentie van psychopathologie, met name atypische depressie. Be-
handeling met glucocorticoïd verminderende/blokkerende middelen kan snel ver-
lichting geven van de symptomen. Na een succesvolle operatie neemt de
prevalentie van psychopathologie af, maar stemming en gedrag lĳken niet te nor-
maliseren. Na langdurige remissie rapporteren patiënten met de ziekte van Cus-
hing nog steeds verminderde kwaliteit van leven en verminderde cognitieve
functies.
In Hoofdstuk 8 beschrĳven we de prevalentie van psychopathologie en maladap-
tieve persoonlĳkheidstrekken, evenals cognitief functioneren (zie ook IV. Cogni-
tief functioneren) van patiënten in remissie van acromegalie. We gebruikten
dezelfde gevalideerde vragenlĳsten als in de studie beschreven in Hoofdstuk 6: de
Apathie Schaal, de Prikkelbaarheid Schaal, de Hospital Anxiety and Depression
Scale, en de Mood and Anxiety Symptom Questionnaire (verkorte vorm). We
hebben de Dimensional Assessment of Personality Pathology (verkorte vorm) ge-
bruikt om persoonlĳkheidskenmerken in kaart te brengen. De studie toonde aan
dat patiënten na behandeling van acromegalie een hogere prevalentie van psy-
chopathologie en maladaptieve persoonlĳkheidstrekken lieten zien dan gematchte
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controles. Patiënten na behandeling van acromegalie toonden ook meer psycho-
pathologie, en vooral meer maladaptieve persoonlĳkheidstrekken, in vergelĳking
met patiënten behandeld voor NFA. Deze waarnemingen geven aan dat de ver-
hoogde prevalentie van psychopathologie en maladaptieve persoonlĳkheidstrek-
ken van patiënten na behandeling van acromegalie niet louter veroorzaakt wordt
door een hypofyse adenoom per se en/of de behandeling daarvan, maar eerder
door de overmatige blootstelling aan GH en/of IGF-I. We speculeren dat de re-
sultaten van ons onderzoek de klinische indruk bevestigen dat patiënten in re-
missie van acromegalie andere en meer ernstige klachten hebben dan patiënten
met NFA, hoewel de patiënten behandeld voor NFA een hogere incidentie heb-
ben van hypofyse uitval.
Bovenstaande resultaten samengevat rapporteren patiënten in remissie van de
ziekte van Cushing een hoge prevalentie van psychopathologie, in vergelĳking
met zowel de gematchte controles als patiënten die behandeld zĳn voor NFA. Bo-
vendien hebben patiënten in remissie van de ziekte van Cushing een hogere pre-
valentie van maladaptieve persoonlĳkheidstrekken. Daarnaast rapporteren
patiënten na behandeling van acromegalie ook een hoge prevalentie van psycho-
pathologie, in vergelĳking met gematchte controles. Patiënten na behandeling
van acromegalie rapporteren een hogere prevalentie van maladaptieve persoon-
lĳkheidstrekken, zowel in vergelĳking met gematchte controles als patiënten be-
handeld voor NFA. De resultaten geven aan dat er onomkeerbare effecten zĳn
van eerder glucocorticoïd dan wel GH en/of IGF-I overschot op het centrale ze-
nuwstelsel. Toekomstige studies zouden moeten onderzoeken of en hoe gluco-
corticoïden en GH/IGF-I veranderingen in (subklinische) psychopathologie
teweeg kunnen brengen.
6. Slotopmerkingen
Dit proefschrift beschrĳft de lange termĳn effecten van hypofyse ziekten vanuit
een psychologisch perspectief. 
Uit de studies beschreven in dit proefschrift concluderen we dat:
• Patiënten in remissie van de ziekte van Cushing hebben meer negatieve ziek-
tepercepties dan patiënten met acute en chronische aandoeningen.
• Patiënten in remissie van acromegalie hebben meer negatieve ziektepercep-
ties dan patiënten met acute aandoeningen.
• Ziektepercepties en kwaliteit van leven zĳn sterk gecorreleerd bĳ patiënten in
remissie van de ziekte van Cushing, evenals bĳ patiënten in remissie van acro-
megalie.
• Patiënten die behandeld zĳn voor een (niet) functionerend hypofyse ade-
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noom, gebruiken andere en minder effectieve copingstrategieën dan gezonde
controle personen.
• Patiënten in remissie van de ziekte van Cushing vertonen subtiele stoornissen
in het cognitief functioneren in vergelĳking met controle personen en pa-
tiënten met niet functionerende hypofyse adenomen.
• Patiënten in remissie van acromegalie verschillen niet in cognitief functione-
ren met controle personen en patiënten behandeld voor niet-functionerende
hypofyse adenomen.
• Patiënten in remissie van de ziekte van Cushing of van acromegalie vertonen
een hoge prevalentie van psychopathologie en maladaptieve persoonlĳk-
heidstrekken in vergelĳking met controle personen en patiënten met niet-
functionerende hypofyse adenomen.
Tegenwoordig kunnen hypofyse adenomen goed worden behandeld, maar de pa-
tiënten houden een verminderde kwaliteit van leven ondanks langdurige remis-
sie of genezing. 
Bĳ patiënten in remissie van de ziekte van Cushing, het syndroom van Cushing
of acromegalie moeten artsen zich bewust zĳn van subtiele cognitieve stoornissen
en een hoge prevalentie van psychopathologie en maladaptieve persoonlĳkheids-
trekken. Bovendien blĳken deze patiënten ineffectieve copingstrategieën te ge-
bruiken en hebben zĳ negatieve ziektepercepties die niet altĳd correct zĳn.
Patiënten worden ‘genezen’ verklaard, maar ervaren nog steeds chronische be-
perkingen als gevolg van hun hypofyse aandoening. Artsen moeten overwegen
deze patiënten veel beter te informeren over deze duidelĳk miskende gevolgen op
lange termĳn. De artsen fungeren daarmee als gids in het ‘acceptatie proces’ van
de patiënt. In ieder geval wordt de patiënt aldus optimaal van informatie voorzien,
hetgeen behulpzaam kan zĳn bĳ de acceptatie van de ziekte en de kennelĳke ge-
volgen daarvan. Het is mogelĳk dat een andere aanpak daarnaast ook effectief zou
kunnen zĳn. Een multidisciplinaire aanpak met endocrinologen, psychologen en
maatschappelĳk werkers zou wellicht ook de acceptatie en het omgaan met de
gevolgen van een hypofyse aandoening kunnen bevorderen.
Wĳ denken dat de ontwikkeling van een zelfmanagement interventie, waaronder
training van copingvaardigheden, voor patiënten met hypofyse ziekten goed zou
werken. Deze interventie kan hypofyse patiënten helpen om te gaan met hun be-
perkingen en kan veranderingen teweeg brengen in ziektepercepties. Hoewel dit
de onomkeerbare gevolgen van de hormoon producerende hypofyse ziekten niet
zal kunnen wegnemen, postuleren we dat deze aanpak uiteindelĳk kan leiden tot
een betere kwaliteit van leven. 
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